WO2024054892A1 - Therapeutic peptides - Google Patents
Therapeutic peptides Download PDFInfo
- Publication number
- WO2024054892A1 WO2024054892A1 PCT/US2023/073613 US2023073613W WO2024054892A1 WO 2024054892 A1 WO2024054892 A1 WO 2024054892A1 US 2023073613 W US2023073613 W US 2023073613W WO 2024054892 A1 WO2024054892 A1 WO 2024054892A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- amino acids
- peptide
- engineered
- seq
- cancer
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 546
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 83
- 230000001225 therapeutic effect Effects 0.000 title claims description 30
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 169
- 201000011510 cancer Diseases 0.000 claims abstract description 54
- 238000000034 method Methods 0.000 claims abstract description 36
- 238000011282 treatment Methods 0.000 claims abstract description 31
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 29
- 201000010099 disease Diseases 0.000 claims abstract description 26
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 24
- 150000001413 amino acids Chemical class 0.000 claims description 1055
- 210000004027 cell Anatomy 0.000 claims description 89
- 239000002253 acid Substances 0.000 claims description 65
- 150000003839 salts Chemical class 0.000 claims description 32
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 26
- 229920001184 polypeptide Polymers 0.000 claims description 23
- 230000035772 mutation Effects 0.000 claims description 19
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 18
- 206010069755 K-ras gene mutation Diseases 0.000 claims description 17
- 238000000099 in vitro assay Methods 0.000 claims description 15
- UOAXMMISMWRAMK-SNVBAGLBSA-N C(=CCCCCCC)N[C@H](C)C(=O)O Chemical group C(=CCCCCCC)N[C@H](C)C(=O)O UOAXMMISMWRAMK-SNVBAGLBSA-N 0.000 claims description 14
- 230000007541 cellular toxicity Effects 0.000 claims description 13
- 230000002601 intratumoral effect Effects 0.000 claims description 12
- 238000002560 therapeutic procedure Methods 0.000 claims description 11
- 201000001441 melanoma Diseases 0.000 claims description 9
- 241000124008 Mammalia Species 0.000 claims description 8
- 239000003085 diluting agent Substances 0.000 claims description 8
- 208000020816 lung neoplasm Diseases 0.000 claims description 8
- 108010062302 rac1 GTP Binding Protein Proteins 0.000 claims description 8
- 102200006531 rs121913529 Human genes 0.000 claims description 8
- 102200006538 rs121913530 Human genes 0.000 claims description 8
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 7
- 238000002703 mutagenesis Methods 0.000 claims description 7
- 231100000350 mutagenesis Toxicity 0.000 claims description 7
- QHRHSDCXMKAXDH-SSDOTTSWSA-N (2r)-2-(pentylamino)propanoic acid Chemical compound CCCCCN[C@H](C)C(O)=O QHRHSDCXMKAXDH-SSDOTTSWSA-N 0.000 claims description 6
- 102100030708 GTPase KRas Human genes 0.000 claims description 6
- 101000584612 Homo sapiens GTPase KRas Proteins 0.000 claims description 6
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 6
- 238000002512 chemotherapy Methods 0.000 claims description 6
- 201000002528 pancreatic cancer Diseases 0.000 claims description 6
- 206010009944 Colon cancer Diseases 0.000 claims description 5
- 208000037538 Myelomonocytic Juvenile Leukemia Diseases 0.000 claims description 5
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 5
- 208000002495 Uterine Neoplasms Diseases 0.000 claims description 5
- 159000000021 acetate salts Chemical class 0.000 claims description 5
- 230000002401 inhibitory effect Effects 0.000 claims description 5
- 201000005992 juvenile myelomonocytic leukemia Diseases 0.000 claims description 5
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 5
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 5
- 238000001959 radiotherapy Methods 0.000 claims description 5
- 238000002626 targeted therapy Methods 0.000 claims description 5
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 5
- 206010046766 uterine cancer Diseases 0.000 claims description 5
- 102100033391 ATP-dependent RNA helicase DDX3X Human genes 0.000 claims description 4
- 206010005003 Bladder cancer Diseases 0.000 claims description 4
- 206010006187 Breast cancer Diseases 0.000 claims description 4
- 208000026310 Breast neoplasm Diseases 0.000 claims description 4
- 102100028914 Catenin beta-1 Human genes 0.000 claims description 4
- 241000700199 Cavia porcellus Species 0.000 claims description 4
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 4
- 241000699800 Cricetinae Species 0.000 claims description 4
- 102000012199 E3 ubiquitin-protein ligase Mdm2 Human genes 0.000 claims description 4
- 108050002772 E3 ubiquitin-protein ligase Mdm2 Proteins 0.000 claims description 4
- 241000282326 Felis catus Species 0.000 claims description 4
- 101000870662 Homo sapiens ATP-dependent RNA helicase DDX3X Proteins 0.000 claims description 4
- 101000916173 Homo sapiens Catenin beta-1 Proteins 0.000 claims description 4
- 101001120056 Homo sapiens Phosphatidylinositol 3-kinase regulatory subunit alpha Proteins 0.000 claims description 4
- 101000686227 Homo sapiens Ras-related protein R-Ras2 Proteins 0.000 claims description 4
- 101000777277 Homo sapiens Serine/threonine-protein kinase Chk2 Proteins 0.000 claims description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 4
- 206010033128 Ovarian cancer Diseases 0.000 claims description 4
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 4
- 208000024313 Testicular Neoplasms Diseases 0.000 claims description 4
- 206010057644 Testis cancer Diseases 0.000 claims description 4
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 claims description 4
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 4
- 201000010881 cervical cancer Diseases 0.000 claims description 4
- 238000001794 hormone therapy Methods 0.000 claims description 4
- 238000009169 immunotherapy Methods 0.000 claims description 4
- 201000005202 lung cancer Diseases 0.000 claims description 4
- 102200006539 rs121913529 Human genes 0.000 claims description 4
- 201000003120 testicular cancer Diseases 0.000 claims description 4
- 208000022679 triple-negative breast carcinoma Diseases 0.000 claims description 4
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims description 3
- 208000006990 cholangiocarcinoma Diseases 0.000 claims description 3
- 201000005787 hematologic cancer Diseases 0.000 claims description 3
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims description 3
- 238000009217 hyperthermia therapy Methods 0.000 claims description 3
- 238000002428 photodynamic therapy Methods 0.000 claims description 3
- 238000009168 stem cell therapy Methods 0.000 claims description 3
- 238000009580 stem-cell therapy Methods 0.000 claims description 3
- 238000001356 surgical procedure Methods 0.000 claims description 3
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 claims description 3
- 230000004663 cell proliferation Effects 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 230000035755 proliferation Effects 0.000 claims description 2
- 238000002424 x-ray crystallography Methods 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 235000001014 amino acid Nutrition 0.000 description 1043
- 229940024606 amino acid Drugs 0.000 description 1042
- 108090000623 proteins and genes Proteins 0.000 description 69
- 150000007513 acids Chemical class 0.000 description 60
- 102000004169 proteins and genes Human genes 0.000 description 54
- 235000018102 proteins Nutrition 0.000 description 52
- 238000012360 testing method Methods 0.000 description 37
- 235000002639 sodium chloride Nutrition 0.000 description 35
- 239000007924 injection Substances 0.000 description 27
- 238000002347 injection Methods 0.000 description 27
- 241000699670 Mus sp. Species 0.000 description 25
- 238000002474 experimental method Methods 0.000 description 20
- 241001465754 Metazoa Species 0.000 description 17
- 238000001727 in vivo Methods 0.000 description 17
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 16
- 238000004422 calculation algorithm Methods 0.000 description 16
- 239000000203 mixture Substances 0.000 description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 14
- 241000699666 Mus <mouse, genus> Species 0.000 description 14
- -1 alkaline earth metal salt Chemical class 0.000 description 14
- 239000012634 fragment Substances 0.000 description 13
- 230000037396 body weight Effects 0.000 description 12
- 229920001223 polyethylene glycol Polymers 0.000 description 12
- 238000012216 screening Methods 0.000 description 12
- 230000004614 tumor growth Effects 0.000 description 12
- 239000003981 vehicle Substances 0.000 description 11
- 108091028043 Nucleic acid sequence Proteins 0.000 description 10
- 229920002472 Starch Polymers 0.000 description 10
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical class OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 239000002202 Polyethylene glycol Substances 0.000 description 9
- 230000003833 cell viability Effects 0.000 description 9
- 239000002773 nucleotide Substances 0.000 description 9
- 125000003729 nucleotide group Chemical group 0.000 description 9
- 239000002953 phosphate buffered saline Substances 0.000 description 9
- 235000019698 starch Nutrition 0.000 description 9
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 8
- 108010033276 Peptide Fragments Proteins 0.000 description 8
- 102000007079 Peptide Fragments Human genes 0.000 description 8
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 8
- 229930006000 Sucrose Natural products 0.000 description 8
- 230000008901 benefit Effects 0.000 description 8
- 239000013078 crystal Substances 0.000 description 8
- 238000009826 distribution Methods 0.000 description 8
- 235000019441 ethanol Nutrition 0.000 description 8
- 239000005720 sucrose Substances 0.000 description 8
- 108020004414 DNA Proteins 0.000 description 7
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 7
- 208000025865 Ulcer Diseases 0.000 description 7
- 239000007884 disintegrant Substances 0.000 description 7
- 238000000338 in vitro Methods 0.000 description 7
- 108010082117 matrigel Proteins 0.000 description 7
- 238000005259 measurement Methods 0.000 description 7
- 239000003921 oil Substances 0.000 description 7
- 235000019198 oils Nutrition 0.000 description 7
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 7
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 7
- 230000000069 prophylactic effect Effects 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- 229940032147 starch Drugs 0.000 description 7
- 239000008107 starch Substances 0.000 description 7
- 230000036269 ulceration Effects 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 6
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 6
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 6
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 238000010609 cell counting kit-8 assay Methods 0.000 description 6
- 230000030833 cell death Effects 0.000 description 6
- 235000011187 glycerol Nutrition 0.000 description 6
- 239000003112 inhibitor Substances 0.000 description 6
- 238000001990 intravenous administration Methods 0.000 description 6
- 238000012986 modification Methods 0.000 description 6
- 230000004048 modification Effects 0.000 description 6
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 6
- 239000001488 sodium phosphate Substances 0.000 description 6
- 235000000346 sugar Nutrition 0.000 description 6
- 210000004881 tumor cell Anatomy 0.000 description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 5
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 5
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 5
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 5
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 5
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 5
- 102100029974 GTPase HRas Human genes 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- 101000584633 Homo sapiens GTPase HRas Proteins 0.000 description 5
- 229930195725 Mannitol Natural products 0.000 description 5
- 239000003963 antioxidant agent Substances 0.000 description 5
- 235000006708 antioxidants Nutrition 0.000 description 5
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 5
- 239000011230 binding agent Substances 0.000 description 5
- 239000006172 buffering agent Substances 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 230000002338 cryopreservative effect Effects 0.000 description 5
- 239000000796 flavoring agent Substances 0.000 description 5
- 235000003599 food sweetener Nutrition 0.000 description 5
- 235000003642 hunger Nutrition 0.000 description 5
- 230000003993 interaction Effects 0.000 description 5
- 238000007913 intrathecal administration Methods 0.000 description 5
- 239000000594 mannitol Substances 0.000 description 5
- 235000010355 mannitol Nutrition 0.000 description 5
- 229960001855 mannitol Drugs 0.000 description 5
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 5
- 239000003755 preservative agent Substances 0.000 description 5
- 239000000600 sorbitol Substances 0.000 description 5
- 229960002920 sorbitol Drugs 0.000 description 5
- 235000010356 sorbitol Nutrition 0.000 description 5
- 239000003381 stabilizer Substances 0.000 description 5
- 230000037351 starvation Effects 0.000 description 5
- 239000003765 sweetening agent Substances 0.000 description 5
- 230000026683 transduction Effects 0.000 description 5
- 238000010361 transduction Methods 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 102000008100 Human Serum Albumin Human genes 0.000 description 4
- 108091006905 Human Serum Albumin Proteins 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 229920000881 Modified starch Polymers 0.000 description 4
- 108091034117 Oligonucleotide Proteins 0.000 description 4
- 102100033479 RAF proto-oncogene serine/threonine-protein kinase Human genes 0.000 description 4
- 102100022851 Rab5 GDP/GTP exchange factor Human genes 0.000 description 4
- 102100022122 Ras-related C3 botulinum toxin substrate 1 Human genes 0.000 description 4
- 101710203837 Replication-associated protein Proteins 0.000 description 4
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 238000012867 alanine scanning Methods 0.000 description 4
- 230000003078 antioxidant effect Effects 0.000 description 4
- 238000004364 calculation method Methods 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 235000010980 cellulose Nutrition 0.000 description 4
- 229920002678 cellulose Polymers 0.000 description 4
- 239000001913 cellulose Substances 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000006731 degradation reaction Methods 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 229960004756 ethanol Drugs 0.000 description 4
- 235000013355 food flavoring agent Nutrition 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000000670 limiting effect Effects 0.000 description 4
- 239000000314 lubricant Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- 229910052751 metal Inorganic materials 0.000 description 4
- 239000002184 metal Substances 0.000 description 4
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 4
- 239000008108 microcrystalline cellulose Substances 0.000 description 4
- 229940016286 microcrystalline cellulose Drugs 0.000 description 4
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 4
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 4
- 229940068968 polysorbate 80 Drugs 0.000 description 4
- 229920000053 polysorbate 80 Polymers 0.000 description 4
- 230000002335 preservative effect Effects 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 201000000849 skin cancer Diseases 0.000 description 4
- 239000004055 small Interfering RNA Substances 0.000 description 4
- 239000001632 sodium acetate Substances 0.000 description 4
- 235000017281 sodium acetate Nutrition 0.000 description 4
- 229910000029 sodium carbonate Inorganic materials 0.000 description 4
- 235000017550 sodium carbonate Nutrition 0.000 description 4
- 239000001509 sodium citrate Substances 0.000 description 4
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 239000004094 surface-active agent Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 4
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 108010088751 Albumins Proteins 0.000 description 3
- 102000009027 Albumins Human genes 0.000 description 3
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 3
- 206010004593 Bile duct cancer Diseases 0.000 description 3
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 3
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 3
- 206010011906 Death Diseases 0.000 description 3
- 108091092584 GDNA Proteins 0.000 description 3
- 206010018338 Glioma Diseases 0.000 description 3
- 239000004471 Glycine Substances 0.000 description 3
- 101000967216 Homo sapiens Eosinophil cationic protein Proteins 0.000 description 3
- 101000712530 Homo sapiens RAF proto-oncogene serine/threonine-protein kinase Proteins 0.000 description 3
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 3
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 3
- 108700020796 Oncogene Proteins 0.000 description 3
- 102000043276 Oncogene Human genes 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- 206010039491 Sarcoma Diseases 0.000 description 3
- 208000000453 Skin Neoplasms Diseases 0.000 description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
- 235000004279 alanine Nutrition 0.000 description 3
- 229910000019 calcium carbonate Inorganic materials 0.000 description 3
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 3
- 229960005243 carmustine Drugs 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 238000007398 colorimetric assay Methods 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 239000008121 dextrose Substances 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 239000003623 enhancer Substances 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 238000007918 intramuscular administration Methods 0.000 description 3
- 238000007912 intraperitoneal administration Methods 0.000 description 3
- 238000007914 intraventricular administration Methods 0.000 description 3
- 229960002247 lomustine Drugs 0.000 description 3
- 208000037841 lung tumor Diseases 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 201000005962 mycosis fungoides Diseases 0.000 description 3
- 150000007523 nucleic acids Chemical group 0.000 description 3
- 229920001542 oligosaccharide Polymers 0.000 description 3
- 230000035699 permeability Effects 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
- 235000021317 phosphate Nutrition 0.000 description 3
- 102000040430 polynucleotide Human genes 0.000 description 3
- 108091033319 polynucleotide Proteins 0.000 description 3
- 239000002157 polynucleotide Substances 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- 229920001592 potato starch Polymers 0.000 description 3
- 229950010131 puromycin Drugs 0.000 description 3
- 238000002864 sequence alignment Methods 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 3
- 229910000162 sodium phosphate Inorganic materials 0.000 description 3
- 235000011008 sodium phosphates Nutrition 0.000 description 3
- 229920003109 sodium starch glycolate Polymers 0.000 description 3
- 239000008109 sodium starch glycolate Substances 0.000 description 3
- 229940079832 sodium starch glycolate Drugs 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 150000008163 sugars Chemical class 0.000 description 3
- 201000008205 supratentorial primitive neuroectodermal tumor Diseases 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 229940033134 talc Drugs 0.000 description 3
- 235000012222 talc Nutrition 0.000 description 3
- 208000008732 thymoma Diseases 0.000 description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
- DJAHKBBSJCDSOZ-AJLBTXRUSA-N (5z,9e,13e)-6,10,14,18-tetramethylnonadeca-5,9,13,17-tetraen-2-one;(5e,9e,13e)-6,10,14,18-tetramethylnonadeca-5,9,13,17-tetraen-2-one Chemical compound CC(C)=CCC\C(C)=C\CC\C(C)=C\CC\C(C)=C/CCC(C)=O.CC(C)=CCC\C(C)=C\CC\C(C)=C\CC\C(C)=C\CCC(C)=O DJAHKBBSJCDSOZ-AJLBTXRUSA-N 0.000 description 2
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 2
- VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 2
- GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 description 2
- 208000002008 AIDS-Related Lymphoma Diseases 0.000 description 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 description 2
- 206010003571 Astrocytoma Diseases 0.000 description 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 2
- 208000003174 Brain Neoplasms Diseases 0.000 description 2
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 2
- 206010007953 Central nervous system lymphoma Diseases 0.000 description 2
- JWBOIMRXGHLCPP-UHFFFAOYSA-N Chloditan Chemical compound C=1C=CC=C(Cl)C=1C(C(Cl)Cl)C1=CC=C(Cl)C=C1 JWBOIMRXGHLCPP-UHFFFAOYSA-N 0.000 description 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 2
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- OVBJJZOQPCKUOR-UHFFFAOYSA-L EDTA disodium salt dihydrate Chemical compound O.O.[Na+].[Na+].[O-]C(=O)C[NH+](CC([O-])=O)CC[NH+](CC([O-])=O)CC([O-])=O OVBJJZOQPCKUOR-UHFFFAOYSA-L 0.000 description 2
- XXPXYPLPSDPERN-UHFFFAOYSA-N Ecteinascidin 743 Natural products COc1cc2C(NCCc2cc1O)C(=O)OCC3N4C(O)C5Cc6cc(C)c(OC)c(O)c6C(C4C(S)c7c(OC(=O)C)c(C)c8OCOc8c37)N5C XXPXYPLPSDPERN-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 239000001856 Ethyl cellulose Substances 0.000 description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- VWUXBMIQPBEWFH-WCCTWKNTSA-N Fulvestrant Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 208000021309 Germ cell tumor Diseases 0.000 description 2
- 208000032612 Glial tumor Diseases 0.000 description 2
- 229920000209 Hexadimethrine bromide Polymers 0.000 description 2
- 101000934489 Homo sapiens Nucleosome-remodeling factor subunit BPTF Proteins 0.000 description 2
- 206010061252 Intraocular melanoma Diseases 0.000 description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical class OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 2
- 206010025312 Lymphoma AIDS related Diseases 0.000 description 2
- 208000000172 Medulloblastoma Diseases 0.000 description 2
- 108700011259 MicroRNAs Proteins 0.000 description 2
- 208000003445 Mouth Neoplasms Diseases 0.000 description 2
- 208000034578 Multiple myelomas Diseases 0.000 description 2
- 241001467552 Mycobacterium bovis BCG Species 0.000 description 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 2
- 201000007224 Myeloproliferative neoplasm Diseases 0.000 description 2
- 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 description 2
- 102100025062 Nucleosome-remodeling factor subunit BPTF Human genes 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 2
- 206010038389 Renal cancer Diseases 0.000 description 2
- 201000000582 Retinoblastoma Diseases 0.000 description 2
- 206010039509 Scab Diseases 0.000 description 2
- 102000039471 Small Nuclear RNA Human genes 0.000 description 2
- 108020003224 Small Nucleolar RNA Proteins 0.000 description 2
- 102000042773 Small Nucleolar RNA Human genes 0.000 description 2
- 108091027967 Small hairpin RNA Proteins 0.000 description 2
- 108020004459 Small interfering RNA Proteins 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 208000021712 Soft tissue sarcoma Diseases 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 2
- FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 2
- 201000005969 Uveal melanoma Diseases 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 229960000473 altretamine Drugs 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 229960002932 anastrozole Drugs 0.000 description 2
- YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 description 2
- 230000001028 anti-proliverative effect Effects 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 239000004599 antimicrobial Substances 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 2
- 229960000190 bacillus calmette–guérin vaccine Drugs 0.000 description 2
- 229960002707 bendamustine Drugs 0.000 description 2
- YTKUWDBFDASYHO-UHFFFAOYSA-N bendamustine Chemical compound ClCCN(CCCl)C1=CC=C2N(C)C(CCCC(O)=O)=NC2=C1 YTKUWDBFDASYHO-UHFFFAOYSA-N 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- 235000012216 bentonite Nutrition 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- 229960002092 busulfan Drugs 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 159000000007 calcium salts Chemical class 0.000 description 2
- 235000013539 calcium stearate Nutrition 0.000 description 2
- 239000008116 calcium stearate Substances 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 230000009702 cancer cell proliferation Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 229960004562 carboplatin Drugs 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 208000002458 carcinoid tumor Diseases 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 229960004630 chlorambucil Drugs 0.000 description 2
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 2
- 229960004316 cisplatin Drugs 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000002591 computed tomography Methods 0.000 description 2
- 229960004397 cyclophosphamide Drugs 0.000 description 2
- SSJJWVREPZVNBF-DGXVIIAXSA-N dG10 Chemical compound C1=NC(C(NC(N)=N2)=O)=C2N1[C@H](O[C@@H]1COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)CO)C[C@@H]1OP(O)(=O)OC[C@@H](O1)[C@@H](O)C[C@@H]1N1C(N=C(NC2=O)N)=C2N=C1 SSJJWVREPZVNBF-DGXVIIAXSA-N 0.000 description 2
- 229960003901 dacarbazine Drugs 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 235000019800 disodium phosphate Nutrition 0.000 description 2
- 229910000397 disodium phosphate Inorganic materials 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 230000008029 eradication Effects 0.000 description 2
- 238000010228 ex vivo assay Methods 0.000 description 2
- 229960000255 exemestane Drugs 0.000 description 2
- 201000008819 extrahepatic bile duct carcinoma Diseases 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 229960002258 fulvestrant Drugs 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 201000007116 gestational trophoblastic neoplasm Diseases 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 229960005150 glycerol Drugs 0.000 description 2
- UUVWYPNAQBNQJQ-UHFFFAOYSA-N hexamethylmelamine Chemical compound CN(C)C1=NC(N(C)C)=NC(N(C)C)=N1 UUVWYPNAQBNQJQ-UHFFFAOYSA-N 0.000 description 2
- 238000013537 high throughput screening Methods 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 235000014304 histidine Nutrition 0.000 description 2
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 2
- 229960001101 ifosfamide Drugs 0.000 description 2
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 238000000126 in silico method Methods 0.000 description 2
- 238000001361 intraarterial administration Methods 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 210000004153 islets of langerhan Anatomy 0.000 description 2
- 201000010982 kidney cancer Diseases 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 229960001375 lactose Drugs 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 2
- 239000001095 magnesium carbonate Substances 0.000 description 2
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 2
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 2
- 239000000347 magnesium hydroxide Substances 0.000 description 2
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 2
- 235000012254 magnesium hydroxide Nutrition 0.000 description 2
- 239000000395 magnesium oxide Substances 0.000 description 2
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- HBNDBUATLJAUQM-UHFFFAOYSA-L magnesium;dodecyl sulfate Chemical compound [Mg+2].CCCCCCCCCCCCOS([O-])(=O)=O.CCCCCCCCCCCCOS([O-])(=O)=O HBNDBUATLJAUQM-UHFFFAOYSA-L 0.000 description 2
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 229960004961 mechlorethamine Drugs 0.000 description 2
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 2
- 229960001924 melphalan Drugs 0.000 description 2
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 2
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 239000002679 microRNA Substances 0.000 description 2
- 229960000350 mitotane Drugs 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 201000008106 ocular cancer Diseases 0.000 description 2
- 201000002575 ocular melanoma Diseases 0.000 description 2
- 150000002482 oligosaccharides Chemical class 0.000 description 2
- 229960001756 oxaliplatin Drugs 0.000 description 2
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000000816 peptidomimetic Substances 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 229940068977 polysorbate 20 Drugs 0.000 description 2
- OQZCJRJRGMMSGK-UHFFFAOYSA-M potassium metaphosphate Chemical compound [K+].[O-]P(=O)=O OQZCJRJRGMMSGK-UHFFFAOYSA-M 0.000 description 2
- 208000016800 primary central nervous system lymphoma Diseases 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 108020001580 protein domains Proteins 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- OHRURASPPZQGQM-GCCNXGTGSA-N romidepsin Chemical compound O1C(=O)[C@H](C(C)C)NC(=O)C(=C/C)/NC(=O)[C@H]2CSSCC\C=C\[C@@H]1CC(=O)N[C@H](C(C)C)C(=O)N2 OHRURASPPZQGQM-GCCNXGTGSA-N 0.000 description 2
- 229960003452 romidepsin Drugs 0.000 description 2
- OHRURASPPZQGQM-UHFFFAOYSA-N romidepsin Natural products O1C(=O)C(C(C)C)NC(=O)C(=CC)NC(=O)C2CSSCCC=CC1CC(=O)NC(C(C)C)C(=O)N2 OHRURASPPZQGQM-UHFFFAOYSA-N 0.000 description 2
- 108010091666 romidepsin Proteins 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 108091029842 small nuclear ribonucleic acid Proteins 0.000 description 2
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 2
- 239000004299 sodium benzoate Substances 0.000 description 2
- 235000010234 sodium benzoate Nutrition 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical compound [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 235000003687 soy isoflavones Nutrition 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 150000005846 sugar alcohols Chemical class 0.000 description 2
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 229960004964 temozolomide Drugs 0.000 description 2
- 229950006156 teprenone Drugs 0.000 description 2
- 238000011191 terminal modification Methods 0.000 description 2
- 229960001196 thiotepa Drugs 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- PKVRCIRHQMSYJX-AIFWHQITSA-N trabectedin Chemical compound C([C@@]1(C(OC2)=O)NCCC3=C1C=C(C(=C3)O)OC)S[C@@H]1C3=C(OC(C)=O)C(C)=C4OCOC4=C3[C@H]2N2[C@@H](O)[C@H](CC=3C4=C(O)C(OC)=C(C)C=3)N(C)[C@H]4[C@@H]21 PKVRCIRHQMSYJX-AIFWHQITSA-N 0.000 description 2
- 229960000977 trabectedin Drugs 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 208000037965 uterine sarcoma Diseases 0.000 description 2
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 description 2
- 229960002066 vinorelbine Drugs 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- 229920001285 xanthan gum Polymers 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 2
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical class O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 description 1
- FPVKHBSQESCIEP-UHFFFAOYSA-N (8S)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol Natural products C1C(O)C(CO)OC1N1C(NC=NCC2O)=C2N=C1 FPVKHBSQESCIEP-UHFFFAOYSA-N 0.000 description 1
- LKJPYSCBVHEWIU-KRWDZBQOSA-N (R)-bicalutamide Chemical compound C([C@@](O)(C)C(=O)NC=1C=C(C(C#N)=CC=1)C(F)(F)F)S(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-KRWDZBQOSA-N 0.000 description 1
- HJTAZXHBEBIQQX-UHFFFAOYSA-N 1,5-bis(chloromethyl)naphthalene Chemical compound C1=CC=C2C(CCl)=CC=CC2=C1CCl HJTAZXHBEBIQQX-UHFFFAOYSA-N 0.000 description 1
- OKMWKBLSFKFYGZ-UHFFFAOYSA-N 1-behenoylglycerol Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- DGHHQBMTXTWTJV-BQAIUKQQSA-N 119413-54-6 Chemical compound Cl.C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 DGHHQBMTXTWTJV-BQAIUKQQSA-N 0.000 description 1
- QXLQZLBNPTZMRK-UHFFFAOYSA-N 2-[(dimethylamino)methyl]-1-(2,4-dimethylphenyl)prop-2-en-1-one Chemical compound CN(C)CC(=C)C(=O)C1=CC=C(C)C=C1C QXLQZLBNPTZMRK-UHFFFAOYSA-N 0.000 description 1
- RTQWWZBSTRGEAV-PKHIMPSTSA-N 2-[[(2s)-2-[bis(carboxymethyl)amino]-3-[4-(methylcarbamoylamino)phenyl]propyl]-[2-[bis(carboxymethyl)amino]propyl]amino]acetic acid Chemical compound CNC(=O)NC1=CC=C(C[C@@H](CN(CC(C)N(CC(O)=O)CC(O)=O)CC(O)=O)N(CC(O)=O)CC(O)=O)C=C1 RTQWWZBSTRGEAV-PKHIMPSTSA-N 0.000 description 1
- BSKHPKMHTQYZBB-UHFFFAOYSA-N 2-methylpyridine Chemical class CC1=CC=CC=N1 BSKHPKMHTQYZBB-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-M 3-carboxy-2,3-dihydroxypropanoate Chemical class OC(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-M 0.000 description 1
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 1
- XAUDJQYHKZQPEU-KVQBGUIXSA-N 5-aza-2'-deoxycytidine Chemical compound O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XAUDJQYHKZQPEU-KVQBGUIXSA-N 0.000 description 1
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 1
- WYWHKKSPHMUBEB-UHFFFAOYSA-N 6-Mercaptoguanine Natural products N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 244000144730 Amygdalus persica Species 0.000 description 1
- 206010061424 Anal cancer Diseases 0.000 description 1
- 244000099147 Ananas comosus Species 0.000 description 1
- 235000007119 Ananas comosus Nutrition 0.000 description 1
- 208000007860 Anus Neoplasms Diseases 0.000 description 1
- 206010073360 Appendix cancer Diseases 0.000 description 1
- 108010039627 Aprotinin Proteins 0.000 description 1
- 108010024976 Asparaginase Proteins 0.000 description 1
- 102000015790 Asparaginase Human genes 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 206010060971 Astrocytoma malignant Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010004146 Basal cell carcinoma Diseases 0.000 description 1
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 208000031648 Body Weight Changes Diseases 0.000 description 1
- 241000167854 Bourreria succulenta Species 0.000 description 1
- 206010006143 Brain stem glioma Diseases 0.000 description 1
- 238000011357 CAR T-cell therapy Methods 0.000 description 1
- 101100189913 Caenorhabditis elegans pept-1 gene Proteins 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 239000001736 Calcium glycerylphosphate Substances 0.000 description 1
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 1
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 206010007275 Carcinoid tumour Diseases 0.000 description 1
- 206010007279 Carcinoid tumour of the gastrointestinal tract Diseases 0.000 description 1
- 229940123169 Caspase inhibitor Drugs 0.000 description 1
- 229940123587 Cell cycle inhibitor Drugs 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 235000013912 Ceratonia siliqua Nutrition 0.000 description 1
- 240000008886 Ceratonia siliqua Species 0.000 description 1
- 235000019499 Citrus oil Nutrition 0.000 description 1
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 108020004394 Complementary RNA Proteins 0.000 description 1
- 244000007835 Cyamopsis tetragonoloba Species 0.000 description 1
- 102100031597 Dedicator of cytokinesis protein 2 Human genes 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical class C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- 231100000491 EC50 Toxicity 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 206010014967 Ependymoma Diseases 0.000 description 1
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 244000004281 Eucalyptus maculata Species 0.000 description 1
- 206010015548 Euthanasia Diseases 0.000 description 1
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 description 1
- 208000017259 Extragonadal germ cell tumor Diseases 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-N Formic acid Chemical class OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 1
- 235000016623 Fragaria vesca Nutrition 0.000 description 1
- 240000009088 Fragaria x ananassa Species 0.000 description 1
- 235000011363 Fragaria x ananassa Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 description 1
- 108010069236 Goserelin Proteins 0.000 description 1
- 102000001398 Granzyme Human genes 0.000 description 1
- 108060005986 Granzyme Proteins 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 101000866237 Homo sapiens Dedicator of cytokinesis protein 2 Proteins 0.000 description 1
- 101001067174 Homo sapiens Plexin-B1 Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010021042 Hypopharyngeal cancer Diseases 0.000 description 1
- 206010056305 Hypopharyngeal neoplasm Diseases 0.000 description 1
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 1
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 208000009164 Islet Cell Adenoma Diseases 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- 206010023347 Keratoacanthoma Diseases 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- 150000000996 L-ascorbic acids Chemical class 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 239000005517 L01XE01 - Imatinib Substances 0.000 description 1
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 1
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 1
- 239000005536 L01XE08 - Nilotinib Substances 0.000 description 1
- 239000003798 L01XE11 - Pazopanib Substances 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 206010023825 Laryngeal cancer Diseases 0.000 description 1
- 235000019501 Lemon oil Nutrition 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 108010000817 Leuprolide Proteins 0.000 description 1
- 206010061523 Lip and/or oral cavity cancer Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 208000006644 Malignant Fibrous Histiocytoma Diseases 0.000 description 1
- 206010025537 Malignant anorectal neoplasms Diseases 0.000 description 1
- 208000030070 Malignant epithelial tumor of ovary Diseases 0.000 description 1
- 208000032271 Malignant tumor of penis Diseases 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000220225 Malus Species 0.000 description 1
- 235000011430 Malus pumila Nutrition 0.000 description 1
- 235000015103 Malus silvestris Nutrition 0.000 description 1
- 235000010654 Melissa officinalis Nutrition 0.000 description 1
- 244000062730 Melissa officinalis Species 0.000 description 1
- 208000002030 Merkel cell carcinoma Diseases 0.000 description 1
- 206010027406 Mesothelioma Diseases 0.000 description 1
- 206010027407 Mesothelioma malignant Diseases 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 1
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 description 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
- 238000011887 Necropsy Methods 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 206010029266 Neuroendocrine carcinoma of the skin Diseases 0.000 description 1
- 101100494726 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) pep-4 gene Proteins 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 235000019502 Orange oil Nutrition 0.000 description 1
- 206010031096 Oropharyngeal cancer Diseases 0.000 description 1
- 206010057444 Oropharyngeal neoplasm Diseases 0.000 description 1
- BPQQTUXANYXVAA-UHFFFAOYSA-N Orthosilicate Chemical compound [O-][Si]([O-])([O-])[O-] BPQQTUXANYXVAA-UHFFFAOYSA-N 0.000 description 1
- 208000007571 Ovarian Epithelial Carcinoma Diseases 0.000 description 1
- 206010061328 Ovarian epithelial cancer Diseases 0.000 description 1
- 206010033268 Ovarian low malignant potential tumour Diseases 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 229940087098 Oxidase inhibitor Drugs 0.000 description 1
- 208000000821 Parathyroid Neoplasms Diseases 0.000 description 1
- 208000002471 Penile Neoplasms Diseases 0.000 description 1
- 206010034299 Penile cancer Diseases 0.000 description 1
- 108010088535 Pep-1 peptide Proteins 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 208000009565 Pharyngeal Neoplasms Diseases 0.000 description 1
- 206010034811 Pharyngeal cancer Diseases 0.000 description 1
- 229940122907 Phosphatase inhibitor Drugs 0.000 description 1
- 206010050487 Pinealoblastoma Diseases 0.000 description 1
- 208000007641 Pinealoma Diseases 0.000 description 1
- 208000007913 Pituitary Neoplasms Diseases 0.000 description 1
- 201000008199 Pleuropulmonary blastoma Diseases 0.000 description 1
- 102100034384 Plexin-B1 Human genes 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 229940079156 Proteasome inhibitor Drugs 0.000 description 1
- 235000009827 Prunus armeniaca Nutrition 0.000 description 1
- 244000018633 Prunus armeniaca Species 0.000 description 1
- 235000006040 Prunus persica var persica Nutrition 0.000 description 1
- 235000014443 Pyrus communis Nutrition 0.000 description 1
- 240000001987 Pyrus communis Species 0.000 description 1
- 108091030071 RNAI Proteins 0.000 description 1
- 102100030706 Ras-related protein Rap-1A Human genes 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 240000007651 Rubus glaucus Species 0.000 description 1
- 235000011034 Rubus glaucus Nutrition 0.000 description 1
- 235000009122 Rubus idaeus Nutrition 0.000 description 1
- 208000004337 Salivary Gland Neoplasms Diseases 0.000 description 1
- 206010061934 Salivary gland cancer Diseases 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 235000015125 Sterculia urens Nutrition 0.000 description 1
- 240000001058 Sterculia urens Species 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 235000006092 Stevia rebaudiana Nutrition 0.000 description 1
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 description 1
- 239000004376 Sucralose Substances 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 108091046869 Telomeric non-coding RNA Proteins 0.000 description 1
- CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 description 1
- 206010043515 Throat cancer Diseases 0.000 description 1
- 201000009365 Thymic carcinoma Diseases 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 206010062129 Tongue neoplasm Diseases 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 108020004566 Transfer RNA Proteins 0.000 description 1
- 206010044407 Transitional cell cancer of the renal pelvis and ureter Diseases 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical class OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical class CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- 241000219793 Trifolium Species 0.000 description 1
- 208000015778 Undifferentiated pleomorphic sarcoma Diseases 0.000 description 1
- 206010046431 Urethral cancer Diseases 0.000 description 1
- 206010046458 Urethral neoplasms Diseases 0.000 description 1
- JARYYMUOCXVXNK-UHFFFAOYSA-N Validamycin A Natural products OC1C(O)C(OC2C(C(O)C(O)C(CO)O2)O)C(CO)CC1NC1C=C(CO)C(O)C(O)C1O JARYYMUOCXVXNK-UHFFFAOYSA-N 0.000 description 1
- 235000009499 Vanilla fragrans Nutrition 0.000 description 1
- 244000263375 Vanilla tahitensis Species 0.000 description 1
- 235000012036 Vanilla tahitensis Nutrition 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- 206010047741 Vulval cancer Diseases 0.000 description 1
- 208000004354 Vulvar Neoplasms Diseases 0.000 description 1
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 description 1
- 208000008383 Wilms tumor Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- GZOSMCIZMLWJML-VJLLXTKPSA-N abiraterone Chemical compound C([C@H]1[C@H]2[C@@H]([C@]3(CC[C@H](O)CC3=CC2)C)CC[C@@]11C)C=C1C1=CC=CN=C1 GZOSMCIZMLWJML-VJLLXTKPSA-N 0.000 description 1
- 229960000853 abiraterone Drugs 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 108010052004 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide Proteins 0.000 description 1
- 229960004308 acetylcysteine Drugs 0.000 description 1
- 208000009621 actinic keratosis Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 208000020990 adrenal cortex carcinoma Diseases 0.000 description 1
- 208000007128 adrenocortical carcinoma Diseases 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229960000548 alemtuzumab Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- 229940063655 aluminum stearate Drugs 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 229960004050 aminobenzoic acid Drugs 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 210000002255 anal canal Anatomy 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 229940121369 angiogenesis inhibitor Drugs 0.000 description 1
- 239000010617 anise oil Substances 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 201000011165 anus cancer Diseases 0.000 description 1
- HJBWBFZLDZWPHF-UHFFFAOYSA-N apalutamide Chemical compound C1=C(F)C(C(=O)NC)=CC=C1N1C2(CCC2)C(=O)N(C=2C=C(C(C#N)=NC=2)C(F)(F)F)C1=S HJBWBFZLDZWPHF-UHFFFAOYSA-N 0.000 description 1
- 229950007511 apalutamide Drugs 0.000 description 1
- 208000021780 appendiceal neoplasm Diseases 0.000 description 1
- 239000000010 aprotic solvent Substances 0.000 description 1
- 229960004405 aprotinin Drugs 0.000 description 1
- 239000011260 aqueous acid Substances 0.000 description 1
- GOLCXWYRSKYTSP-UHFFFAOYSA-N arsenic trioxide Inorganic materials O1[As]2O[As]1O2 GOLCXWYRSKYTSP-UHFFFAOYSA-N 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 229960003272 asparaginase Drugs 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-M asparaginate Chemical compound [O-]C(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-M 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 150000001509 aspartic acid derivatives Chemical class 0.000 description 1
- 229960003852 atezolizumab Drugs 0.000 description 1
- 229950002916 avelumab Drugs 0.000 description 1
- 229960002756 azacitidine Drugs 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 229960004217 benzyl alcohol Drugs 0.000 description 1
- BJJPNOGMLLUCER-KUTQPOQPSA-N benzyl n-[(2s)-1-[[(2s)-1-[[(2s,3r,4r,5s)-3,4-dihydroxy-5-[[(2s)-3-methyl-2-[[(2s)-2-(phenylmethoxycarbonylamino)propanoyl]amino]butanoyl]amino]-1,6-diphenylhexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxopropan-2-yl]carbamate Chemical compound N([C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)[C@@H](O)[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)OCC=1C=CC=CC=1)C(C)C)C(=O)OCC1=CC=CC=C1 BJJPNOGMLLUCER-KUTQPOQPSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 229960000397 bevacizumab Drugs 0.000 description 1
- 229960000997 bicalutamide Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 230000004579 body weight change Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 208000012172 borderline epithelial tumor of ovary Diseases 0.000 description 1
- 150000001642 boronic acid derivatives Chemical class 0.000 description 1
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 description 1
- 229960001467 bortezomib Drugs 0.000 description 1
- 201000002143 bronchus adenoma Diseases 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- TVFDJXOCXUVLDH-UHFFFAOYSA-N caesium atom Chemical class [Cs] TVFDJXOCXUVLDH-UHFFFAOYSA-N 0.000 description 1
- VSGNNIFQASZAOI-UHFFFAOYSA-L calcium acetate Chemical compound [Ca+2].CC([O-])=O.CC([O-])=O VSGNNIFQASZAOI-UHFFFAOYSA-L 0.000 description 1
- 239000001639 calcium acetate Substances 0.000 description 1
- 235000011092 calcium acetate Nutrition 0.000 description 1
- 229960005147 calcium acetate Drugs 0.000 description 1
- NKWPZUCBCARRDP-UHFFFAOYSA-L calcium bicarbonate Chemical compound [Ca+2].OC([O-])=O.OC([O-])=O NKWPZUCBCARRDP-UHFFFAOYSA-L 0.000 description 1
- 229910000020 calcium bicarbonate Inorganic materials 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- UHHRFSOMMCWGSO-UHFFFAOYSA-L calcium glycerophosphate Chemical compound [Ca+2].OCC(CO)OP([O-])([O-])=O UHHRFSOMMCWGSO-UHFFFAOYSA-L 0.000 description 1
- 229940095618 calcium glycerophosphate Drugs 0.000 description 1
- 235000019299 calcium glycerylphosphate Nutrition 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 239000001175 calcium sulphate Substances 0.000 description 1
- 235000011132 calcium sulphate Nutrition 0.000 description 1
- 229940022399 cancer vaccine Drugs 0.000 description 1
- 238000009566 cancer vaccine Methods 0.000 description 1
- 229960004117 capecitabine Drugs 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 125000005588 carbonic acid salt group Chemical group 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 238000000423 cell based assay Methods 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 238000012054 celltiter-glo Methods 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 201000007455 central nervous system cancer Diseases 0.000 description 1
- YMNCVRSYJBNGLD-KURKYZTESA-N cephalotaxine Chemical compound C([C@@]12C=C([C@H]([C@H]2C2=C3)O)OC)CCN1CCC2=CC1=C3OCO1 YMNCVRSYJBNGLD-KURKYZTESA-N 0.000 description 1
- 201000007335 cerebellar astrocytoma Diseases 0.000 description 1
- 208000030239 cerebral astrocytoma Diseases 0.000 description 1
- 229960005395 cetuximab Drugs 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 235000019693 cherries Nutrition 0.000 description 1
- 201000004677 childhood cerebellar astrocytic neoplasm Diseases 0.000 description 1
- 201000008522 childhood cerebral astrocytoma Diseases 0.000 description 1
- 208000011654 childhood malignant neoplasm Diseases 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 239000010630 cinnamon oil Substances 0.000 description 1
- 239000010500 citrus oil Substances 0.000 description 1
- 229960002436 cladribine Drugs 0.000 description 1
- 229960000928 clofarabine Drugs 0.000 description 1
- WDDPHFBMKLOVOX-AYQXTPAHSA-N clofarabine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F WDDPHFBMKLOVOX-AYQXTPAHSA-N 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000005056 compaction Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 description 1
- 208000017763 cutaneous neuroendocrine carcinoma Diseases 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 229960002433 cysteine Drugs 0.000 description 1
- 229960000684 cytarabine Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 229950001379 darolutamide Drugs 0.000 description 1
- 229960000975 daunorubicin Drugs 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 229960003603 decitabine Drugs 0.000 description 1
- 229960002272 degarelix Drugs 0.000 description 1
- MEUCPCLKGZSHTA-XYAYPHGZSA-N degarelix Chemical compound C([C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CC=1C=CC(NC(=O)[C@H]2NC(=O)NC(=O)C2)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(NC(N)=O)C=C1 MEUCPCLKGZSHTA-XYAYPHGZSA-N 0.000 description 1
- 229960002923 denileukin diftitox Drugs 0.000 description 1
- 108010017271 denileukin diftitox Proteins 0.000 description 1
- 229960001251 denosumab Drugs 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 229940120124 dichloroacetate Drugs 0.000 description 1
- JXTHNDFMNIQAHM-UHFFFAOYSA-N dichloroacetic acid Chemical compound OC(=O)C(Cl)Cl JXTHNDFMNIQAHM-UHFFFAOYSA-N 0.000 description 1
- QGGZBXOADPVUPN-UHFFFAOYSA-N dihydrochalcone Chemical class C=1C=CC=CC=1C(=O)CCC1=CC=CC=C1 QGGZBXOADPVUPN-UHFFFAOYSA-N 0.000 description 1
- MUCZHBLJLSDCSD-UHFFFAOYSA-N diisopropyl fluorophosphate Chemical compound CC(C)OP(F)(=O)OC(C)C MUCZHBLJLSDCSD-UHFFFAOYSA-N 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- FSBVERYRVPGNGG-UHFFFAOYSA-N dimagnesium dioxido-bis[[oxido(oxo)silyl]oxy]silane hydrate Chemical compound O.[Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O FSBVERYRVPGNGG-UHFFFAOYSA-N 0.000 description 1
- AMTWCFIAVKBGOD-UHFFFAOYSA-N dioxosilane;methoxy-dimethyl-trimethylsilyloxysilane Chemical compound O=[Si]=O.CO[Si](C)(C)O[Si](C)(C)C AMTWCFIAVKBGOD-UHFFFAOYSA-N 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical class CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical class CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 229950009791 durvalumab Drugs 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000002357 endometrial effect Effects 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940095399 enema Drugs 0.000 description 1
- 229960004671 enzalutamide Drugs 0.000 description 1
- WXCXUHSOUPDCQV-UHFFFAOYSA-N enzalutamide Chemical compound C1=C(F)C(C(=O)NC)=CC=C1N1C(C)(C)C(=O)N(C=2C=C(C(C#N)=CC=2)C(F)(F)F)C1=S WXCXUHSOUPDCQV-UHFFFAOYSA-N 0.000 description 1
- 229960001904 epirubicin Drugs 0.000 description 1
- 229960003649 eribulin Drugs 0.000 description 1
- UFNVPOGXISZXJD-XJPMSQCNSA-N eribulin Chemical compound C([C@H]1CC[C@@H]2O[C@@H]3[C@H]4O[C@H]5C[C@](O[C@H]4[C@H]2O1)(O[C@@H]53)CC[C@@H]1O[C@H](C(C1)=C)CC1)C(=O)C[C@@H]2[C@@H](OC)[C@@H](C[C@H](O)CN)O[C@H]2C[C@@H]2C(=C)[C@H](C)C[C@H]1O2 UFNVPOGXISZXJD-XJPMSQCNSA-N 0.000 description 1
- 229960001433 erlotinib Drugs 0.000 description 1
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 239000000686 essence Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 150000002169 ethanolamines Chemical class 0.000 description 1
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 235000010944 ethyl methyl cellulose Nutrition 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960005167 everolimus Drugs 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 210000001808 exosome Anatomy 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 238000011347 external beam therapy Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 208000024519 eye neoplasm Diseases 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 229960000390 fludarabine Drugs 0.000 description 1
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 1
- 238000002594 fluoroscopy Methods 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 229960005051 fluostigmine Drugs 0.000 description 1
- 229960002074 flutamide Drugs 0.000 description 1
- MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229960002737 fructose Drugs 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 201000010175 gallbladder cancer Diseases 0.000 description 1
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 description 1
- 229960002584 gefitinib Drugs 0.000 description 1
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 229960005277 gemcitabine Drugs 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- 229960003297 gemtuzumab ozogamicin Drugs 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 230000009368 gene silencing by RNA Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229960001031 glucose Drugs 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 235000003969 glutathione Nutrition 0.000 description 1
- 229940049654 glyceryl behenate Drugs 0.000 description 1
- FETSQPAGYOVAQU-UHFFFAOYSA-N glyceryl palmitostearate Chemical compound OCC(O)CO.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O FETSQPAGYOVAQU-UHFFFAOYSA-N 0.000 description 1
- 229940046813 glyceryl palmitostearate Drugs 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 229960002913 goserelin Drugs 0.000 description 1
- 239000010651 grapefruit oil Substances 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 238000001631 haemodialysis Methods 0.000 description 1
- 201000009277 hairy cell leukemia Diseases 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 230000000322 hemodialysis Effects 0.000 description 1
- 208000029824 high grade glioma Diseases 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 201000006866 hypopharynx cancer Diseases 0.000 description 1
- 230000002267 hypothalamic effect Effects 0.000 description 1
- 229960001001 ibritumomab tiuxetan Drugs 0.000 description 1
- 229960000908 idarubicin Drugs 0.000 description 1
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 1
- 229960002411 imatinib Drugs 0.000 description 1
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 description 1
- 238000010324 immunological assay Methods 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000006882 induction of apoptosis Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 238000000185 intracerebroventricular administration Methods 0.000 description 1
- 208000014899 intrahepatic bile duct cancer Diseases 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000007919 intrasynovial administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 229960004903 invert sugar Drugs 0.000 description 1
- 229960005386 ipilimumab Drugs 0.000 description 1
- 229960004768 irinotecan Drugs 0.000 description 1
- GURKHSYORGJETM-WAQYZQTGSA-N irinotecan hydrochloride (anhydrous) Chemical compound Cl.C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 GURKHSYORGJETM-WAQYZQTGSA-N 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- FABUFPQFXZVHFB-CFWQTKTJSA-N ixabepilone Chemical compound C/C([C@@H]1C[C@@H]2O[C@]2(C)CCC[C@@H]([C@@H]([C@H](C)C(=O)C(C)(C)[C@H](O)CC(=O)N1)O)C)=C\C1=CSC(C)=N1 FABUFPQFXZVHFB-CFWQTKTJSA-N 0.000 description 1
- 229960002014 ixabepilone Drugs 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 229960004125 ketoconazole Drugs 0.000 description 1
- 210000000244 kidney pelvis Anatomy 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical class CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 1
- 239000000832 lactitol Substances 0.000 description 1
- 235000010448 lactitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 description 1
- 229960003451 lactitol Drugs 0.000 description 1
- 206010023841 laryngeal neoplasm Diseases 0.000 description 1
- 239000010501 lemon oil Substances 0.000 description 1
- 229960003881 letrozole Drugs 0.000 description 1
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 description 1
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 1
- 229960004338 leuprorelin Drugs 0.000 description 1
- 229940059904 light mineral oil Drugs 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 208000019420 lymphoid neoplasm Diseases 0.000 description 1
- 201000000564 macroglobulinemia Diseases 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 235000001055 magnesium Nutrition 0.000 description 1
- QWDJLDTYWNBUKE-UHFFFAOYSA-L magnesium bicarbonate Chemical compound [Mg+2].OC([O-])=O.OC([O-])=O QWDJLDTYWNBUKE-UHFFFAOYSA-L 0.000 description 1
- 239000002370 magnesium bicarbonate Substances 0.000 description 1
- 229910000022 magnesium bicarbonate Inorganic materials 0.000 description 1
- 235000014824 magnesium bicarbonate Nutrition 0.000 description 1
- 229960000816 magnesium hydroxide Drugs 0.000 description 1
- OVGXLJDWSLQDRT-UHFFFAOYSA-L magnesium lactate Chemical compound [Mg+2].CC(O)C([O-])=O.CC(O)C([O-])=O OVGXLJDWSLQDRT-UHFFFAOYSA-L 0.000 description 1
- 239000000626 magnesium lactate Substances 0.000 description 1
- 235000015229 magnesium lactate Nutrition 0.000 description 1
- 229960004658 magnesium lactate Drugs 0.000 description 1
- 229940037627 magnesium lauryl sulfate Drugs 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 229910052919 magnesium silicate Inorganic materials 0.000 description 1
- 235000019792 magnesium silicate Nutrition 0.000 description 1
- 229940091250 magnesium supplement Drugs 0.000 description 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 150000002689 maleic acids Chemical class 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 208000030883 malignant astrocytoma Diseases 0.000 description 1
- 201000011614 malignant glioma Diseases 0.000 description 1
- 208000026045 malignant tumor of parathyroid gland Diseases 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 229960002160 maltose Drugs 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
- 229960004616 medroxyprogesterone Drugs 0.000 description 1
- FRQMUZJSZHZSGN-HBNHAYAOSA-N medroxyprogesterone Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](O)(C(C)=O)CC[C@H]21 FRQMUZJSZHZSGN-HBNHAYAOSA-N 0.000 description 1
- 229960001786 megestrol Drugs 0.000 description 1
- RQZAXGRLVPAYTJ-GQFGMJRRSA-N megestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 description 1
- 239000001525 mentha piperita l. herb oil Substances 0.000 description 1
- 229960001428 mercaptopurine Drugs 0.000 description 1
- 210000000716 merkel cell Anatomy 0.000 description 1
- 229910001463 metal phosphate Inorganic materials 0.000 description 1
- 208000037970 metastatic squamous neck cancer Diseases 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 229960004452 methionine Drugs 0.000 description 1
- 235000006109 methionine Nutrition 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 1
- 229920003087 methylethyl cellulose Polymers 0.000 description 1
- 229960004584 methylprednisolone Drugs 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 229960001156 mitoxantrone Drugs 0.000 description 1
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 206010051747 multiple endocrine neoplasia Diseases 0.000 description 1
- 208000017869 myelodysplastic/myeloproliferative disease Diseases 0.000 description 1
- BLIJXOOIHRSQRB-PXYINDEMSA-N n-[(2s)-1-[3-(3-chloro-4-cyanophenyl)pyrazol-1-yl]propan-2-yl]-5-(1-hydroxyethyl)-1h-pyrazole-3-carboxamide Chemical compound C([C@H](C)NC(=O)C=1NN=C(C=1)C(C)O)N(N=1)C=CC=1C1=CC=C(C#N)C(Cl)=C1 BLIJXOOIHRSQRB-PXYINDEMSA-N 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 208000018795 nasal cavity and paranasal sinus carcinoma Diseases 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 229960000801 nelarabine Drugs 0.000 description 1
- IXOXBSCIXZEQEQ-UHTZMRCNSA-N nelarabine Chemical compound C1=NC=2C(OC)=NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O IXOXBSCIXZEQEQ-UHTZMRCNSA-N 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 201000011682 nervous system cancer Diseases 0.000 description 1
- 238000010984 neurological examination Methods 0.000 description 1
- HHZIURLSWUIHRB-UHFFFAOYSA-N nilotinib Chemical compound C1=NC(C)=CN1C1=CC(NC(=O)C=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)=CC(C(F)(F)F)=C1 HHZIURLSWUIHRB-UHFFFAOYSA-N 0.000 description 1
- 229960001346 nilotinib Drugs 0.000 description 1
- 229960002653 nilutamide Drugs 0.000 description 1
- XWXYUMMDTVBTOU-UHFFFAOYSA-N nilutamide Chemical compound O=C1C(C)(C)NC(=O)N1C1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 XWXYUMMDTVBTOU-UHFFFAOYSA-N 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 229960003301 nivolumab Drugs 0.000 description 1
- 108091027963 non-coding RNA Proteins 0.000 description 1
- 102000042567 non-coding RNA Human genes 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 229960002450 ofatumumab Drugs 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229940005619 omacetaxine Drugs 0.000 description 1
- 244000309459 oncolytic virus Species 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 201000005443 oral cavity cancer Diseases 0.000 description 1
- 239000010502 orange oil Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 201000006958 oropharynx cancer Diseases 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 208000021284 ovarian germ cell tumor Diseases 0.000 description 1
- 150000002942 palmitic acid derivatives Chemical class 0.000 description 1
- 208000022102 pancreatic neuroendocrine neoplasm Diseases 0.000 description 1
- 229960001972 panitumumab Drugs 0.000 description 1
- 208000003154 papilloma Diseases 0.000 description 1
- 229960000639 pazopanib Drugs 0.000 description 1
- CUIHSIWYWATEQL-UHFFFAOYSA-N pazopanib Chemical compound C1=CC2=C(C)N(C)N=C2C=C1N(C)C(N=1)=CC=NC=1NC1=CC=C(C)C(S(N)(=O)=O)=C1 CUIHSIWYWATEQL-UHFFFAOYSA-N 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 229960001744 pegaspargase Drugs 0.000 description 1
- 108010001564 pegaspargase Proteins 0.000 description 1
- 229960002621 pembrolizumab Drugs 0.000 description 1
- 229960005079 pemetrexed Drugs 0.000 description 1
- QOFFJEBXNKRSPX-ZDUSSCGKSA-N pemetrexed Chemical compound C1=N[C]2NC(N)=NC(=O)C2=C1CCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 QOFFJEBXNKRSPX-ZDUSSCGKSA-N 0.000 description 1
- 229960002340 pentostatin Drugs 0.000 description 1
- FPVKHBSQESCIEP-JQCXWYLXSA-N pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 description 1
- 235000019477 peppermint oil Nutrition 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 230000003239 periodontal effect Effects 0.000 description 1
- 239000008024 pharmaceutical diluent Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 208000028591 pheochromocytoma Diseases 0.000 description 1
- 150000003016 phosphoric acids Chemical class 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 201000003113 pineoblastoma Diseases 0.000 description 1
- 208000010916 pituitary tumor Diseases 0.000 description 1
- 208000010626 plasma cell neoplasm Diseases 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 238000002600 positron emission tomography Methods 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- 229940094025 potassium bicarbonate Drugs 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 229940099402 potassium metaphosphate Drugs 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 235000019828 potassium polyphosphate Nutrition 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 229960000214 pralatrexate Drugs 0.000 description 1
- OGSBUKJUDHAQEA-WMCAAGNKSA-N pralatrexate Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CC(CC#C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OGSBUKJUDHAQEA-WMCAAGNKSA-N 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 1
- 229960000624 procarbazine Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000473 propyl gallate Substances 0.000 description 1
- 235000010388 propyl gallate Nutrition 0.000 description 1
- 229940075579 propyl gallate Drugs 0.000 description 1
- 239000003207 proteasome inhibitor Substances 0.000 description 1
- 150000003222 pyridines Chemical class 0.000 description 1
- 229960004622 raloxifene Drugs 0.000 description 1
- GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 description 1
- 108010036805 rap1 GTP-Binding Proteins Proteins 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 208000030859 renal pelvis/ureter urothelial carcinoma Diseases 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 229960004641 rituximab Drugs 0.000 description 1
- 102200006532 rs112445441 Human genes 0.000 description 1
- 102200006537 rs121913529 Human genes 0.000 description 1
- 102200006540 rs121913530 Human genes 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 229940083037 simethicone Drugs 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 201000008261 skin carcinoma Diseases 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 201000002314 small intestine cancer Diseases 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- HELHAJAZNSDZJO-OLXYHTOASA-L sodium L-tartrate Chemical compound [Na+].[Na+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O HELHAJAZNSDZJO-OLXYHTOASA-L 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 235000011083 sodium citrates Nutrition 0.000 description 1
- FQENQNTWSFEDLI-UHFFFAOYSA-J sodium diphosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 description 1
- 239000011775 sodium fluoride Substances 0.000 description 1
- 235000013024 sodium fluoride Nutrition 0.000 description 1
- 235000019830 sodium polyphosphate Nutrition 0.000 description 1
- 229940048086 sodium pyrophosphate Drugs 0.000 description 1
- 229940045902 sodium stearyl fumarate Drugs 0.000 description 1
- 229940001482 sodium sulfite Drugs 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 239000001433 sodium tartrate Substances 0.000 description 1
- 229960002167 sodium tartrate Drugs 0.000 description 1
- 235000011004 sodium tartrates Nutrition 0.000 description 1
- IVDHYUQIDRJSTI-UHFFFAOYSA-N sorafenib tosylate Chemical compound [H+].CC1=CC=C(S([O-])(=O)=O)C=C1.C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 IVDHYUQIDRJSTI-UHFFFAOYSA-N 0.000 description 1
- 229960000487 sorafenib tosylate Drugs 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 229940013618 stevioside Drugs 0.000 description 1
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 description 1
- 235000019202 steviosides Nutrition 0.000 description 1
- 229960001052 streptozocin Drugs 0.000 description 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 235000019408 sucralose Nutrition 0.000 description 1
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 229960000235 temsirolimus Drugs 0.000 description 1
- QFJCIRLUMZQUOT-UHFFFAOYSA-N temsirolimus Natural products C1CC(O)C(OC)CC1CC(C)C1OC(=O)C2CCCCN2C(=O)C(=O)C(O)(O2)C(C)CCC2CC(OC)C(C)=CC=CC=CC(C)CC(C)C(=O)C(OC)C(O)C(C)=CC(C)C(=O)C1 QFJCIRLUMZQUOT-UHFFFAOYSA-N 0.000 description 1
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 1
- 229960001278 teniposide Drugs 0.000 description 1
- RYCLIXPGLDDLTM-UHFFFAOYSA-J tetrapotassium;phosphonato phosphate Chemical compound [K+].[K+].[K+].[K+].[O-]P([O-])(=O)OP([O-])([O-])=O RYCLIXPGLDDLTM-UHFFFAOYSA-J 0.000 description 1
- 235000019818 tetrasodium diphosphate Nutrition 0.000 description 1
- 239000001577 tetrasodium phosphonato phosphate Substances 0.000 description 1
- 238000005382 thermal cycling Methods 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 229940098465 tincture Drugs 0.000 description 1
- 229960003087 tioguanine Drugs 0.000 description 1
- MNRILEROXIRVNJ-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=NC=N[C]21 MNRILEROXIRVNJ-UHFFFAOYSA-N 0.000 description 1
- QQHMKNYGKVVGCZ-UHFFFAOYSA-N tipiracil Chemical compound N1C(=O)NC(=O)C(Cl)=C1CN1C(=N)CCC1 QQHMKNYGKVVGCZ-UHFFFAOYSA-N 0.000 description 1
- 229960002952 tipiracil Drugs 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 229960000303 topotecan Drugs 0.000 description 1
- 229960005026 toremifene Drugs 0.000 description 1
- XFCLJVABOIYOMF-QPLCGJKRSA-N toremifene Chemical compound C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 XFCLJVABOIYOMF-QPLCGJKRSA-N 0.000 description 1
- 229960005267 tositumomab Drugs 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 206010044412 transitional cell carcinoma Diseases 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000001296 transplacental effect Effects 0.000 description 1
- 229960000575 trastuzumab Drugs 0.000 description 1
- 229960003962 trifluridine Drugs 0.000 description 1
- VSQQQLOSPVPRAZ-RRKCRQDMSA-N trifluridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(C(F)(F)F)=C1 VSQQQLOSPVPRAZ-RRKCRQDMSA-N 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 229910000404 tripotassium phosphate Inorganic materials 0.000 description 1
- 235000019798 tripotassium phosphate Nutrition 0.000 description 1
- 229910000406 trisodium phosphate Inorganic materials 0.000 description 1
- 235000019801 trisodium phosphate Nutrition 0.000 description 1
- IHIXIJGXTJIKRB-UHFFFAOYSA-N trisodium vanadate Chemical compound [Na+].[Na+].[Na+].[O-][V]([O-])([O-])=O IHIXIJGXTJIKRB-UHFFFAOYSA-N 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 210000000626 ureter Anatomy 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 201000009825 uterine corpus cancer Diseases 0.000 description 1
- 206010046885 vaginal cancer Diseases 0.000 description 1
- 208000013139 vaginal neoplasm Diseases 0.000 description 1
- JARYYMUOCXVXNK-CSLFJTBJSA-N validamycin A Chemical compound N([C@H]1C[C@@H]([C@H]([C@H](O)[C@H]1O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)CO)[C@H]1C=C(CO)[C@@H](O)[C@H](O)[C@H]1O JARYYMUOCXVXNK-CSLFJTBJSA-N 0.000 description 1
- 229960000653 valrubicin Drugs 0.000 description 1
- ZOCKGBMQLCSHFP-KQRAQHLDSA-N valrubicin Chemical compound O([C@H]1C[C@](CC2=C(O)C=3C(=O)C4=CC=CC(OC)=C4C(=O)C=3C(O)=C21)(O)C(=O)COC(=O)CCCC)[C@H]1C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O1 ZOCKGBMQLCSHFP-KQRAQHLDSA-N 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- 210000000239 visual pathway Anatomy 0.000 description 1
- 230000004400 visual pathway Effects 0.000 description 1
- 229960000237 vorinostat Drugs 0.000 description 1
- WAEXFXRVDQXREF-UHFFFAOYSA-N vorinostat Chemical compound ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1 WAEXFXRVDQXREF-UHFFFAOYSA-N 0.000 description 1
- 201000005102 vulva cancer Diseases 0.000 description 1
- 229940124024 weight reducing agent Drugs 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 229940100445 wheat starch Drugs 0.000 description 1
- 239000009637 wintergreen oil Substances 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
Definitions
- an engineered peptide has at least about 84% sequence identity to any one of SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3. In some embodiments, the engineered peptide has a length of from about 10 amino acids to about 40 amino acids or of from about 10 amino acids to 39 amino acids. In some embodiments, the engineered peptide has a length of at most 15 amino acids. In some embodiments, the engineered peptide has a length of 13 amino acids or 14 amino acids. In some embodiments, the engineered peptide has the amino acid sequence of any one of SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3.
- the engineered peptide adopts an alpha helical structure at physiological salt concentrations and physiological temperature.
- the engineered peptide is a stapled peptide
- the stapled peptide is an (i, i + 3) stapled peptide or an (i, i + 7) stapled peptide.
- the stapled peptide is an (i, i + 7) stapled peptide.
- the (i) residue of the stapled peptide is R-octenylalanine (R8), S-octenylalanine (S8), R-pentylalanine (R5), or S-pentenylalanine (S5).
- the (i+3) residue or the (i+7) residue of the stapled peptide is R-octenylalanine (R8), S-octenylalanine (S 8), R- pentylalanine (R5), or S-pentenylalanine (S5).
- the (i) residue of the stapled peptide is at amino acid 3 or amino acid 4 of any one of SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3
- the (i) residue of the stapled peptide is R-octenylalanine (R8) and the (i+3) residue of the stapled peptide is S-pentenylalanine (S5).
- the (i) residue of the stapled peptide is R-octenylalanine (R8) and the (i+7) residue of the stapled peptide is S-pentenylalanine (S5).
- the engineered peptide has at least 84% sequence identity to any one of SEQ ID NO: 4, SEQ ID NO: 5, or SEQ ID NO: 6.
- the engineered peptide has the amino acid sequence of any one of SEQ ID NO: 4, SEQ ID NO: 5, or SEQ ID NO: 6.
- the engineered peptide has an IC50 of from about 1 nM to about 50 pM against a cancer cell line, as determined in an in vitro assay.
- an engineered peptide comprises (a) at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to a contiguous portion of an RBI peptide, a CHEK2 peptide, an MDM2 peptide, a RAFI peptide, an RRAS2 peptide, a RAC1 peptide, a PIK3Ca peptide, a PIK3R1 peptide, a VHL peptide, a DDX3X peptide, or a CTNNB1 peptide; and (b) a length of from about 10 ammo acids to about 20 ammo acids; wherein the engineered peptide has an IC50 of from about 1 nM to about 50 pM against a cancer cell line, as determined in an in vitro assay.
- the engineered peptide is a salt of an engineered peptide.
- the salt of the engineered peptide is an acetate salt or a trifluoroacetate (TFA) salt.
- the engineered peptide is a stapled peptide.
- the stapled peptide is an (i, i + 3) stapled peptide or an (i, i + 7) stapled peptide.
- the stapled peptide is an (i, i + 7) stapled peptide.
- a pharmaceutical composition that comprises the engineered peptide of any one of the embodiments described herein and a pharmaceutically acceptable excipient, diluent, or carrier.
- the pharmaceutical composition is in unit dose form.
- the engineered peptide in unit dose form is about 5 mg/kg, about 15 mg/kg, about 50 mg/kg, about 55 mg/kg, about 60 mg/kg, about 65 mg/kg, about 75 mg/kg, about 100 mg/kg, about 150 mg/kg, about 200 mg/kg, about 240 mg/kg, or about 300 mg/kg.
- a method of treating a disease or condition in a subject in need thereof comprises administering to the subject the engineered peptide of any one of the embodiments disclosed herein or the pharmaceutical composition of any one of the embodiments disclosed herein, wherein the administering is sufficient to treat the disease or condition.
- the disease or condition is a cancer.
- the cancer comprises a KRAS mutation.
- the KRAS mutation comprises a G12V mutation, a G12C mutation, or a G12D mutation of KRAS.
- the cancer is a melanoma, a colorectal cancer, a pancreatic cancer, a bladder cancer, a breast cancer, a triple negative breast cancer, an ovarian cancer, a juvenile myelomonocytic leukemia (JMML), a hematologic malignancy, a cholangiocarcmoma, a uterine cancer, a cervical cancer, a testicular cancer, a lung cancer, or any combination thereof.
- the administering is parenteral or intra-tumoral.
- the subject in need thereof is a mammal.
- the mammal is a human, non-human primate, dog, cat, hamster, guinea pig, rat, or mouse.
- the method further comprises administering a second therapy to the subject.
- the second therapy comprises a chemotherapy, a radiation therapy, a hormone therapy, a hyperthermia therapy, an immunotherapy, a photodynamic therapy, a stem cell therapy, a surgery, a targeted therapy, or any combination thereof.
- the second therapy is administered concurrently or consecutively with the engineered peptide or the pharmaceutical composition.
- a method of making engineered therapeutic peptides for treatment of cancer comprises (a) selecting portions of a candidate polypeptide that display cellular toxicity, as determined in an in vitro assay; (b) curating the portions of the candidate polypeptides to select a subset of the portions of the candidate polypeptide that adopt an alpha helical structure, as determined by x-ray crystallography; (c) modifying the subset using mutagenesis to generate engineered therapeutic peptides, and (d) selecting engineered therapeutic peptides having an IC50 of from about 1 nM to about 50 pM against a cancer cell line, as determined in an in vitro assay.
- the modifying of (c) further comprising making an (i, i+7) staple within the engineered therapeutic peptides.
- a method of inhibiting cell proliferation in a cancerous cell comprises administering to the cancerous cell the engineered peptide of any one of the embodiments disclosed herein or the pharmaceutical composition of any one of the embodiments disclosed herein, wherein the administering is sufficient to inhibit proliferation of the cancerous cell.
- FIG. 1 depicts peptide fragments count distribution for fitness score and Log2FC values after filtering for alpha helical regions, crystal structure availability and interacting residue inclusion. Each count is a 40-mer peptide from the fitness screen that meets the filtering requirements.
- FIG 2 depicts a workflow diagram for in silico identification of mutations that improve binding affinity between a 40-mer peptide and an interacting protein, and subsequent screening.
- FIG. 3A depicts a heatmap of computational alanine scanning results of identified alpha helical 40-mer peptides (5 out of 11) binding to interacting proteins.
- the Protein Data Bank Identifier (PDB ID) followed by the interacting protein is labeled on the right side.
- the amino acid sequence of the 40-mer peptide is labeled on the bottom and the corresponding computational alanine binding energy with the interacting protein, delta-delta-G (ddG), is plotted. The higher the value is, the more likely that particular residue is important for binding.
- 3B is a heatmap of the point mutation scanning result of RAF1 78 binding to RAP1 A (PDB ID: 1C1Y).
- the residues for conducting site saturation mutagenesis are identified via the results from computational scanning and is labelled on the bottom.
- the mutated amino acids are labelled to the left and the ddG of the final mutated structure is plotted. The more negative the value is, the higher the binding affinity is between the 40-mer peptide-interacting protein complex.
- the circled residue is A85K and has been identified as increasing binding affinity between RAFI and HRAS.
- FIG. 4 depicts the structure of the interaction between RAFI and interacting proteins (RAP1 A (top) and HRAS (bottom)).
- FIG. 5A and 5B are zoomed in structures of the interaction between RAFI and interacting proteins (RAP1A (top) and HRAS (bottom)) (FIG. 5A) or RAC1 and interacting proteins (PREXI (top), DOCK2 (middle), and PLXNB1 (bottom)) (FIG. 5B) .
- FIG. 6A-6B shows dose response curves of engineered peptides (SEQ ID NO: 4 peptide, SEQ ID NO: 5 peptide, or SEQ ID NO: 6 peptide) on MDA-MB-231 or A375 cell survival at 24- hours (FIG. 6A) and 48-hours (FIG. 6B) post-treatment.
- TAT-FLAG is a negative control.
- FIG. 7A-7B depict starvation potentiates the anti-proliferative effect of the engineered peptide, SEQ ID NO: 4 peptide.
- FIG. 7B shows quantification of cell viability measured by the colorimetric assay Cell Counting Kit-8 (CCK8).
- FIGS. 8A-8B show tumor experiment timeline and results.
- FIG. 8A shows a timeline for tumor experiments.
- FIG. 8B depicts the change in tumor volume observed after injection of SEQ ID NO: 4 peptide or a Flag control.
- FIGS. 9A-9C show tumor experiment timeline and results.
- FIG. 9A shows a timeline for tumor experiments.
- FIG. 9B depicts the change in tumor volume observed after injection of SEQ ID NO: 4 peptide or a Flag control.
- FIG. 9C shows tumor size after the day of injection (Day 7) and the day after injection (Day 8).
- FIGS. 10A-10B show tumor experiment timeline and results.
- FIG. 10A shows a timeline for tumor experiments.
- FIG. 10B depicts the change in tumor volume observed after injection of SEQ ID NO: 4 peptide (15 mg/kg, 10 mg/kg, or 5 mg/kg) or a Flag control (15 mg/kg).
- FIGS. 11A-11C show Half Maximal Inhibitory Concentration (IC50) curves for SEQ ID NO: 4 and a control peptide (TAT-Flag peptide) against different KRAS-mutant cell lines.
- FIG. HA shows IC50 curves for the control peptide (top) or SEQ ID NO: 4 peptide (bottom) for the H358 cell line;
- FIG. 11B shows IC50 curves for the control peptide (top) or SEQ ID NO: 4 peptide (bottom) for the H441 cell line; and
- FIG. 11C shows IC50 curves for the control peptide (top) and SEQ ID NO: 4 peptide (bottom) for the SW480 cell line.
- FIGS. 12A-12B show the tumor weight from necropsy of animals after 4 weeks of treatment.
- FIG. 12A shows the grouped data from the vehicle group, the control peptide (TAT- FLAG) group, the SEQ ID NO: 4 peptide low dose group, and the SEQ ID NO: 4 peptide high dose group.
- FIG. 12B shows the individual data from the vehicle group, the control peptide (TAT-FLAG) group, the SEQ ID NO: 4 peptide low dose group, and the SEQ ID NO: 4 peptide high dose group.
- the tumor weight is shown on the Y-axis
- the tumor group is indicated on the X-axis
- the number of animals per group is indicated below the X axis.
- From left to right the data is presented as the vehicle group, the control peptide (TAT-FLAG) group, the SEQ ID NO: 4 peptide low dose group, and the SEQ ID NO: 4 peptide high dose group.
- FIGS. 13A-13C show the mean tumor volumes for the SW480 model, the NCI-H358 model, and the NCI-H441 model.
- FIG. 13A shows the mean tumor volume for the SW480 model.
- FIG. 13B shows the mean tumor volume for the NCI-H358 model.
- FIG. 13C shows the mean tumor volume for the NCI-H441 model.
- the tumor volume (mm 3 ) is shown on the Y-axis, and the days post start of dosing is indicated on the X-axis. The tumor volume was measured with a caliper.
- FIGS. 14A-14C show tumor volume by tumor weight correlations for the SW480 model, the NCI-H358 model, and the NCI-H441 model
- FIG. 14A shows the tumor volume by tumor weight correlation for the SW480 model.
- FIG. 14B shows the tumor volume by tumor weight correlation for the NCI-H358 model.
- FIG. 14C shows the tumor volume by tumor weight correlation for the NCI-H441 model. In all figures, the tumor volume is shown on the Y-axis and the tumor weight is shown on the X-axis.
- G1 is the vehicle group
- G2 is the control TAT-Flag peptide group
- G3 is the SEQ ID NO: 4 peptide low dose group
- G4 is the SEQ ID NO: 4 peptide high dose group.
- FIGS. 15A-15C show the mean body weights of mice for the SW480 model, the NCI- H358 model, and the NC1-H441 model.
- FIG. 15A shows the mean body weight for the SW480 model.
- FIG. 15B shows the mean body weight for the NCI-H358 model.
- FIG. 15C shows the mean body weight for the NCI-H441 model.
- percent body weight change is shown on the Y-axis, and the days from the start of the dosing is indicated on the X-axis.
- engineered peptides Disclosed herein are engineered peptides, methods of screening for engineered peptides, and methods of treating diseases or conditions utilizing engineered peptides.
- An engineered peptide of the present disclosure can be a therapeutic peptide and can be selected to exhibit cellular toxicity upon administration, which can be useful for treating diseases such as cancer.
- a range should be considered to have specifically disclosed all the possible subranges as well as individual numerical values within that range.
- description of a range such as from 1 to 6 should be considered to have specifically disclosed subranges such as from 1 to 3, from 1 to 4, from 1 to 5, from 2 to 4, from 2 to 6, from 3 to 6 etc., as well as individual numbers within that range, for example, 1 , 2, 3, 4, 5, and 6. This applies regardless of the breadth of the range.
- substantially refers to a qualitative condition that exhibits an entire or nearly total range or degree of a feature or characteristic of interest. In some cases, substantially refers to at least about: 70%, 75%, 80%, 85%, 90%, 95%, 99%, 99.9% or 99.99% of the total range or degree of a feature or characteristic of interest. In some cases, the substantially or essentially refers to an amount that can be about 100% of a total amount.
- determining can be used interchangeably herein to refer to forms of measurement.
- the terms include determining if an element is present or not (for example, detection). These terms can include quantitative, qualitative or quantitative and qualitative determinations. Assessing can be relative or absolute. “Detecting the presence of’ can include determining the amount of something present in addition to determining whether it is present or absent depending on the context.
- encode refers to an ability of a polynucleotide to provide information or instructions sequence sufficient to produce a corresponding gene expression product.
- mRNA can encode for a polypeptide during translation
- DNA can encode for an mRNA molecule during transcription.
- ex vivo refers to an event that takes place outside of a subject’s body.
- An ex vivo assay may not be performed on a subject. Rather, it can be performed upon a sample separate from a subject.
- An example of an ex vivo assay performed on a sample can be an “in vitro” assay.
- percent “identity,” in the context of two or more nucleic acid or polypeptide sequences, refers to two or more sequences or subsequences that have a specified percentage of nucleotides or amino acid residues that are the same, when compared and aligned for maximum correspondence, as measured using one of the sequence comparison algorithms described below (e.g., BLASTP and BLASTN or other algorithms available to persons of skill) or by visual inspection.
- sequence comparison algorithms e.g., BLASTP and BLASTN or other algorithms available to persons of skill
- the percent “identity” can exist over a region of the sequence being compared, e.g., over a functional domain, or, alternatively, exist over the full length of the two sequences to be compared.
- sequence comparison typically one sequence acts as a reference sequence (also called the subject sequence) to which test sequences (also called query sequences) are compared.
- the percent sequence identity is defined as a test sequence’s percent identity to a reference sequence
- Sequence A having a sequence identity of 50% to Sequence B
- Sequence A is the test sequence
- Sequence B is the reference sequence.
- sequence comparison algorithm When using a sequence comparison algorithm, test and reference sequences are input into a computer program, subsequence coordinates are designated, if necessary, and sequence algorithm program parameters are designated. The sequence comparison algorithm then aligns the sequences to achieve the maximum alignment, based on the designated program parameters, introducing gaps in the alignment if necessary.
- the percent sequence identity for the test sequence(s) relative to the reference sequence can then be determined from the alignment of the test sequence to the reference sequence.
- the equation for percent sequence identity from the aligned sequence is as follows: [(Number of Identical Positions)/(Total Number of Positions in the Test Sequence)] x 100% [0035]
- percent identity and sequence similarity calculations are performed using the BLAST algorithm for sequence alignment, which is described in Altschul et al., J. Mol Biol. 215:403-410 (1990).
- Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information (www.ncbi.nlm.nih.gov/).
- the BLAST algorithm uses a test sequence (also called a query sequence) and a reference sequence (also called a subject sequence) to search against, or in some cases, a database of multiple reference sequences to search against.
- the BLAST algorithm performs sequence alignment by finding high-scoring alignment regions between the test and the reference sequences by scoring alignment of short regions of the test sequence (termed “words”) to the reference sequence.
- the scoring of each alignment is determined by the BLAST algorithm and takes factors into account, such as the number of aligned positions, as well as whether introduction of gaps between the test and the reference sequences would improve the alignment.
- the alignment scores for nucleic acids can be scored by set match/mismatch scores.
- the alignment scores can be scored using a substitution matrix to evaluate the significance of the sequence alignment, for example, the similarity between aligned amino acids based on their evolutionary probability of substitution.
- the substitution matrix used is the BLOSUM62 matrix.
- the public default values of April 6, 2023 are used when using the BLASTN and BLASTP algorithms.
- the BLASTN and BLASTP algorithms then output a “Percent Identity” output value and a “Query Coverage” output value.
- Percent Sequence Identity (“Percent Identity” output value) x (“Query Coverage” output value)
- the following non-limiting examples illustrate the calculation of percent identity between two nucleic acids sequences.
- the percent identity' is calculated as follows: [(number of identical nucleotide positions)/(total number of nucleotides in the test sequence)] x 100%.
- test sequence 1 has 50% sequence identity to reference sequence 2.
- Test sequence 3 has 50% sequence identity to reference sequence 4.
- Test sequence 5 has 100% sequence identity to reference sequence 6.
- the following non-limiting examples illustrate the calculation of percent identity between two protein sequences.
- sequence comparison typically one sequence acts as a reference sequence to which test sequences are compared.
- test and reference sequences are input into a computer, subsequence coordinates are designated, if necessary, and sequence algorithm program parameters are designated.
- sequence comparison algorithm then calculates the percent sequence identity for the test sequence(s) relative to the reference sequence, based on the designated program parameters.
- percent identity and sequence similarity can be performed using the BLAST algorithm, which is described in Altschul et al. (J. Mol. Biol. 215:403-410 (1990)). Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information.
- in vitro refers to an event that takes places contained in a container for holding laboratory reagent such that it can be separated from the biological source from which the material can be obtained.
- in vitro assays can encompass cell-based assays in which living or dead cells can be employed.
- In vitro assays can also encompass a cell-free assay in which no intact cells can be employed.
- in vivo refers to an event that takes place in a subject’s body.
- polynucleotide refers to a single or double-stranded polymer of deoxyribonucleotide (DNA) or ribonucleotide (RNA) bases read from the 5’ to the 3’ end.
- RNA is inclusive of dsRNA (double stranded RNA), snRNA (small nuclear RNA), IncRNA (long non-coding RNA), mRNA (messenger RNA), miRNA (microRNA) RNAi (inhibitory RNA), siRNA (small interfering RNA), shRNA (short hairpin RNA), tRNA (transfer RNA), rRNA (ribosomal RNA), snoRNA (small nucleolar RNA), and cRNA (complementary RNA).
- DNA is inclusive of cDNA, genomic DNA, and DNA-RNA hybrids.
- a sequence of a polynucleotide may be provided interchangeably as an RNA sequence (containing U) or a DNA sequence (containing T).
- a sequence provided as an RNA sequence is intended to also cover the corresponding DNA sequence and the reverse complement RNA sequence or DNA sequence.
- a sequence provided as a DNA sequence is intended to also cover the corresponding RNA sequence and the reverse complement RNA sequence or DNA sequence.
- protein can be used interchangeably and in their broadest sense can refer to a compound of two or more subunit amino acids, amino acid analogs or peptidomimetics.
- the subunits can be linked by peptide bonds. In another embodiment, the subunit can be linked by other bonds, e.g., ester, ether, etc.
- a protein or peptide can contain at least two amino acids and no limitation can be placed on the maximum number of amino acids which can comprise a protein’s or peptide's sequence.
- amino acid can refer to either natural amino acids, unnatural amino acids, or synthetic amino acids, including glycine and both the D and L optical isomers, amino acid analogs and peptidomimetics.
- fusion protein can refer to a protein comprised of domains from more than one naturally occurring or recombinantly produced protein, where generally each domain serves a different function.
- linker can refer to a protein fragment that can be used to link these domains together - optionally to preserve the conformation of the fused protein domains, prevent unfavorable interactions between the fused protein domains which can compromise their respective functions, or both.
- “pharmaceutically acceptable salt” may refer to pharmaceutical molecules, which may be formed as a weak acid or base, chemically made into their salt forms, most frequently as the hydrochloride, sodium, or sulfate salts. Drug products synthesized as salts may enhance drug dissolution, boost absorption into the bloodstream, facilitate therapeutic effects, and increase its effectiveness. Pharmaceutically acceptable salts may also facilitate the development of controlled-release dosage forms, improve drug stability, extend shelf life, enhance targeted drug delivery, and improve drug effectiveness. [0045] The terms “subject,” “individual,” or “patient” can be used interchangeably herein. A “subject” refers to a biological entity containing expressed genetic materials.
- the biological entity can be a plant, animal, or microorganism, including, for example, bacteria, viruses, fungi, and protozoa.
- the subject can be tissues, cells and their progeny of a biological entity obtained in vivo or cultured in vitro.
- the subject can be a mammal.
- the mammal can be a human.
- the subject can be diagnosed or suspected of being at high risk for a disease. In some cases, the subject is not necessarily diagnosed or suspected of being at high risk for the disease [0046]
- the terms “treatment” or “treating” can be used in reference to a pharmaceutical or other intervention regimen for obtaining beneficial or desired results in the recipient. Beneficial or desired results include but are not limited to a therapeutic benefit and/or a prophylactic benefit.
- a therapeutic benefit can refer to eradication or amelioration of one or more symptoms of an underlying disorder being treated. Also, a therapeutic benefit can be achieved with the eradication or amelioration of one or more of the physiological symptoms associated with the underlying disorder such that an improvement can be observed in the subject, notwithstanding that the subject can still be afflicted with the underlying disorder.
- a prophylactic effect includes delaying, preventing, or eliminating the appearance of a disease or condition, delaying or eliminating the onset of one or more symptoms of a disease or condition, slowing, halting, or reversing the progression of a disease or condition, or any combination thereof. For prophylactic benefit, a subject at risk of developing a particular disease, or to a subject reporting one or more of the physiological symptoms of a disease can undergo treatment, even though a diagnosis of this disease may not have been made.
- engineered peptides useful for treatment of a disease or condition in a subject can be a therapeutic peptide.
- a therapeutic peptide exhibits a therapeutic property useful for treatment of a disease or condition.
- the disease or condition is a cancer.
- an engineered peptide of the present disclosure is a therapeutic peptide that exhibits cellular toxicity.
- an engineered peptide of the present disclosure is a therapeutic peptide exhibiting cellular toxicity can be useful to treat diseases or conditions such as cancer.
- contacting an engineered peptide of the present disclosure with a cancer cell can arrest cancer cell growth.
- contacting an engineered of the present disclosure can reduce the size of a cancer cell (e.g. can decrease tumor volume).
- contacting an engineered of the present disclosure can induce apoptosis or cell death of the cancer cell.
- an engineered peptide of the present disclosure can be alphahelical (e g.
- a physiological temperature can be from about 36 °C to about 38 °C, or about 37 °C degrees.
- a physiological salt concentration can be from about 0.5% to about 15%, 1% to about 10%, 1% to about 5%, or about 0.9%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10% of a solution.
- a physiological salt can be a sodium chloride, a sodium phosphate, a potassium phosphate, a sodium carbonate, a potassium iodide, or any combination thereof.
- an alpha-helical engineered peptide of the present disclosure may have improved cell permeability, relative to a corresponding non-alpha helical peptide.
- an alpha-helical engineered peptide of the present disclosure is useful for producing cellular toxicity to treat diseases or conditions described herein.
- an engineered peptide of the present disclosure can be a stapled peptide.
- an alpha-helical engineered peptide of the present disclosure can be a stapled peptide.
- a stapled peptide of the present disclosure is a peptide in which two or more amino acids of the peptide are covalently linked by way of their side chains. Without wishing to be bound by theory, utilizing peptide stapling can stabilize a secondary structure adopted by the stapled peptide.
- a peptide herein can comprise one or more staples.
- a stapled peptide encompasses a stitched peptide having, for example, a plurality of staples (e.g., 2, 3, 4, 5, 6, or 7 staples).
- a stitched peptide contains 2 or more staples.
- a first residue (i) can be stapled to a residue that is n residues downstream (i+n).
- a first residue (i) can be stapled to a residue 3 amino acids downstream (i+3), 4 amino acids downstream (i+4), 5 amino acids downstream (i+5), 6 amino acids downstream (i+6), 7 amino acids downstream (i+7), 8 amino acids downstream (i+8), 9 amino acids downstream (i+9), 10 amino acids downstream (i+10), 11 amino acids downstream (i+11), 12 amino acids downstream (i+12), 13 amino acids downstream (i+13), 14 amino acids downstream (i+14), etc.
- a therapeutic peptide of the present disclosure is an (i, i+3) stapled peptide.
- an engineered peptide of the present disclosure is an (i, i+7) stapled peptide.
- the first residue (i) in a peptide staple can be any residue that is at least n upstream of the last residue an engineered peptide as disclosed herein.
- the first residue (i) can be amino acid 1, 2, 3, 4, 5, or 6 of the engineered peptide.
- an engineered peptide having a length of 13 amino acids and a stapled peptide at (i, i+7) comprises a first residue (i) at amino acid 3 of the engineered peptide that is stapled to residue (i+7) at amino acid 10 of the engineered peptide.
- the first residue (i) can be amino acid 1, 2, 3, 4, 5, 6, or 7 of the engineered peptide.
- an engineered peptide having a length of 14 amino acids and a stapled peptide at (i, i+7) comprises a first residue (i) at amino acid 4 of the engineered peptide that is stapled to residue (i+7) at amino acid 11 of the engineered peptide.
- the first residue (i) can be amino acid 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 of the engineered peptide.
- the first residue (i) can be amino acid 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or 11 of the engineered peptide.
- a (i) residue is a non-natural amino acid.
- a (i+n) residue that is n amino acids downstream of the (i) residue is a non-natural amino acid.
- the (i) residue is an a, oc-disubstituted nonnatural amino acid.
- the (i) residue is S-pentenylalanme (S5), R- pentylalanine (R5), S-octenylalanine (S8), or R-octenylalanine (R8).
- the (i+n) residue is S-pentenylalanine (S5), R-pentylalanine (R5), S-octenylalanine (S8), or R- octenylalanine (R8).
- the residue (i) can be R8 and the (i+n) residue can be S5.
- Engineered peptides of the present disclosure can be engineered or non-naturally occurring peptides.
- an engineered peptide indicates the involvement of the hand of man.
- An engineered peptide is at least substantially free from at least one feature that is naturally associated or found in a naturally occurring peptide (e.g., length), and/or contains a modification (e.g, chemical modification or ammo acid sequence) that is not present in the naturally occurring peptide.
- engineered peptides of the present disclosure are selected through screening, rational design, and the like, to exhibit improved properties relative to naturally occurring peptides.
- an engineered peptide of the present disclosure can have increased cellular toxicity relative to a naturally occurring peptide, and/or can have increased cell permeability relative to a naturally occurring peptide.
- a peptide herein can have an N-terminal modification such as an acetyl modification.
- a peptide herein can have a C-terminal modification such as an amide modification.
- an engineered peptide of the present disclosure has an half maximal inhibitory concentration (ICso) of less than 200 pM, less than 165 pM, less than 100 pM, less than 95 pM, less than 90 pM, less than 85 pM, less than 80 pM, less than 75 pM, less than 70 pM, less than 65 pM, less than 60 pM, less than 55 pM, less than 50 pM, less than 45 pM, less than 40 pM, less than 35 pM, less than 30 pM, less than 25 pM, less than 20 pM, less than 15 pM, less than 10 pM, less than 5 pM, less than 1 pM, less than 100 nM, or less than 10 nM ; as determined in an in vitro assay against a cancer cell line.
- ICso half maximal inhibitory concentration
- an engineered peptide of the present disclosure has an ICso of from about 1 nM to about 50 pM, 1 pM to about 50 pM, from about 100 pM to about 200 pM, from about 150 pM to about 200 pM, from about 10 pM to about 100 pM, from about 10 pM to about 60 pM, from about 10 pM to about 50 pM, from about 10 pM to about 45 pM, from about 5 pM to about 10 pM, from about 5 pM to about 15 pM, from about 40 pM to about 60 pM, from about 10 pM to about 30 pM, from about 10 pM to about 25 pM, from about 10 pM to about 20 pM, from about 10 pM to about 15 pM, from about 1 pM to about 5 pM, from about 500 nM to about 1 pM, from about 100 nM to about 500 nM, from about
- an engineered peptide of the present disclosure has an ICso of about 50 pM, about 49 pM, about 48 pM, about 47 pM, about 46 pM, about 45 pM, about 44 pM, about 43 pM, about 42 pM, about 41 pM, 40 pM, about 39 pM, about 38 pM, about 37 pM, about 36 pM, about 35 pM, about 34 pM, about 33 pM, about 32 pM, about 31 pM, about 30 pM, about 29 pM, about 28 pM, about 27 pM, about 26 pM, about 25 pM, about 24 pM, about 23 pM, about 22 pM, about 21 pM,
- an engineered peptide of the present disclosure has an ICso of from 10 pM to 60 pM, from 10 pM to 50 pM, from 1 pM to 50 pM, from 10 pM to 45 pM, from 40 pM to 60 pM, from 5 pM to 10 pM, from 5 pM to 15 pM, from 10 pM to 30 pM, from 10 pM to 25 pM, from 10 pM to 15 pM, from 10 pM to 20 pM, from 1 pM to 5 pM, from 500 nM to 1 pM, from 500 nM to 800 nM, from 100 nM to 500 nM, from 50 nM to 250 nM, from 10 nM to 100 nM, from 0.1 nM to 1 nM, from 0.01 nM to 0.
- an engineered peptide of the present disclosure has an ICso of no more than 50 pM, no more than 49 pM, no more than 48 pM, no more than 47 pM, no more than 46 pM, no more than 45 pM, no more than 44 pM, no more than 43 pM, no more than 42 pM, no more than 41 pM, no more than 40 pM, no more than 39 pM, no more than 38 pM, no more than 37 pM, no more than 36 pM, no more than 35 pM, no more than 34 pM, no more than 33 pM, no more than 32 pM, no more than 31 pM, no more than 30 pM, no more than 29 pM, no more than 28 pM, no more than 27 pM, no more than 26 pM,
- an engineered peptide of the present disclosure can comprise a portion of a naturally occurring peptide.
- an engineered peptide of the present disclosure can comprise a portion of an alpha helical domain of a naturally occurring protein. As described herein, such portions can be further engineered in the development of the engineered peptides to deviate from the portion of the naturally occurring peptide.
- an engineered peptide of the present disclosure can comprise, or can be derived from prior to engineering, a portion of an RBI peptide, a CHEK2 peptide, an MDM2 peptide, a RAFI peptide, a RAC1 peptide, an RRAS2 peptide, a FAC1 peptide, a PIK3Ca peptide, a PIK3R1 peptide, a VHL peptide, a DDX3X peptide, or a CTNNB1 peptide.
- a therapeutic peptide of the present disclosure can have at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to a contiguous portion of an RBI peptide, a CHEK2 peptide, an MDM2 peptide, a RAFI peptide, a RAC1 peptide, an RRAS2 peptide, a FAC1 peptide, a PIK3Ca peptide, a PIK3R1 peptide, a VHL peptide, a DDX3X peptide, or a CTNNB1 peptide.
- an engineered peptide can comprise, or be derived from a portion of a naturally occurring protein that is from about 5 amino acids to about 40 amino acids, from about 6 amino acids to about 40 amino acids, from about 7 amino acids to about 40 amino acids, from about 8 amino acids to about 40 amino acids, from about 9 amino acids to about 40 amino acids, from about 10 amino acids to about 40 amino acids, from about 11 amino acids to about 40 amino acids, from about 12 amino acids to about 40 ammo acids, from about 13 amino acids to about 40 amino acids, from about 14 amino acids to about 40 amino acids, from about 15 amino acids to about 40 amino acids, from about 16 amino acids to about 40 amino acids, from about 17 amino acids to about 40 amino acids, from about 18 amino acids to about 40 amino acids, from about 19 ammo acids to about 40 ammo acids, from about 20 ammo acids to about 40 amino acids, from about 21 amino acids to about 40 amino acids, from about 22 amino acids to about 40 amino acids, from about 23 amino acids to about 40 amino acids, from about 24 amino acids
- an engineered peptide can comprise, or be derived from prior to engineered, a portion of a naturally occurring protein that is from about 5 amino acids to about 20 amino acids, from about 6 ammo acids to about 20 amino acids, from about 7 amino acids to about 20 amino acids, from about 8 amino acids to about 20 amino acids, from about 9 amino acids to about 20 amino acids, from about 10 amino acids to about 20 amino acids, from about 11 amino acids to about 20 amino acids, from about 12 amino acids to about 20 amino acids, from about 13 amino acids to about 20 amino acids, from about 14 amino acids to about 20 amino acids, from about 15 amino acids to about 20 amino acids, from about 16 amino acids to about 20 amino acids, from about 17 amino acids to about 20 amino acids, from about 18 amino acids to about 20 amino acids, or from about 19 amino acids to about 20 amino acids.
- an engineered peptide can comprise, or be denved from, a portion of a naturally occurring protein that is from 5 ammo acids to 40 amino acids, from 6 amino acids to 40 amino acids, from 7 amino acids to 40 amino acids, from 8 amino acids to 40 amino acids, from 9 amino acids to 40 amino acids, from 10 amino acids to 40 amino acids, from 11 amino acids to 40 amino acids, from 12 amino acids to 40 amino acids, from 13 amino acids to 40 amino acids, from 14 amino acids to 40 ammo acids, from 15 amino acids to 40 amino acids, from 16 amino acids to 40 amino acids, from 17 amino acids to 40 amino acids, from 18 amino acids to 40 amino acids, from 19 amino acids to 40 amino acids, from 20 amino acids to 40 amino acids, from 21 amino acids to 40 amino acids, from 22 amino acids to 40 amino acids, from 23 amino acids to 40 amino acids, from 24 amino acids to 40 amino acids, from 25 amino acids to 40 amino acids, from 26 amino acids to 40 amino acids, from 27 amino acids to 40 amino acids, from 28 amino acids to 40 amino acids, from 29 amino acids
- an engineered peptide can comprise, or be derived from, a portion of a naturally occurring protein that is from 5 amino acids to 39 amino acids, from 6 amino acids to 39 amino acids, from 7 amino acids to 39 amino acids, from 8 amino acids to 39 amino acids, from 9 amino acids to 39 amino acids, from 10 amino acids to 39 amino acids, from 11 amino acids to 39 amino acids, from 12 amino acids to 39 amino acids, from 13 amino acids to 39 amino acids, from 14 amino acids to 39 amino acids, from 15 amino acids to 39 amino acids, from 16 amino acids to 39 amino acids, from 17 amino acids to 39 amino acids, from 18 amino acids to 39 amino acids, from 19 amino acids to 39 amino acids, from 20 amino acids to 39 amino acids, from 21 amino acids to 39 amino acids, from 22 amino acids to 39 amino acids, from 23 amino acids to 39 amino acids, from 24 amino acids to 39 amino acids, from 25 amino acids to 39 amino acids, from 26 amino acids to 39 amino acids, from 27 amino acids to 39 amino acids, from 28 amino acids to 39 amino acids, from 29 amino acids to 39 amino acids,
- an engineered peptide can comprise, or be derived from, a portion of a naturally occurring protein that is from 5 amino acids to 20 amino acids, from 6 amino acids to 20 amino acids, from 7 amino acids to 20 amino acids, from 8 amino acids to 20 amino acids, from 9 amino acids to 20 amino acids, from 10 amino acids to 20 ammo acids, from 10 ammo acids to 15 ammo acids, from 11 ammo acids to 20 ammo acids, from 12 amino acids to 20 amino acids, from 13 amino acids to 20 amino acids, from 14 amino acids to 20 amino acids, from 15 amino acids to 20 amino acids, from 16 amino acids to 20 amino acids, from 17 amino acids to 20 amino acids, from 18 amino acids to 20 amino acids, or from 19 amino acids to 20 amino acids.
- an engineered peptide can comprise, or be derived from, a portion of a naturally occurring protein that is at most 40 amino acids, at most 39 amino acids, at most 38 amino acids, at most 37 amino acids, at most 36 amino acids, at most 35 amino acids, at most 34 amino acids, at most 33 amino acids, at most 32 amino acids, at most 31 amino acids, at most 30 amino acids, at most 29 amino acids, at most 28 amino acids, at most 27 amino acids, at most 26 amino acids, at most 25 amino acids, at most 24 amino acids, at most 23 amino acids, at most 22 amino acids, at most 21 amino acids, at most 20 amino acids, at most 19 amino acids, at most 18 amino acids, at most 17 amino acids, at most 16 amino acids, at most 15 amino acids, at most 14 amino acids, at most 13 amino acids, at most 12 amino acids, at most 11 amino acids, at most 10 ammo acids, at most 9 ammo acids, at most 8 ammo acids, at most 7 amino acids, at most 6 amino acids, or at most 5 amino acids.
- an engineered peptide can comprise, or be derived from, a portion of a naturally occurring protein that is 40 amino acids, 39 amino acids, 38 amino acids, 37 amino acids, 36 amino acids, 35 amino acids, 34 amino acids, 33 amino acids, 32 amino acids, 31 amino acids, 30 amino acids, 29 amino acids, 28 amino acids, 27 amino acids, 26 amino acids, 25 amino acids, 24 amino acids, 23 amino acids, 22 amino acids, 21 amino acids, 20 amino acids, 19 amino acids, 18 amino acids, 17 amino acids, 16 amino acids, 15 amino acids, 14 amino acids, 13 amino acids, 12 amino acids, 11 amino acids, 10 amino acids, 9 amino acids, 8 amino acids, 7 amino acids, 6 amino acids, or 5 amino acids.
- an engineered peptide can consist of a portion of a naturally occurring protein or of a portion derived a naturally occurring protein that is from about 5 amino acids to about 40 amino acids, from about 6 amino acids to about 40 amino acids, from about 7 amino acids to about 40 ammo acids, from about 8 amino acids to about 40 amino acids, from about 9 amino acids to about 40 amino acids, from about 10 amino acids to about 40 amino acids, from about 11 amino acids to about 40 amino acids, from about 12 amino acids to about 40 amino acids, from about 13 amino acids to about 40 amino acids, from about 14 amino acids to about 40 amino acids, from about 15 amino acids to about 40 amino acids, from about 16 amino acids to about 40 amino acids, from about 17 amino acids to about 40 amino acids, from about 18 amino acids to about 40 amino acids, from about 19 amino acids to about 40 amino acids, from about 20 amino acids to about 40 amino acids, from about 21 amino acids to about 40 amino acids, from about 22 amino acids to about 40 amino acids, from about 23 amino acids to about 40 ammo acids, from about
- an engineered peptide can consist of a portion of a naturally occurring protein or of a portion derived a naturally occurring protein that is from about 5 amino acids to about 20 amino acids, from about 6 amino acids to about 20 amino acids, from about 7 amino acids to about 20 amino acids, from about 8 amino acids to about 20 amino acids, from about 9 ammo acids to about 20 ammo acids, from about 10 ammo acids to about 20 amino acids, from about 11 amino acids to about 20 amino acids, from about 12 amino acids to about 20 amino acids, from about 13 amino acids to about 20 amino acids, from about 14 amino acids to about 20 amino acids, from about 15 amino acids to about 20 amino acids, from about 16 amino acids to about 20 amino acids, from about 17 amino acids to about 20 amino acids, from about 18 amino acids to about 20 amino acids, or from about 19 amino acids to about 20 amino acids.
- an engineered peptide can consist of a portion of a naturally occurring protein or of a portion derived a naturally occurring protein that is from 5 amino acids to 40 amino acids, from 6 amino acids to 40 amino acids, from 7 amino acids to 40 amino acids, from 8 amino acids to 40 amino acids, from 9 amino acids to 40 amino acids, from 10 amino acids to 40 amino acids, from 11 amino acids to 40 amino acids, from 12 amino acids to 40 amino acids, from 13 amino acids to 40 amino acids, from 14 amino acids to 40 amino acids, from 15 amino acids to 40 amino acids, from 16 amino acids to 40 amino acids, from 17 amino acids to 40 amino acids, from 18 amino acids to 40 amino acids, from 19 amino acids to 40 amino acids, from 20 amino acids to 40 amino acids, from 21 amino acids to 40 amino acids, from 22 amino acids to 40 amino acids, from 23 amino acids to 40 amino acids, from 24 amino acids to 40 amino acids, from 25 amino acids to 40 amino acids, from 26 amino acids to 40 amino acids, from 27 amino acids to 40 amino acids, from 28 amino acids to 40 amino acids, from 29 amino acids to 40
- an engineered peptide can consist of a portion of a naturally occurring protein or of a portion derived a naturally occurring protein that is from 5 amino acids to 39 amino acids, from 6 amino acids to 39 amino acids, from 7 amino acids to 39 amino acids, from 8 amino acids to 39 amino acids, from 9 amino acids to 39 amino acids, from 10 amino acids to 39 amino acids, from 11 amino acids to 39 amino acids, from 12 amino acids to 39 amino acids, from 13 amino acids to 39 amino acids, from 14 amino acids to 39 amino acids, from 15 amino acids to 39 amino acids, from 16 amino acids to 39 amino acids, from 17 amino acids to 39 amino acids, from 18 amino acids to 39 amino acids, from 19 amino acids to 39 amino acids, from 20 amino acids to 39 amino acids, from 21 amino acids to 39 amino acids, from 22 amino acids to 39 amino acids, from 23 amino acids to 39 amino acids, from 24 amino acids to 39 amino acids, from 25 amino acids to 39 amino acids, from 26 amino acids to 39 amino acids, from 27 amino acids to 39 amino acids, from 28 amino acids to 39 amino acids, from 29 amino acids, from
- an engineered peptide can consist of a portion of a naturally occurring protein or of a portion derived a naturally occurring protein that is from 5 amino acids to 20 amino acids, from 6 amino acids to 20 amino acids, from 7 amino acids to 20 amino acids, from 8 amino acids to 20 amino acids, from 9 amino acids to 20 amino acids, from 10 amino acids to 20 amino acids, from 10 amino acids to 15 amino acids, from 11 amino acids to 20 amino acids, from 12 amino acids to 20 amino acids, from 13 amino acids to 20 amino acids, from 14 amino acids to 20 amino acids, from 15 amino acids to 20 amino acids, from 16 amino acids to 20 amino acids, from 17 amino acids to 20 amino acids, from 18 amino acids to 20 amino acids, or from 19 amino acids to 20 amino acids.
- an engineered peptide can consist of a portion of a naturally occurring protein or of a portion derived a naturally occurring protein that is at most 40 amino acids, at most 39 amino acids, at most 38 amino acids, at most 37 amino acids, at most 36 amino acids, at most 35 amino acids, at most 34 amino acids, at most 33 amino acids, at most 32 amino acids, at most 31 amino acids, at most 30 amino acids, at most 29 amino acids, at most 28 amino acids, at most 27 amino acids, at most 26 amino acids, at most 25 amino acids, at most 24 amino acids, at most 23 amino acids, at most 22 amino acids, at most 21 amino acids, at most 20 amino acids, at most 19 amino acids, at most 18 amino acids, at most 17 amino acids, at most 16 amino acids, at most 15 amino acids, at most 14 amino acids, at most 13 amino acids, at most 12 amino acids, at most 11 amino acids, at most 10 amino acids, at most 9 amino acids, at most 8 amino acids, at most 7 ammo acids, at most 6 ammo acids, or at most 5
- an engineered peptide can consist of a portion of a naturally occurring protein or of a portion derived a naturally occurring protein that is 40 amino acids, 39 amino acids, 38 amino acids, 37 amino acids, 36 amino acids, 35 amino acids, 34 amino acids, 33 amino acids, 32 amino acids, 31 amino acids, 30 amino acids, 29 amino acids, 28 amino acids, 27 amino acids, 26 amino acids, 25 amino acids, 24 amino acids, 23 amino acids, 22 amino acids, 21 amino acids, 20 amino acids, 19 amino acids, 18 amino acids, 17 amino acids, 16 amino acids, 15 amino acids, 14 amino acids, 13 amino acids, 12 amino acids, 11 amino acids, 10 amino acids, 9 amino acids, 8 amino acids, 7 amino acids, 6 amino acids, or 5 amino acids in length.
- an engineered peptide of the present disclosure can have varying lengths depending on their functionality. In some cases, engineered peptides of the present disclosure are short peptides of low molecular weight. In some embodiments, an engineered peptide of the present disclosure can have a length of at most 40 amino acids, at most 39 amino acids, at most 38 amino acids, at most 37 amino acids, at most 36 ammo acids, at most 35 ammo acids, at most 34 ammo acids, at most 33 amino acids, at most 32 amino acids, at most 31 amino acids, at most 30 amino acids, at most 29 amino acids, at most 28 amino acids, at most 27 amino acids, at most 26 amino acids, at most 25 amino acids, at most 24 amino acids, at most 23 amino acids, at most 22 amino acids, at most 21 amino acids, at most 20 amino acids, at most 19 amino acids, at most 18 amino acids, at most 17 amino acids, at most 16 amino acids, at most 15 amino acids, at most 14 amino acids, at most 13 amino acids, at most 12 amino acids, at most
- an engineered peptide of the present disclosure can have a length of from about 5 amino acids to about 40 amino acids, from about 6 amino acids to about 40 amino acids, from about 7 amino acids to about 40 amino acids, from about 8 amino acids to about 40 amino acids, from about 9 amino acids to about 40 amino acids, from about 10 amino acids to about 40 amino acids, from about 11 amino acids to about 40 amino acids, from about 12 amino acids to about 40 ammo acids, from about 13 amino acids to about 40 amino acids, from about 14 amino acids to about 40 amino acids, from about 15 amino acids to about 40 amino acids, from about 16 amino acids to about 40 amino acids, from about 17 amino acids to about 40 amino acids, from about 18 amino acids to about 40 amino acids, from about 19 amino acids to about 40 amino acids, from about 20 amino acids to about 40 amino acids, from about 21 amino acids to about 40 ammo acids, from about 22 amino acids to about 40 amino acids, from about 23 amino acids to about 40 amino acids, from about 24 amino acids to about 40 amino acids, from about 25 amino acids to about 40 amino acids
- an engineered peptide of the present disclosure can have a length of from about 5 amino acids to about 20 amino acids, from about 6 amino acids to about 20 amino acids, from about 7 amino acids to about 20 amino acids, from about 8 amino acids to about 20 amino acids, from about 9 amino acids to about 20 amino acids, from about 10 amino acids to about 20 amino acids, from about 10 amino acids to about 15 amino acids, from about 11 amino acids to about 20 amino acids, from about 12 amino acids to about 20 amino acids, from about 13 amino acids to about 20 ammo acids, from about 14 ammo acids to about 20 ammo acids, from about 15 ammo acids to about 20 amino acids, from about 16 amino acids to about 20 amino acids, from about 17 amino acids to about 20 amino acids, from about 18 amino acids to about 20 amino acids, or from about 19 amino acids to about 20 amino acids.
- an engineered peptide of the present disclosure can have a length of from 5 amino acids to 40 amino acids, from 6 amino acids to 40 amino acids, from 7 amino acids to 40 amino acids, from 8 amino acids to 40 amino acids, from 9 amino acids to 40 amino acids, from 10 amino acids to 40 amino acids, from 11 amino acids to 40 amino acids, from 12 amino acids to 40 amino acids, from 13 amino acids to 40 amino acids, from 14 amino acids to 40 amino acids, from 15 amino acids to 40 amino acids, from 16 amino acids to 40 amino acids, from 17 amino acids to 40 amino acids, from 18 amino acids to 40 amino acids, from 19 amino acids to 40 amino acids, from 20 amino acids to 40 amino acids, from 21 amino acids to 40 amino acids, from 22 amino acids to 40 amino acids, from 23 amino acids to 40 amino acids, from 24 amino acids to 40 amino acids, from 25 amino acids to 40 amino acids, from 26 ammo acids to 40 amino acids, from 27 amino acids to 40 amino acids, from 28 amino acids to 40 amino acids, from 29 amino acids to 40 amino acids, from 30 amino acids to 40 amino acids, from 5
- an engineered peptide can have a length of from 5 amino acids to 39 amino acids, from 6 amino acids to 39 amino acids, from 7 amino acids to 39 amino acids, from 8 amino acids to 39 amino acids, from 9 amino acids to 39 amino acids, from 10 ammo acids to 39 ammo acids, from 11 ammo acids to 39 ammo acids, from 12 amino acids to 39 amino acids, from 13 amino acids to 39 amino acids, from 14 amino acids to 39 amino acids, from 15 amino acids to 39 amino acids, from 16 amino acids to 39 amino acids, from 17 amino acids to 39 amino acids, from 18 amino acids to 39 amino acids, from 19 amino acids to 39 amino acids, from 20 amino acids to 39 amino acids, from 21 amino acids to 39 ammo acids, from 22 amino acids to 39 amino acids, from 23 amino acids to 39 amino acids, from 24 amino acids to 39 amino acids, from 25 amino acids to 39 amino acids, from 26 amino acids to 39 amino acids, from 27 amino acids to 39 amino acids, from 28 amino acids to 39 amino acids, from 29 amino acids to 39 amino acids, from 30 amino acids
- an engineered peptide of the present disclosure can have a length of from 5 ammo acids to 20 amino acids, from 6 ammo acids to 20 amino acids, from 7 amino acids to 20 amino acids, from 8 amino acids to 20 amino acids, from 9 amino acids to 20 amino acids, from 10 amino acids to 20 amino acids, from 11 amino acids to 20 amino acids, from 12 amino acids to 20 amino acids, from 13 amino acids to 20 amino acids, from 14 amino acids to 20 amino acids, from 15 amino acids to 20 amino acids, from 16 amino acids to 20 amino acids, from 17 amino acids to 20 amino acids, from 18 amino acids to 20 amino acids, or from 19 amino acids to 20 amino acids.
- an engineered peptide can have a length of 40 amino acids, 39 amino acids, 38 amino acids, 37 amino acids, 36 amino acids, 35 amino acids, 34 amino acids, 33 amino acids, 32 amino acids, 31 amino acids, 30 amino acids, 29 amino acids, 28 amino acids, 27 amino acids, 26 amino acids, 25 amino acids, 24 amino acids, 23 amino acids, 22 amino acids, 21 amino acids, 20 amino acids, 19 amino acids, 18 amino acids, 17 amino acids, 16 amino acids, 15 amino acids, 14 amino acids, 13 amino acids, 12 amino acids, 11 amino acids, 10 amino acids, 9 amino acids, 8 amino acids, 7 amino acids, 6 amino acids, or 5 amino acids.
- an engineered peptide can have a length of 10 amino acids.
- an engineered peptide can have a length of 11 amino acids. In some embodiments, an engineered peptide can have a length of 12 amino acids. In some embodiments, an engineered peptide can have a length of 13 amino acids. In some embodiments, an engineered peptide can have a length of 14 amino acids. In some embodiments, an engineered peptide can have a length of 15 amino acids.
- an engineered peptide can have at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO: 1.
- an engineered peptide can have a polypeptide sequence of SEQ ID NO: 1.
- an engineered peptide can have at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO: 2.
- an engineered peptide can have a polypeptide sequence of SEQ ID NO: 2.
- an engineered peptide can have at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO: 3.
- an engineered peptide can have a polypeptide sequence of SEQ ID NO: 3.
- an engineered peptide can have at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO: 1 and further comprise a peptide staple.
- an engineered peptide can have a polypeptide sequence of SEQ ID NO: 1 and further comprise a peptide staple.
- an engineered peptide can have at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO: 2 and further comprise a peptide staple.
- an engineered peptide can have a polypeptide sequence of SEQ ID NO: 2 and further comprise a peptide staple.
- an engineered peptide can have at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO: 3 and further comprise a peptide staple.
- an engineered peptide can have a polypeptide sequence of SEQ ID NO: 3 and further comprise a peptide staple.
- the peptide staple can be (i, i+n) as previously described.
- an engineered peptide can have at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO: 1 and further comprise a peptide staple (i, i+7), wherein i is 3, the (i) residue is R8 and the (i+7) residue is S5.
- an engineered peptide can have a polypeptide sequence of SEQ ID NO: 1 and further comprise a peptide staple further comprise a peptide staple (i, i+7), wherein i is 3, the (i) residue is R8 and the (i+7) residue is S5.
- an engineered peptide can have at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO: 2 and further comprise a peptide staple (i, i+7), wherein i is 3, the (i) residue is R8 and the (i+7) residue is S5.
- an engineered peptide can have a polypeptide sequence of SEQ ID NO: 2 and further comprise a peptide staple (i, i+7), wherein i is 3, the (i) residue is R8 and the (i+7) residue is S5.
- an engineered peptide can have at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO: 3 and further comprise a peptide staple (i, i+7), wherein i is 4, the (i) residue is R8 and the (i+7) residue is S5.
- an engineered peptide can have a polypeptide sequence of SEQ ID NO: 3 and further comprise a peptide staple (i, i+7), wherein i is 4, the (i) residue is R8 and the (i+7) residue is S5.
- an engineered peptide can have at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO: 4.
- an engineered peptide can have a polypeptide sequence of SEQ ID NO: 4.
- an engineered peptide can have at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO: 5.
- an engineered peptide can have a polypeptide sequence of SEQ ID NO: 5.
- an engineered peptide can have at least 80%, at least 81 %, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO: 6.
- an engineered peptide can have a polypeptide sequence of SEQ ID NO: 6.
- an engineered peptide can be a stapled peptide having a polypeptide sequence of SEQ ID NO: 4, SEQ ID NO: 5, or SEQ ID NO: 6.
- Engineered peptides as descnbed herein can be formulated with a pharmaceutically acceptable carrier for administration to a subject (e.g., a human or a non-human animal).
- a pharmaceutically acceptable carrier can include, but is not limited to, phosphate buffered saline solution, water, emulsions (e.g., an oil/water emulsion or a water/oil emulsions), glycerol, liquid polyethylene glycols, aprotic solvents such (e g., dimethylsulfoxide, N-methylpyrrolidone, or mixtures thereof), and various types of wetting agents, solubilizing agents, anti-oxidants, bulking agents, protein carriers such as albumins, any and all solvents, dispersion media, coatings, sodium lauryl sulfate, isotonic and absorption delaying agents, disintegrants (e.g., potato starch or sodium starch glycolate), and the like.
- compositions also can include stabilizers and preservatives. Additional examples of carriers, stabilizers and adjuvants consistent with the compositions of the present disclosure can be found in, for example, Remington's Pharmaceutical Sciences, 21st Ed., Mack Publ. Co., Easton, Pa. (2005), incorporated herein by reference in its entirety.
- the pharmaceutical composition can be formulated in unit dose forms or multiple-dose forms.
- the unit dose forms can be physically discrete units suitable for administration to human or non-human subjects (e.g., animals).
- the unit dose forms can be packaged individually.
- each unit dose contains a predetermined quantity of an active ingredient(s) that can be sufficient to produce the desired therapeutic effect in association with pharmaceutical carriers, diluents, excipients, or any combination thereof.
- the unit dose forms comprise ampules, syringes, or individually packaged tablets and capsules, or any combination thereof.
- a unit dose form can be comprised in a disposable syringe.
- unit-dosage forms can be administered in fractions or multiples thereof.
- a multiple-dose form comprises a plurality of identical unit dose forms packaged in a single container, which can be administered in segregated a unit dose form.
- multiple dose forms comprise vials, bottles of tablets or capsules, or bottles of pints or gallons.
- a multipledose forms comprise the same pharmaceutically active agents.
- a multipledose forms comprise different pharmaceutically active agents.
- the peptides disclosed herein can be formulated as a salt of the peptide.
- the salt comprises an HC1 salt, an ascorbic acid salt, a mandelic acid salt, an aspartic acid salt, a carbonic acid salt, a citric acid salt, a formic acid salt, a glutamic acid salt, a lactic acid salt, a lauric acid salt, a maleic acid salt, a borate salt, a bitartrate salt, a palmitic acid salt, a phosphoric acid salt, or any combination thereof.
- a salt comprises an acetate salt.
- a salt comprises a trifluoroacetate (TFA) salt.
- pharmaceutically acceptable salts include, but are not limited to, metal salts such as a sodium salt, a potassium salt, a cesium salt and the like; an alkaline earth metal salt such as a calcium salt, a magnesium salt and the like; an organic amine salts such as a tri ethylamine salt, a pyridine salt, a picoline salt, a ethanolamine salt, a triethanolamine salt, a dicyclohexylamine salt, a N,N'-dibenzylethylenediamme salt and the like; an inorganic acid salt such as a hydrochloride, a hydrobromide, a phosphate, a sulphate and the like; an organic acid salt such as a citrate, a lactate, a tartrate, a maleate, a fumarate, a mandelate, an acetate, a dichloroacetate, a trifluoroacetate, an oxalate, a
- the pharmaceutical composition comprises a pharmaceutically acceptable excipient.
- the excipient comprises a buffering agent, a cryopreservative, a preservative, a stabilizer, a binder, a compaction agent, a lubricant, a chelator, a dispersion enhancer, a disintegration agent, a flavoring agent, a sweetener, or a coloring agent, or any combination thereof.
- an excipient comprises a buffering agent.
- the buffering agent comprises sodium citrate, magnesium carbonate, magnesium bicarbonate, calcium carbonate, calcium bicarbonate, or any combination thereof.
- the buffering agent comprises sodium bicarbonate, potassium bicarbonate, magnesium hydroxide, magnesium lactate, magnesium glucomate, aluminum hydroxide, sodium citrate, sodium tartrate, sodium acetate, sodium carbonate, sodium polyphosphate, potassium polyphosphate, sodium pyrophosphate, potassium pyrophosphate, disodium hydrogen phosphate, dipotassium hydrogen phosphate, trisodium phosphate, tripotassium phosphate, potassium metaphosphate, magnesium oxide, magnesium hydroxide, magnesium carbonate, magnesium silicate, calcium acetate, calcium glycerophosphate, calcium chloride, or calcium hydroxide and other calcium salts, or any combination thereof.
- an excipient comprises a cryopreservative.
- the cryopreservative comprises DMSO, glycerol, polyvinylpyrrolidone (PVP), or any combination thereof.
- a cryopreservative comprises a sucrose, a trehalose, a starch, a salt of any of these, a derivative of any of these, or any combination thereof.
- an excipient comprises a pH agent (to minimize oxidation or degradation of a component of the composition), a stabilizing agent (to prevent modification or degradation of a component of the composition), a buffering agent (to enhance temperature stability), a solubilizing agent (to increase protein solubility), or any combination thereof.
- an excipient comprises a surfactant, a sugar, an ammo acid, an antioxidant, a salt, a non-iomc surfactant, a solubilizer, a triglyceride, an alcohol, or any combination thereof.
- an excipient comprises sodium carbonate, acetate, citrate, phosphate, poly -ethylene glycol (PEG), human serum albumin (HSA), sorbitol, sucrose, trehalose, polysorbate 80, sodium phosphate, sucrose, disodium phosphate, mannitol, polysorbate 20, histidine, citrate, albumin, sodium hydroxide, glycine, sodium citrate, trehalose, arginine, sodium acetate, acetate, HC1, disodium edetate, lecithin, glycerin, xanthan rubber, soy isoflavones, polysorbate 80, ethyl alcohol, water, teprenone, or any combination thereof.
- the excipient can be an excipient described in the Handbook of Pharmaceutical Excipients, American Pharmaceutical Association (1986).
- the excipient comprises a preservative.
- the preservative comprises an antioxidant, such as alpha-tocopherol and ascorbate, an antimicrobial, such as parabens, chlorobutanol, and phenol, or any combination thereof.
- the antioxidant comprises EDTA, citric acid, ascorbic acid, but lated hydroxytoluene (BHT), butylated hydroxy anisole (BHA), sodium sulfite, p-amino benzoic acid, glutathione, propyl gallate, cysteine, methionine, ethanol or N- acetyl cysteine, or any combination thereof.
- the preservative comprises validamycin A, TL-3, sodium ortho vanadate, sodium fluoride, N-a-tosyl-Phe- chloromethylketone, N-a-tosyl-Lys-chloromethylketone, aprotinin, phenylmethylsulfonyl fluoride, diisopropylfluorophosphate, kinase inhibitor, phosphatase inhibitor, caspase inhibitor, granzyme inhibitor, cell adhesion inhibitor, cell division inhibitor, cell cycle inhibitor, lipid signaling inhibitor, protease inhibitor, reducing agent, alkylating agent, antimicrobial agent, oxidase inhibitor, or other inhibitors, or any combination thereof.
- the excipient comprises a binder.
- the binder comprises starches, pregelatinized starches, gelatin, polyvinylpyrolidone, cellulose, methylcellulose, sodium carboxymethylcellulose, ethylcellulose, polyacrylamides, polyvinyloxoazolidone, polyvinylalcohols, C12-C18 fatty acid alcohol, polyethylene glycol, polyols, saccharides, oligosaccharides, or any combination thereof.
- the binder can be a starch, for example a potato starch, com starch, or wheat starch; a sugar such as sucrose, glucose, dextrose, lactose, or maltodextrin; a natural and/or synthetic gum; a gelatin; a cellulose derivative such as microcrystalline cellulose, hydroxypropyl cellulose, hydroxyethyl cellulose, hydroxypropyl methyl cellulose, carboxymethyl cellulose, methyl cellulose, or ethyl cellulose; polyvinylpyrrolidone (povidone); polyethylene glycol (PEG); a wax; calcium carbonate; calcium phosphate; an alcohol such as sorbitol, xylitol, mannitol, or water, or any combination thereof.
- a starch for example a potato starch, com starch, or wheat starch
- a sugar such as sucrose, glucose, dextrose, lactose, or maltodextrin
- the excipient comprises a lubricant.
- the lubricant comprises magnesium stearate, calcium stearate, zinc stearate, hydrogenated vegetable oils, sterotex, polyoxyethylene monostearate, talc, polyethyleneglycol, sodium benzoate, sodium lauryl sulfate, magnesium lauryl sulfate, or light mineral oil, or any combination thereof.
- the lubricant comprises metallic stearates (such as magnesium stearate, calcium stearate, aluminum stearate), fatty acid esters (such as sodium stearyl fumarate), fatty acids (such as stearic acid), fatty alcohols, glyceryl behenate, mineral oil, paraffins, hydrogenated vegetable oils, leucine, polyethylene glycols (PEG), metallic lauryl sulphates (such as sodium lauryl sulphate, magnesium lauryl sulphate), sodium chloride, sodium benzoate, sodium acetate or talc or a combination thereof.
- metallic stearates such as magnesium stearate, calcium stearate, aluminum stearate
- fatty acid esters such as sodium stearyl fumarate
- fatty acids such as stearic acid
- fatty alcohols such as sodium stearic acid
- fatty alcohols such as sodium stearyl fumarate
- fatty acids such as stearic acid
- the excipient comprises a dispersion enhancer.
- the dispersion enhancer comprises starch, alginic acid, polyvinylpyrrolidones, guar gum, kaolin, bentonite, purified wood cellulose, sodium starch glycolate, isomorphous silicate, or microcrystalline cellulose, or any combination thereof as high HLB emulsifier surfactants.
- the excipient comprises a dismtegrant.
- a disintegrant comprises a non-efferv escent disintegrant.
- a non-effervescent disintegrants comprises starches such as com starch, potato starch, pregelatinized and modified starches thereof, sweeteners, clays, such as bentonite, micro-crystalline cellulose, alginates, sodium starch glycolate, or gums such as agar, guar, locust bean, karaya, pectin, and tragacanth, or any combination thereof.
- a disintegrant comprises an effervescent disintegrant.
- a suitable elfervescent disintegrant comprises bicarbonate in combination with citric acid, and sodium bicarbonate in combination with tartaric acid.
- the excipient comprises a sweetener, a flavoring agent or both.
- a sweetener comprises glucose (com syrup), dextrose, invert sugar, fructose, and mixtures thereof (when not used as a carrier); saccharin and its various salts such as a sodium salt; dipeptide sweeteners such as aspartame; dihydrochalcone compounds, glycyrrhizin; Stevia Rebaudiana (Stevioside); chloro derivatives of sucrose such as sucralose; and sugar alcohols such as sorbitol, mannitol, sylitol, and the like, or any combination thereof.
- flavoring agents incorporated into a composition comprise synthetic flavor oils and flavoring aromatics; natural oils; extracts from plants, leaves, flowers, and fruits; or any combination thereof.
- a flavoring agent comprises a cinnamon oils; oil of wintergreen; peppermint oils; clover oil; hay oil; anise oil; eucalyptus; vanilla; citrus oil such as lemon oil, orange oil, grape and grapefruit oil; and fruit essences including apple, peach, pear, strawberry, raspberry, cherry, plum, pineapple, and apricot, or any combination thereof.
- the excipient comprises a pH agent (e.g., to minimize oxidation or degradation of a component of the composition), a stabilizing agent (e.g., to prevent modification or degradation of a component of the composition), a buffenng agent (e.g., to enhance temperature stability), a solubilizing agent (e.g., to increase protein solubility), or any combination thereof.
- the excipient comprises a surfactant, a sugar, an amino acid, an antioxidant, a salt, a non-ionic surfactant, a solubilizer, a trigylceride, an alcohol, or any combination thereof.
- the excipient comprises sodium carbonate, acetate, citrate, phosphate, poly-ethylene glycol (PEG), human serum albumin (HSA), sorbitol, sucrose, trehalose, polysorbate 80, sodium phosphate, sucrose, disodium phosphate, mannitol, polysorbate 20, histidine, citrate, albumin, sodium hydroxide, glycine, sodium citrate, trehalose, arginine, sodium acetate, acetate, HC1, disodium edetate, lecithin, glycerine, xanthan rubber, soy isoflavones, polysorbate 80, ethyl alcohol, water, teprenone, or any combination thereof.
- PEG poly-ethylene glycol
- HSA human serum albumin
- the excipient comprises a cryo-preservative.
- the excipient comprises DMSO, glycerol, polyvinylpyrrolidone (PVP), or any combination thereof.
- the excipient comprises a sucrose, a trehalose, a starch, a salt of any of these, a derivative of any of these, or any combination thereof.
- the pharmaceutical composition comprises a diluent.
- the diluent comprises water, glycerol, methanol, ethanol, or other similar biocompatible diluents, or any combination thereof.
- a diluent comprises an aqueous acid such as acetic acid, citric acid, maleic acid, hydrochloric acid, phosphoric acid, nitric acid, sulfuric acid, or any combination thereof.
- a diluent comprises an alkaline metal carbonates such as calcium carbonate; alkaline metal phosphates such as calcium phosphate; alkaline metal sulphates such as calcium sulphate; cellulose derivatives such as cellulose, microcrystalline cellulose, cellulose acetate; magnesium oxide, dextrin, fructose, dextrose, glyceryl palmitostearate, lactitol, choline, lactose, maltose, mannitol, simethicone, sorbitol, starch, pregelatinized starch, talc, xylitol and/or anhydrates, hydrates and/or pharmaceutically acceptable derivatives thereof or combinations thereof.
- alkaline metal carbonates such as calcium carbonate
- alkaline metal phosphates such as calcium phosphate
- alkaline metal sulphates such as calcium sulphate
- cellulose derivatives such as cellulose, microcrystalline cellulose, cellulose acetate
- magnesium oxide de
- the pharmaceutical composition comprises a carrier.
- the carrier comprises a liquid or solid filler, solvent, or encapsulating material.
- the carrier comprises additives proteins, peptides, amino acids, lipids, and carbohydrates (e.g., sugars, including monosaccharides, di-, tri-, tetra-oligosaccharides, and oligosaccharides; derivatized sugars such as alditols, aldolic acids, esterified sugars and the like; and polysaccharides or sugar polymers), alone or in combination.
- kits comprising the pharmaceutical compositions herein.
- a kit comprises a container.
- a container can be any material such as a glass, a metal, a plastic or a combination thereof.
- a kit can comprise an engineered peptide disclosed herein such as a peptide of SEQ ID NOs: 1-6 and optionally, a pharmaceutically acceptable: excipient, earner, or diluent.
- an initial screen can be utilized to select for portions of polypeptides that exhibit a property of interest.
- An example of such screening can be found in WO2021041953, which is incorporated by reference in its entirety.
- an initial screen can be used to tile portions of oncogenes that display cell toxicity. Hits from the initial screen can be further engineered as described herein to produce improved engineered peptides with enhanced efficacy relative to naturally occurring portions of oncogenes.
- peptide candidates found in an initial screen to display cellular toxicity are curated to select for certain properties using external databases such as Unitprot, Genebank, and PDB.
- peptide candidates can be selected based on their propensity to form an alpha helical structure in the context of a full length peptide.
- an alpha-helical engineered peptide of the present disclosure can have improved cell permeability, relative to a corresponding nonalpha helical peptide.
- Alpha helical propensity can be determined by comparing the peptide candidates to deposited protein structures showing the presence of the peptide candidate in an annotated alpha helical structure in the deposited protein structure.
- Curated peptide candidates e.g. peptide candidates selected for cellular toxicity in an initial screen and for their propensity to form alpha helices based on deposited structures
- mutagenesis can be utilized to improve the activity of the candidate peptides.
- high throughput screening can be utilized to screen libraries of rationally designed engineered peptides based on peptide candidates selected in the initial screen.
- computational screening e.g., computational alanine scanning
- both methods can be combined to generate engineered peptides with improved properties relative to the peptide candidates.
- Advanced candidates selected by screening with improved properties relative to the peptide candidates can be further optimized to improve efficacy.
- each advanced candidate can be modeled to predict the key interactions between the candidate peptide and the target.
- the length of the candidate can be modified to include key residues.
- the length of the candidate can be modified to minimize the length of the peptide while still including key residues.
- modifications such as stapling can be employed as described herein to stabilize the secondary structure (e.g. alpha helical structure) of the therapeutic peptide by reducing the entropic penalty for adopting the structure.
- Engineered peptides as described herein can be used to treat diseases or conditions upon administration to a subject in need thereof.
- engineered peptides of the present disclosure exhibit cellular toxicity that allows for treatment of diseases such as cancer.
- contacting an engineered peptide of the present disclosure with a cancer cell can arrest cancer cell growth.
- contacting an engineered peptide of the present disclosure w ith a cancer cell can inhibit cancer cell proliferation.
- contacting an engineered peptide of the present disclosure can reduce the size of a cancer cell (e.g. can decrease tumor volume).
- contacting an engineered peptide of the present disclosure can induce apoptosis or cell death of the cancer cell.
- the arrest of cancer cell growth, the inhibition of cancer cell proliferation, the reduction of the tumor volume, or the induction of apoptosis of a cell by a peptide of the present disclosure can be compared to the results from a control peptide.
- an engineered peptide of the present disclosure can be used to treat cancer upon administration.
- the cancer is selected from the group consisting of: adrenocortical carcinoma, AIDS-related cancers, AIDS-related lymphoma, anal cancer, anorectal cancer, cancer of the anal canal, appendix cancer, childhood cerebellar astrocytoma, childhood cerebral astrocytoma, basal cell carcinoma, skin cancer (non-melanoma), biliary cancer, extrahepatic bile duct cancer, intrahepatic bile duct cancer, bladder cancer, urinary bladder cancer, bone and joint cancer, osteosarcoma and malignant fibrous histiocytoma, brain cancer, brain tumor, brain stem glioma, cerebellar astrocytoma, cerebral astrocytoma/malignant glioma, ependymoma, medulloblastoma, supratentorial primitive neuroectodermal tumors, visual
- the cancer is a colorectal cancer. In some embodiments, the cancer is a lung cancer. In some embodiments, the cancer is a melanoma cancer. In some embodiments, the cancer is a breast cancer. In some embodiments, the cancer is a pancreatic cancer, a bladder cancer, a triple negative breast cancer, an ovarian cancer, a juvenile myelomonocytic leukemia (IMML), a hematologic malignancy, a cholangiocarcinoma, a uterine cancer, a cervical cancer, a testicular cancer, or any combination thereof. In some embodiments, the cancer is a cancer comprising a KRAS mutation.
- IMML juvenile myelomonocytic leukemia
- a KRAS mutation can comprise a G12V mutation, a G12C mutation, or a G12D mutation of KRAS.
- a KRAS mutation can comprise a G13D mutation, a G12R mutation, or a G12A mutation of KRAS.
- an administration of a peptide herein can be used to treat any cancer with a KRAS mutation, such as those with a G12V mutation, a G12C mutation, or a G12D mutation.
- Administration disclosed herein to an area in need of treatment or therapy can be achieved by, for example, and not by way of limitation, oral administration, topical administration, intravenous administration, inhalation administration, or any combination thereof.
- delivery can include inhalation, otic, buccal, conjunctival, dental, endocervical, endosinusial, endotracheal, enteral, epidural, extra-amniotic, extracorporeal, hemodialysis, infiltration, interstitial, intraabdominal, intraamniotic, intraarterial, intraarticular, intrabiliary, intrabronchial, intrabursal, intracardiac, intracartilaginous, intracaudal, intracavemous, intracavitary, intracerebroventricular, mtracistemal, intracorneal, intracoronal, intracoronary, intracorpous cavemaosum, intradermal, intradiscal, intraductal, intraduodenal, intradural, intraepidermal, intraesophageal, intragastric, intragingival, intrahippocampal, intraileal, intralesional, intraluminal, intralymphatic, intramedullary, intramening
- Delivery can include parenteral administration (including intravenous, subcutaneous, intrathecal, intraperitoneal, intramuscular, intravascular or infusion), oral administration, inhalation administration, intraduodenal administration, rectal administration, or a combination thereof. Delivery can include direct application to the affected tissue or region of the body.
- topical administration can comprise administering a lotion, a solution, an emulsion, a cream, a balm, an oil, a paste, a stick, an aerosol, a foam, a jelly, a foam, a mask, a pad, a powder, a solid, a tincture, a butter, a patch, a gel, a spray, a drip, a liquid formulation, an ointment to an external surface of a surface, such as a skin.
- Delivery can include a parenchymal injection, an intra-thecal injection, an intra-ventricular injection, intratumoral injection, or an intra-cistemal injection.
- a composition provided herein can be administered by any method.
- a method of administration can be by intra-arterial injection, intracistemal injection, intramuscular injection, intraparenchymal injection, intraperitoneal injection, intraspinal injection, intrathecal injection, intravenous injection, intraventricular injection, stereotactic injection, subcutaneous injection, epidural, or any combination thereof.
- Delivery can include parenteral administration (including intravenous, subcutaneous, intrathecal, intraperitoneal, intramuscular, intravascular or infusion administration).
- delivery can comprise a nanoparticle, a liposome, an exosome, an extracellular vesicle, an implant, or a combination thereof.
- delivery can be from a device.
- delivery can be administered by a pump, an infusion pump, or a combination thereof. In some embodiments, delivery can be by an enema, an eye drop, a nasal spray, or any combination thereof. In some instances, a subject can administer the composition in the absence of supervision. In some instances, a subject can administer the composition under the supervision of a medical professional (e.g., a physician, nurse, physician’s assistant, orderly, hospice worker, etc.). In some embodiments, a medical professional can administer the composition.
- a medical professional e.g., a physician, nurse, physician’s assistant, orderly, hospice worker, etc.
- Dosing may include single or multiple administrations of a pharmaceutical composition described herein. Examples include: multiple times a day, daily, every other day, 1, 2, 3, 5, 6, or 7 times a week, weekly, or less often, a single administration, a course of treatment involving several treatments on a regular or irregular basis, or multiple administrations for a period of time until the treatment of a cancer is achieved. In some embodiments, dosing may be performed for about: 1 day to about 8 days, 1 week to about 5 weeks, 1 month to about 12 months, 1 year to about 3 years, 3 years to about 10 years, 10 years to about 50 years, 25 years to about 100 years, or 50 years to about 130 years.
- dosing can occur every day, 2 days, 3 days, 4 days, 5 days, 6 days, 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, 1 year, 2 years, or as needed.
- the dosing regimen including the regularity of and mode of administration, may be dependent on factors including but not limited to the subject being treated; the severity of the condition; the manner of administration, or the presence of one or more additional diseases or conditions.
- a pharmaceutical composition disclosed herein can be administered at dosage levels sufficient to deliver from about 0.0001 mg/kg to about 100 mg/kg, from about 0.001 mg/kg to about 0.05 mg/kg, from about 0.005 mg/kg to about 0.05 mg/kg, from about 0.001 mg/kg to about 0.005 mg/kg, from about 0.05 mg/kg to about 0.5 mg/kg, from about 0.01 mg/kg to about 50 mg/kg, from about 0. 1 mg/kg to about 40 mg/kg, from about 0.5 mg/kg to about 30 mg/kg, from about 0.01 mg/kg to about 10 mg/kg, from about 0. 0.
- 1 mg/kg to about 10 mg/kg from about 1 mg/kg to about 25 mg/kg, from about 1 mg/kg to about 300 mg/kg, from about 0.001 mg/kg to about 300 mg/kg, from about 10 mg/kg to about 300 mg/kg, from about 50 mg/kg to about 300 mg/kg, from about 75 mg/kg to about 300 mg/kg, from about 100 mg/kg to about 300 mg/kg, from about 200 mg/kg to about 300 mg/kg, from about 5 mg/kg to about 250 mg/kg, from about 50 mg/kg to about 250 mg/kg, from about 100 mg/kg to about 250 mg/kg, from about 150 mg/kg to about 250 mg/kg, from about 50 mg/kg to about 150 mg/kg, or from about 100 mg/kg to about 200 mg/kg of subject body weight per day, one or more times a day, to obtain the desired therapeutic, diagnostic, or prophylactic, effect.
- a pharmaceutical composition disclosed herein can be administered at dosage levels sufficient to deliver from 0.0001 mg/kg to 100 mg/kg, from 0.001 mg/kg to 0.05 mg/kg, from 0.005 mg/kg to 0.05 mg/kg, from 0.001 mg/kg to 0.005 mg/kg, from 0.05 mg/kg to 0.5 mg/kg, from 0.01 mg/kg to 50 mg/kg, from 0. 1 mg/kg to 40 mg/kg, from 0.5 mg/kg to 30 mg/kg, from 0.01 mg/kg to 10 mg/kg, from 0.
- 1 mg/kg to 10 mg/kg from 5 mg/kg to 20 mg/kg, from 5 mg/kg to 15 mg/kg, from 8 mg/kg to 12 mg/kg, from 5 mg/kg to 10 mg/kg, from 40 mg/kg to 70 mg/kg, from 50 mg/kg to 70 mg/kg, from 55 mg/kg to 65 mg/kg, from 58 mg/kg to 64 mg/kg, from 59 mg/kg to 61 mg/kg, from 1 mg/kg to 25 mg/kg, from 1 mg/kg to 300 mg/kg, from 0.001 mg/kg to 300 mg/kg, from 10 mg/kg to 300 mg/kg, from 50 mg/kg to 300 mg/kg, from 75 mg/kg to 300 mg/kg, from 100 mg/kg to 300 mg/kg, from 200 mg/kg to 300 mg/kg, from 5 mg/kg to 250 mg/kg, from 50 mg/kg to 250 mg/kg, from 100 mg/kg to 250 mg/kg, from 150 mg/kg to 250 mg/kg, from 50 mg/kg to 150 mg/
- a pharmaceutical composition disclosed herein can be administered at dosage levels sufficient to deliver about 0.0001 mg/kg, about 0.001 mg/kg, about 0.005 mg/kg, about 0.01 mg/kg, about 0.05 mg/kg, about 0.1 mg/kg, about 0.5 mg/kg, about 1 mg/kg, about 5 mg/kg, about 6 mg/kg, about 7 mg/kg, about 8 mg/kg, about 9 mg/kg, about 10 mg/kg, about 11 mg/kg, about 12 mg/kg, about 13 mg/kg, about 14 mg/kg, about 15 mg/kg, about 20 mg/kg, about 25 mg/kg, about 30 mg/kg, about 35 mg/kg, about 40 mg/kg, about 45 mg/kg, about 50 mg/kg, about 55 mg/kg, about 56 mg/kg, about 57 mg/kg, about 58 mg/kg, about 59 mg/kg, about 60 mg/kg, about 61 mg/kg, about 62 mg/kg, about 63 mg/kg, about 64 mg/kg, about 65
- a pharmaceutical composition disclosed herein can be administered at dosage levels sufficient to deliver 0.0001 mg/kg, 0.001 mg/kg, 0.005 mg/kg, 0.01 mg/kg, 0.05 mg/kg, 0.1 mg/kg, 0.5 mg/kg, 1 mg/kg, 5 mg/kg, 6 mg/kg, 7 mg/kg, 8 mg/kg, 9 mg/kg, 10 mg/kg, 11 mg/kg, 12 mg/kg, 13 mg/kg, 14 mg/kg, 15 mg/kg, 20 mg/kg, 25 mg/kg, 30 mg/kg, 35 mg/kg, 40 mg/kg, 45 mg/kg, 50 mg/kg, 55 mg/kg, 56 mg/kg, 57 mg/kg, 58 mg/kg, 59 mg/kg, 60 mg/kg, 61 mg/kg, 62 mg/kg, 63 mg/kg, 64 mg/kg, 65 mg/kg, 70 mg/kg, 75 mg/kg, 80 mg/kg, 85 mg/kg, 90 mg/kg, 95 mg/kg, 100 mg/kg, 0.00
- the dosage levels of the pharmaceutical composition as disclosed herein are administered to a mammal, including, but not limited to a human, a non-human primate, a dog, a cat, a hamster, a guinea pig, a rat, or a mouse.
- a subject in need thereof is a mammal, including, but not limited to a human, a non-human primate, a dog, a cat, a hamster, a guinea pig, a rat, or a mouse.
- the subject is an infant.
- the infant can be up to 24 months old.
- the subject is a child.
- the child may be 2 years to 21 years old.
- the subject is an adult.
- Adults may be 21 years old or more.
- the adult is of advanced age, such as 65 years or older.
- a method can comprise administering a second therapy.
- a second therapy can be administered concurrently or consecutively with a composition disclosed herein.
- a second therapy can comprise a chemotherapy, a radiation therapy, a hormone therapy, a hyperthermia therapy, an immunotherapy, a photodynamic therapy, a stem cell therapy, a surgery, a targeted therapy, or any combination thereof.
- a chemotherapy can comprise an altretamine, a bendamustine, a busulfan, a carboplatin, a carmustine, a chlorambucil, a cisplatin, a cyclophosphamide, a dacarbazine, an ifosfamide, a lomustine, a mechlorethamine, a melphalan, an oxaliplatin, a temozolomide, a thiotepa, a trabectedin, or any combination thereof.
- a chemotherapy can comprise an altretamine, a bendamustine, a busulfan, a carboplatin, a carmustine, a chlorambucil, a cisplatin, a cyclophosphamide, a dacarbazine, an ifosfamide, a lomustine, a mechlorethamine, a melphalan, an oxaliplatin, a temozolomide, a thiotepa, a trabectedin, a salt of any of these, or any combination thereof.
- a chemotherapy can comprise a carmustine, a lomustine, a streptozocin, an azacitidine, a 5 -fluorouracil (5-fu), a 6-mercaptopurine (6-mp), a capecitabine, a cladribine, a clofarabine, a cytarabine (ara-c), a decitabine, a floxundme, a fludarabine, a gemcitabine, a hydroxyurea, a methotrexate, a nel arabine, a pemetrexed, a pentostatin, a pralatrexate, a thioguanine, a trifluridine/tipiracil combination, a daunorubicin, a doxorubicin, an epirubicin, an idarubicin, a valrubicin, a irinotecan, a topotecan, an etop
- a radiation therapy can comprise an internal radiation therapy or an external radiation therapy.
- a hormone therapy can comprise an anastrozole, an exemestane, a letrozole, a tamoxifen, a raloxifene, a fulvestrant, a toremifene, a goserelin, a leuprolide, a triptorelinan apalutamide, an enzalutamide, a darolutamide, a bicalutamide, a flutamide, a nilutamide, an abiraterone, a ketoconazole, a degarelix, a medroxyprogesterone, a megestrol, an etrozole, an anastrozole, and an exemestane.
- an immunotherapy can comprise a checkpoint inhibitor, an atezolizumab, an avelumab, a dostarlizumab, a durvalumab, an ipilimumab, an nivolumab, an pembrolizumab, an interferon, an interleukin, a Bacillus Calmette-Guerin (BCG), a oncolytic virus therapy, a CAR T-Cell therapy, a CAR cell therapy, a cancer vaccine, a salt of any of these, or any combination thereof.
- BCG Bacillus Calmette-Guerin
- a targeted therapy can comprise an angiogenesis inhibitor, a monoclonal antibody, a proteasome inhibitor, a signal transduction inhibitor.
- a targeted therapy can comprise a denosumab, a romidepsin, a ofatumumab, a pazopanib, an everolimus, a nilotinib, a temsirolimus, a lapatmib, a sumtinib malate, a dasatmib, a vonnostat, a panitumumab, a sorafenib tosylate, a erlotinib, a bevacizumab, a cetuximab, a tositumomab, a bortezomib, a gefitinib, an ibritumomab tiuxetan, an alemtuzumab, an imatinib,
- a method can comprise diagnosing a patient with a cancer prior to, during, or after treatment with a composition herein.
- the diagnosing can comprise a physical examination, a blood test, an imaging assay, a neurological examination, an immunological assay, or any combination thereof.
- an imaging assay can comprise an X-ray, a computed tomography (CT scan), a magnetic resonance imaging (MRI), an ultrasound, a positron emission tomography (PET scan), a fluoroscopy, or any combination thereof.
- This example demonstrates initial screening of 40mer peptides generated from various oncogenes. Each peptide was screened for its ability to exhibit cell toxicity, and variants displaying cell toxicity were utilized in the subsequent examples.
- Peptide coding gene fragments from target genes were composed of the DNA coding sequence for all 40mer amino acids from the genes/mutants listed in TABLE 1 below:
- Peptide coding gene fragment libraries were synthesized as pooled single stranded oligonucleotides by Custom Array. These oligonucleotides were then PCR amplified to generate double stranded gene fragments compatible with Gibson cloning. 50ml PCR reactions were set up with 25 ng of pooled oligonucleotide template and 2.5 ml of primers PEP_1 and PEP_2 (lOmM). The thermal cycler was programmed to run at 95C for 3 minutes, followed by 12 cycles of 98C for 20 seconds, 65C for 15 seconds, and 72C for 45 seconds. This was followed by a final 5-minute extension at 72C. PCR products were then purified.
- Hs578T cells and MDA-MB-231 cells were cultured in DMEM media supplemented with 10% FBS. Cells were transduced with the peptide coding gene fragment library at an MOI ⁇ .3 to ensure each cell received a single construct. Viral transduction was performed in media containing 8mg/ml polybrene to improve transduction efficiency. For each cell line, screening was conducted with two biological replicates. 24 hours after transduction the cell culture media was changed back to DMEM without polybrene supplementation. [0098] 48 hours after transduction, the cell culture media was changed to DMEM containing puromycin to select for transduced cells.
- Peptide coding gene fragments for each time point and replicate were then amplified from the genomic DNA.
- the fragments serve as their own barcodes for downstream abundance calculations.
- Illumina compatible libraries were prepared using 2.5ml of primers PEP_3 and PEP_4 (lOrnM) per 50ml reaction.
- PEP_3 and PEP_4 lOrnM
- 10 separate 50ml PCR reactions with 4mg of gDNA each (40mg total) were performed to ensure adequate library coverage.
- Thermal cycling parameters were identical to those used to amplify the gene fragment oligos, with the exception that the gDNA required 26 cycles to amplify.
- Sequencing was performed and samples were indexed. Greater than 500-fold sequencing depth was used to ensure accurate abundance quantitation.
- the number of PCR reactions was scaled to process 300mg of total gDNA per timepoint and replicate. The larger libraries were then sequenced with 100-bp paired end reads.
- Hits selected in the initial screen of Example 1 were curated to identify hit alpha helical peptides for further engineering to improve binding affinity and enable more effective drug-like function.
- the data from Example 1 was filtered to only have peptide fragments that had a Log2FC of less than 2.5 and a computed fitness score of less than 0, which selects for peptides with a negative impact on cell fitness.
- the peptides were then mapped to the Uniprot database for their gene names, annotated regions for containing alpha helices and regions that had crystal structures available. The focus was primarily on extracting alpha helices as it was needed for engineering staples and crystal structure availability as it was needed for the downstream algorithms for optimizing binding affinity.
- the Interactome INSIDER database was used to extract experimentally curated and computationally predicted interacting residues/regions of proteins.
- the peptide fragments filtered earlier with a negative impact on cell fitness based on our screen was then filtered to ensure crystal structure availability, include alpha helical region, and span the predicted interacting residue regions.
- the count distribution of the peptides that passed these filters are shown in FIG 1. [00102] Based on the count distribution above, the fitness score cutoff was adjusted to less than 0.5 and a final list of 66 peptide fragments for 18 genes were compiled.
- the RCSB database was then manually searched for each peptide fragment to filter fragments that had co-crystal structures with different binding partners. Those that did not have crystal structures with binding partners and/or had too many unmodelled residues were dropped. For each peptide fragment that spanned the same region and shared the same structure file for its binding partners, the most negative Log2FC fragment was chosen.
- the final list of peptides consisted of 11 peptide fragments for 11 genes summarized in TABLE 2.
- the alpha coverage is the number of residues that are part of an alpha helix contained in the 40-mer peptide and the PDB IDs are the ID of the structure files that contains both the target protein and a binding partner.
- the workflow consists of starting with the structure file (PDB) of an identified alpha helical 40-mer peptide binding to an interacting protein.
- the computational alanine scanning algorithm is then used to identify residues in the binding interface by calculating the binding energy of the structure after mutating each residue at the interface to alanine.
- the residue mutated that destabilizes the binding is predicted to be a residue that is important for binding.
- FIG. 3A depicts a heatmap of computational alanine scanning results of identified alpha helical 40-mer peptides (5 out of 11) binding to interacting proteins.
- the Protein Data Bank Identifier (PDB ID) followed by the interacting protein is labeled on the right side.
- FIG. 3B is a heatmap of the point mutation scanning result of RAF1 78 binding to RAP1 A (PDB ID: 1C1Y).
- the residues for conducting site saturation mutagenesis are identified via the results from computational scanning and is labelled on the bottom.
- the mutated amino acids are labelled to the left and the ddG of the final mutated structure is plotted. The more negative the value is, the higher the binding affinity is between the 40-mer peptide-interacting protein complex.
- the circled residue is A85K and has been identified as increasing binding affinity between RAF I and HRAS.
- FIG. 4 depicts the structure of the interaction between RAFI and an interacting protein (RAP1 A or HRAS).
- RAC1 and RAFI were identified from the workflow of Example 1 and Example 2 regarding identifying alpha-helical 40-mer peptides from the peptide screens and the workflow of Example 3 was performed on select identified alpha-helical 40-mer peptides.
- RAC1-61 and RAFI-78 were two alpha-helical 40-mer peptides that had a region of alpha helix that fit the binding interface with their interacting proteins really well. Based on their co-crystal structures as shown in FIG. 5A- 5B, the 40-mer peptide was shortened to only span the alpha helical region.
- staples were designed to enable cell-penetrating capabilities of these peptides to improve their drug-like function. Shorter staples (i, i + 3) and longer (i, i + 7) staples were both evaluated. The longer staple (i, i + 7) was chosen for the subsequent examples.
- R-octenylalanine (R8) and S-pentenylalanine (S5) are non-naturally occurring amino acid residues that allow the formation of the hydrocarbon staple.
- SEQ ID NOS 8-10 discloses SEQ ID NOS 8-10, respectively, in order of appearance.
- FIG. 6A and FIG. 6B depicts dose response curves for each peptide.
- Cell viability was measured at 24-hours (FIG. 6A) and 48-hours (FIG. 6B) post treatment using the colorimetric assay Cell Counting Kit-8 (CCK8).
- TAT-Flag peptide treatment did not affect cell viability at 24 and 48 hours, while peptide of SEQ ID NO: 4 or SEQ ID NO: 5 affected cell viability of both cell lines, and peptide of SEQ ID NO: 6 only affected cell viability of A375 cells.
- A375 and MDA-MB-231 cells responded to both peptide of SEQ ID NO: 4 and peptide of SEQ ID NO: 5 in a similar fashion as shown by the overlapping dose response curves.
- A375 cells were starved by replacing the normal media (DMEM/10% FBS) by a media without FBS (DMEM/0% FBS) for 24 hours. Then, cells were treated with peptide of SEQ ID NO: 4 at 10 pM for 48 hours and cell viability was quantified using colorimetric assay CCK8. Under normal condition (10% FBS), treatment with SEQ ID NO: 4 peptide decreased cell viability by 16.6 % compared to the vehicle condition. When A375 were depnved of FBS, treatment with SEQ ID NO: 4 peptide decreased cell viability by 49.6 % compared to the vehicle under starved condition. Thus, when A375 cells were starved, sensitivity to SEQ ID NO: 4 peptide was increased by ⁇ 3 fold.
- FIG. 7A and 7B show starvation potentiates the anti-proliferative effect of SEQ ID NO: 4 peptide.
- A375 cells were treated for 48-hours with SEQ ID NO: 4 peptide at lOpM or vehicle (PBS) with either 10% FBS or 0% FBS (starvation condition).
- FIG. 7B shows quantification of cell viability measured by CCK8.
- This example shows tumor growth arrest in vivo after administration of SEQ ID NO: 4 peptide in three different sets of tumor efficacy experiments.
- FIG. 8A shows atimeline for a first set of tumor efficacy experiments. 1.5 million A375 cells in 50% Matrigel were injected subcutaneously in the back ofNOD-scid gamma mice. At Day 9 post-injection, tumor volumes reach an average of 102 ⁇ 31 mm 3 and then mice were split into two groups with similar tumor size distribution. At Day 12 postinjections, tumors were injected with either SEQ ID NO: 4 peptide, or Flag peptides (Flag) resuspended in PBS at 60 mg/kg. Each mouse was treated with 1 intra-tumoral injection every day for 3 days.
- FIG. 8B depicts the change in tumor volume observed with SEQ ID NO: 4 peptide or a Flag (Flag) control.
- FIG. 9A shows a timeline for a second set of tumor efficacy experiments. 1.5 million A375 cells in 50% Matrigel were injected subcutaneously in the back ofNOD-scid gamma mice.
- tumor volumes reached an average of 149 ⁇ 27 mm 3 and mice were divided into two cohorts, Flag 60 mg/kg and SEQ ID NO: 4 peptide 60 mg/kg. Tumor volumes were measured every two days. At day 6, tumors volume in both groups were greater than 500 mm 3 . At day 7 and 8, tumors were treated by intratumoral injections with either Flag or SEQ ID NO: 4 peptides at 60 mg/kg. Each mouse received two injections in total. Strikingly, the day after the first injection (day 8), tumors appeared to flatten down in SEQ ID NO: 4 peptide treated group but not in the Flag treated group (FIG. 9C). This observation was confirmed by tumor volume measurement on day 8. In the Flag treated group, tumors kept growing after the first injection reaching 2001 mm 3 on day 13, while tumors in SEQ ID NO: 4 peptide treated group appeared to stop growing (FIG. 9B).
- FIG. 10A shows a timeline for a third set of tumor efficacy experiments.
- 1.5 million A375 cells in 50% Matrigel were injected subcutaneously in the back ofNOD-scid gamma mice. 13 days later (D-l), tumor volumes reached an average of about 200 mm 3 and mice were divided into four cohorts: Flag 15 mg/kg, and SEQ ID NO: 4 peptide at 15 mg/kg, 10 10 mg/kg, or 5 mg/kg.
- Mice were treated with the control (Flag) or SEQ ID NO: 4 peptides at the indicated dosage every day for 11 days. Tumor volumes were measured about every two days. At day 6, tumors volume in all groups were greater than 500 mm 3 .
- the mice receiving the SEQ ID NO: 4 peptide at the indicated dosage had reduced tumor volumes as compared to the control group (Flag peptide), as shown in FIG. 10B.
- the tumors in the first set of tumor efficacy experiments and the second set of tumor efficacy experiments were treated with dose of 60 mg/kg but at different stage of tumor growth.
- the tumors in the first set of tumor efficacy experiments were treated once reaching a volume greater than 100 mm 3 versus tumors in the second set of tumor efficacy experiments were treated tumors were greater than 500 mm 3 .
- SEQ ID NO: 4 peptide stopped the tumor growth, and the effect on the tumor shape could be observed one day after the injection.
- mice treated daily with SEQ ID NO: 4 peptide had reduced tumor volume in all tested conditions (5-15 mg/kg) compared to the control.
- SEQ ID NO: 4 peptide had in vivo bioactivity and reduced tumor growth of human melanoma cells.
- This example describes assessment of tumor growth in vivo after administration of SEQ ID NO: 1 peptide, SEQ ID NO: 2 peptide, SEQ ID NO: 3 peptide, SEQ ID NO: 4 peptide, SEQ ID NO: 5 peptide, or SEQ ID NO: 6 peptide in different KRAS mutant tumor models.
- a pancreatic tumor cell line having a G12V KRAS mutation or G12C KRAS mutation in 50% Matrigel are injected subcutaneously in the back of NOD-scid gamma mice. Tumor volumes are allowed to grow and then mice are split into two groups with similar tumor size distribution. Tumors are injected either intra-tumoral or intraperitoneally with SEQ ID NO: 1 peptide, SEQ ID NO: 2 peptide, SEQ ID NO: 3 peptide, SEQ ID NO: 4 peptide, SEQ ID NO: 5 peptide, SEQ ID NO: 6 peptide or a control peptide resuspended in PBS at 5 mg/kg, 15 mg/kg, 60 mg/kg, or 240 mg/kg. Each mouse is treated with 1 intra-tumoral injection every 3 days. Tumor growth is measured.
- a lung tumor cell line having a G12V KRAS mutation or G12C KRAS mutation in 50% Matrigel are injected subcutaneously in the back of NOD-scid gamma mice. Tumor volumes are allowed to grow and then mice are split into two groups with similar tumor size distribution. Tumors are injected either intra-tumoral or intraperitoneally with SEQ ID NO: 1 peptide, SEQ ID NO: 2 peptide, SEQ ID NO: 3 peptide, SEQ ID NO: 4 peptide, SEQ ID NO: 5 peptide, SEQ ID NO: 6 peptide or a control peptide resuspended in PBS at 5 mg/kg, 15 mg/kg, 60 mg/kg, or 240 mg/kg. Each mouse is treated with 1 intra-tumoral injection every 3 days. Tumor growth is measured.
- a colorectal tumor cell line having a G12V KRAS mutation or G12C KRAS mutation in 50% Matrigel are injected subcutaneously in the back of NOD-scid gamma mice. Tumor volumes are allowed to grow and then mice are split into two groups with similar tumor size distribution.
- Tumors are injected either intra-tumoral or intraperitoneally with SEQ ID NO: 1 peptide, SEQ ID NO: 2 peptide, SEQ ID NO: 3 peptide, SEQ ID NO: 4 peptide, SEQ ID NO: 5 peptide, SEQ ID NO: 6 peptide or a control peptide resuspended in PBS at 5 mg/kg, 15 mg/kg, 60 mg/kg, or 240 mg/kg. Each mouse is treated with 1 intra-tumoral or intraperitoneal injection every 3 days. Tumor growth is measured.
- This example shows in vitro testing of SEQ ID NO: 4 peptide potency against KRAS-mutant cell lines and selection of cell lines for in vivo testing.
- the SEQ ID NO: 4 peptide Prior to in vitro testing, the SEQ ID NO: 4 peptide was determined to have solubility in PBS of up to at least 100 mg/mL. The peptide was prepared by a contract manufacturer and lyophilized prior to being reconstituted. The acetate salt of the SEQ ID NO: 4 peptide and the control peptide was used in this example and the examples described below. SEQ ID NO: 4 was tested in a 10-point dose curve at a 1 :2 dilution with a top concentration of 100 pM and a 72 hour endpoint against different KRAS-mutant cell lines. A cell titer-glo assay was used to determine the potency of the peptide against different cell lines.
- TABLE 4 shows the mutant cell line tested, the tumor type of the mutant cell line, the KRAS mutation status, the half maximal effective concentration (EC50) of the TAT-Flag control (GRKKRRQRRRPQDYKDDDDK SEQ ID NO: 7), the EC50 of the SEQ ID NO: 4 peptide, and if the cell line was selected for an in vivo study (Example 9).
- FIGS. 11A-11C show IC50 curves for SEQ ID NO: 4 peptide and a control peptide (TAT-Flag peptide, SEQ ID NO: 7) against different KRAS-mutant cell lines for a 72- hour endpoint and using a Cell Titer Gio assay.
- FIG. 11A shows an IC50 of 1.667e-005 M of the SEQ ID NO: 4 peptide against the NC1-H358 cell line;
- FIG. 11B shows EC50 of 9.187e-006 M of the SEQ ID NO: 4 peptide against the NCI-H441 cell line; and
- FIG. 11C shows EC50 of 5.231e-005 for the SEQ ID NO: 4 peptide against for the SW480 cell line.
- the NCI-H441 cell line (lung tumor), NCI-H358 cell line (lung tumor), and the SW480 cell line (colorectal tumor) were selected for further in vivo studies (See Example 9).
- SEQ ID NO: 4 peptide had EC50 values ranging from 9.18 pM to 161 pM against most of the KRAS mutant cell lines tested.
- mice tumor models show tumor growth arrest in vivo after administration of SEQ ID NO: 4 peptide in different mice tumor cell models.
- the mice tumor models are summarized in TABLE 5, which shows the cell line used for the tumor model, the mouse strain used for the tumor model, the number of cells injected subcutaneously in the back of the mice, the volume of cells injected and the formulation used for injection, the tumor size at the randomization and start of treatment, and the max tumor volume observed.
- NCI-H358, NCI-H441, and SW480 the mouse age at the start of the study was 8-12 weeks.
- the mouse strain for the NCI-H358 (H358) tumor model was Female CB.17 severe combined immunodeficient (SCID) mouse.
- the mouse strain for the NCI-H441 (H441) tumor model and the SW480 tumor model was the Female NCr mouse.
- mice were separated into 4 groups with 8 mice per group.
- Group 1 was the vehicle alone;
- Group 2 was the TAT-Flag control peptide (SEQ ID NO: 7) at 4.5 mg per dose;
- Group 3 was low dose SEQ ID NO: 4 peptide at 1.5 mg per dose; and
- Group 4 was high dose SEQ ID NO: 4 peptide at 4.5 mg per dose.
- the peptides were administered mtra-tumorally three times weekly and for four weeks (or until the tumor volume was too large). Measurements were recorded such as body weight, tumor volume, and tumor weight.
- TABLE 6 A summary of the study design is shown in TABLE 6.
- SW480 group animals were either found dead or reached a humane endpoint due to ulcerations.
- G4A5 and G4A6 were found dead and listed as not treatment-related as the ulcerations did not appear significant enough to induce death.
- G4A3 had a physical injury that prevented mobility so euthanasia was required.
- G4A8 and G4A1 were euthanized for extensive ulceration.
- G4A4 SEQ ID NO: 4 peptide - high dose animal 4) died in the study.
- FIGS. 12A and 12B The tumor weight results after 4 weeks of treatment are shown in FIGS. 12A and 12B.
- the results show that treatment by injecting SEQ ID NO: 4 peptide reduced the tumor weight in the H358 and SW480 tumor mouse models as compared to the vehicle and control peptide.
- both the low dose (1.5 mg) and the high dose (4.5 mg) of SEQ ID NO: 4 peptide lowered the tumor weight of the animal.
- the high dose (4.5 mg) of SEQ ID NO: 4 peptide lowered the tumor weight of the animal.
- FIGS. 13A-13C Mean tumor volumes for the groups were recorded throughout the study and are shown in FIGS. 13A-13C for the SW480 (FIG. 13A), NC1-H358 (FIG. 13B), and NC1-H441 (FIG. 13C) treatment groups.
- FIG. 13A the tumor volume was decreased in the SEQ ID NO: 4 peptide low dose (1.5 mg) and high dose (4.5 mg) treatment groups in the SW480 tumor model as compared to the control treatment groups.
- This data shows the peptide (SEQ ID NO: 4 peptide) can reduce tumor volume.
- FIGS. 14A-14C show tumor volume by tumor weight correlations for the SW480 model (FIG. 14A), the NCI-H358 model (FIG.
- FIGS. 14A-14C show that tumor volumes may not be the most correlative measurement to track anti-tumor efficacy.
- in vivo tumor weight as an endpoint may be a more reliable measurement of efficacy than tumor volume for the H441 model and the SW480 model due to inflammation, ulceration, and scabbing.
- Several animals in high dose group (SEQ ID NO: 4 peptide - 4.5 mg) for the SW480 model were found dead or had to be euthanized but this is likely a modeldependent byproduct of anti-tumor efficacy rather than compound toxicity.
- In vivo efficacy was observed for the SEQ ID NO: 4 peptide with 3x per week intra-tumoral dosing in the H358 model and SW480 model and shows the peptides of the present disclosure can be used to treat cancers.
- This example describes assessment of tumor growth in vivo after administration of SEQ ID NO: 1 peptide, SEQ ID NO: 2 peptide, SEQ ID NO: 3 peptide, SEQ ID NO: 4 peptide, SEQ ID NO: 5 peptide, or SEQ ID NO: 6 peptide an SW480 model and/or aH358 mouse model.
- a SW480 and/or NCI-H358 tumor cell line having a G12V KRAS mutation or G12C KRAS mutation in 50% Matrigel are injected subcutaneously in the back of NOD-scid gamma mice. Tumor volumes are allowed to grow and then mice are split into groups with similar tumor size distribution. Mice are systemically administered and repeat-dosed with SEQ ID NO: 1 peptide, SEQ ID NO: 2 peptide, SEQ ID NO: 3 peptide, SEQ ID NO: 4 peptide, SEQ ID NO: 5 peptide, SEQ ID NO: 6 peptide or a control peptide resuspended in PBS at 5 mg/kg, 15 mg/kg, 60 mg/kg, or 100 mg/kg. Tumor growth is measured. [00140] Prior to the systemic study, a pharmacokinetics assessment is completed with a small single dose rodent study. This is used to determine and confirm doses and administration schedules for the systemic in vivo study.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Disclosed herein are engineered peptides for treatment of diseases or conditions such as cancer. Also disclosed herein are pharmaceutical compositions containing engineered peptides of the present disclosure. Also disclosed herein are methods of treating a disease or condition by administering an engineered peptide of the present disclosure. Also disclosed herein are methods of making engineered peptides described herein.
Description
THERAPEUTIC PEPTIDES
CROSS-REFERENCE
[0001] This application claims the benefit of U.S. Provisional Application No. 63/404,990, filed September 09, 2022, the disclosure of which is incorporated herein by reference in its entirety.
INCORPORATION BY REFERENCE
[0002] All publications, patents, and patent applications herein are incorporated by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference. In the event of a conflict between a term herein and a term in an incorporated reference, the term herein controls.
SUMMARY
[0003] In some aspects, an engineered peptide has at least about 84% sequence identity to any one of SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3. In some embodiments, the engineered peptide has a length of from about 10 amino acids to about 40 amino acids or of from about 10 amino acids to 39 amino acids. In some embodiments, the engineered peptide has a length of at most 15 amino acids. In some embodiments, the engineered peptide has a length of 13 amino acids or 14 amino acids. In some embodiments, the engineered peptide has the amino acid sequence of any one of SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3. In some embodiments, the engineered peptide adopts an alpha helical structure at physiological salt concentrations and physiological temperature. In some embodiments, the engineered peptide is a stapled peptide In some embodiments, the stapled peptide is an (i, i + 3) stapled peptide or an (i, i + 7) stapled peptide. In some embodiments, the stapled peptide is an (i, i + 7) stapled peptide. In some embodiments, the (i) residue of the stapled peptide is R-octenylalanine (R8), S-octenylalanine (S8), R-pentylalanine (R5), or S-pentenylalanine (S5). In some embodiments, the (i+3) residue or the (i+7) residue of the stapled peptide is R-octenylalanine (R8), S-octenylalanine (S 8), R- pentylalanine (R5), or S-pentenylalanine (S5). In some embodiments, the (i) residue of the stapled peptide is at amino acid 3 or amino acid 4 of any one of SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3 In some embodiments, the (i) residue of the stapled peptide is R-octenylalanine (R8) and the (i+3) residue of the stapled peptide is S-pentenylalanine (S5). In some embodiments, the (i) residue of the stapled peptide is R-octenylalanine (R8) and the (i+7) residue of the stapled peptide is S-pentenylalanine (S5). In some embodiments, the engineered peptide
has at least 84% sequence identity to any one of SEQ ID NO: 4, SEQ ID NO: 5, or SEQ ID NO: 6. In some embodiments, the engineered peptide has the amino acid sequence of any one of SEQ ID NO: 4, SEQ ID NO: 5, or SEQ ID NO: 6. In some embodiments, the engineered peptide has an IC50 of from about 1 nM to about 50 pM against a cancer cell line, as determined in an in vitro assay.
[0004] In some aspects, an engineered peptide comprises (a) at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to a contiguous portion of an RBI peptide, a CHEK2 peptide, an MDM2 peptide, a RAFI peptide, an RRAS2 peptide, a RAC1 peptide, a PIK3Ca peptide, a PIK3R1 peptide, a VHL peptide, a DDX3X peptide, or a CTNNB1 peptide; and (b) a length of from about 10 ammo acids to about 20 ammo acids; wherein the engineered peptide has an IC50 of from about 1 nM to about 50 pM against a cancer cell line, as determined in an in vitro assay. In some embodiments, the engineered peptide is a salt of an engineered peptide. In some embodiments, the salt of the engineered peptide is an acetate salt or a trifluoroacetate (TFA) salt. In some embodiments, the engineered peptide is a stapled peptide. In some embodiments, the stapled peptide is an (i, i + 3) stapled peptide or an (i, i + 7) stapled peptide. In some embodiments, the stapled peptide is an (i, i + 7) stapled peptide.
[0005] In some aspects, a pharmaceutical composition that comprises the engineered peptide of any one of the embodiments described herein and a pharmaceutically acceptable excipient, diluent, or carrier. In some embodiments, the pharmaceutical composition is in unit dose form. In some embodiments, the engineered peptide in unit dose form is about 5 mg/kg, about 15 mg/kg, about 50 mg/kg, about 55 mg/kg, about 60 mg/kg, about 65 mg/kg, about 75 mg/kg, about 100 mg/kg, about 150 mg/kg, about 200 mg/kg, about 240 mg/kg, or about 300 mg/kg.
[0006] In some aspects, a method of treating a disease or condition in a subject in need thereof, the method comprises administering to the subject the engineered peptide of any one of the embodiments disclosed herein or the pharmaceutical composition of any one of the embodiments disclosed herein, wherein the administering is sufficient to treat the disease or condition. In some embodiments, the disease or condition is a cancer. In some embodiments, the cancer comprises a KRAS mutation. In some embodiments, the KRAS mutation comprises a G12V mutation, a G12C mutation, or a G12D mutation of KRAS. In some embodiments, the cancer is a melanoma, a colorectal cancer, a pancreatic cancer, a bladder cancer, a breast cancer, a triple negative breast cancer, an ovarian cancer, a juvenile myelomonocytic leukemia (JMML), a hematologic malignancy, a cholangiocarcmoma, a uterine cancer, a cervical cancer, a testicular cancer, a lung cancer, or any combination thereof. In some embodiments, the administering is parenteral or intra-tumoral. In some embodiments, the subject in need thereof is a mammal. In some embodiments, the mammal is a human, non-human primate, dog, cat, hamster, guinea pig, rat, or
mouse. In some embodiments, the method further comprises administering a second therapy to the subject. In some embodiments, the second therapy comprises a chemotherapy, a radiation therapy, a hormone therapy, a hyperthermia therapy, an immunotherapy, a photodynamic therapy, a stem cell therapy, a surgery, a targeted therapy, or any combination thereof. In some embodiments, the second therapy is administered concurrently or consecutively with the engineered peptide or the pharmaceutical composition.
[0007] In some aspects, a method of making engineered therapeutic peptides for treatment of cancer comprises (a) selecting portions of a candidate polypeptide that display cellular toxicity, as determined in an in vitro assay; (b) curating the portions of the candidate polypeptides to select a subset of the portions of the candidate polypeptide that adopt an alpha helical structure, as determined by x-ray crystallography; (c) modifying the subset using mutagenesis to generate engineered therapeutic peptides, and (d) selecting engineered therapeutic peptides having an IC50 of from about 1 nM to about 50 pM against a cancer cell line, as determined in an in vitro assay. In some embodiments, the modifying of (c) further comprising making an (i, i+7) staple within the engineered therapeutic peptides.
[0008] In some aspects, a method of inhibiting cell proliferation in a cancerous cell comprises administering to the cancerous cell the engineered peptide of any one of the embodiments disclosed herein or the pharmaceutical composition of any one of the embodiments disclosed herein, wherein the administering is sufficient to inhibit proliferation of the cancerous cell.
BRIEF DESCRIPTION OF THE DRAWINGS
[0009] Novel features of exemplary embodiments are set forth with particularity in the appended claims. Abetter understanding of the features and advantages will be obtained by reference to the following detailed description that sets forth illustrative embodiments, in which the principles of the disclosed systems and methods are utilized, and the accompanying drawings of which: [0010] FIG. 1 depicts peptide fragments count distribution for fitness score and Log2FC values after filtering for alpha helical regions, crystal structure availability and interacting residue inclusion. Each count is a 40-mer peptide from the fitness screen that meets the filtering requirements.
[0011] FIG 2 depicts a workflow diagram for in silico identification of mutations that improve binding affinity between a 40-mer peptide and an interacting protein, and subsequent screening. [0012] FIG. 3A depicts a heatmap of computational alanine scanning results of identified alpha helical 40-mer peptides (5 out of 11) binding to interacting proteins. The Protein Data Bank Identifier (PDB ID) followed by the interacting protein is labeled on the right side. The amino
acid sequence of the 40-mer peptide is labeled on the bottom and the corresponding computational alanine binding energy with the interacting protein, delta-delta-G (ddG), is plotted. The higher the value is, the more likely that particular residue is important for binding. FIG. 3B is a heatmap of the point mutation scanning result of RAF1 78 binding to RAP1 A (PDB ID: 1C1Y). The residues for conducting site saturation mutagenesis are identified via the results from computational scanning and is labelled on the bottom. The mutated amino acids are labelled to the left and the ddG of the final mutated structure is plotted. The more negative the value is, the higher the binding affinity is between the 40-mer peptide-interacting protein complex. The circled residue is A85K and has been identified as increasing binding affinity between RAFI and HRAS.
[0013] FIG. 4 depicts the structure of the interaction between RAFI and interacting proteins (RAP1 A (top) and HRAS (bottom)).
[0014] FIG. 5A and 5B are zoomed in structures of the interaction between RAFI and interacting proteins (RAP1A (top) and HRAS (bottom)) (FIG. 5A) or RAC1 and interacting proteins (PREXI (top), DOCK2 (middle), and PLXNB1 (bottom)) (FIG. 5B) .
[0015] FIG. 6A-6B shows dose response curves of engineered peptides (SEQ ID NO: 4 peptide, SEQ ID NO: 5 peptide, or SEQ ID NO: 6 peptide) on MDA-MB-231 or A375 cell survival at 24- hours (FIG. 6A) and 48-hours (FIG. 6B) post-treatment. TAT-FLAG is a negative control.
[0016] FIG. 7A-7B depict starvation potentiates the anti-proliferative effect of the engineered peptide, SEQ ID NO: 4 peptide. FIG. 7A shows A375 cells that were treated for 48-hours with SEQ ID NO: 4 peptide at lOpM or vehicle (PBS) with either 10% FBS or 0% FBS (starvation condition). Bright field images were taken with 20x magnification objective. Scale bar = 100pm. FIG. 7B shows quantification of cell viability measured by the colorimetric assay Cell Counting Kit-8 (CCK8).
[0017] FIGS. 8A-8B show tumor experiment timeline and results. FIG. 8A shows a timeline for tumor experiments. FIG. 8B depicts the change in tumor volume observed after injection of SEQ ID NO: 4 peptide or a Flag control.
[0018] FIGS. 9A-9C show tumor experiment timeline and results. FIG. 9A shows a timeline for tumor experiments. FIG. 9B depicts the change in tumor volume observed after injection of SEQ ID NO: 4 peptide or a Flag control. FIG. 9C shows tumor size after the day of injection (Day 7) and the day after injection (Day 8).
[0019] FIGS. 10A-10B show tumor experiment timeline and results. FIG. 10A shows a timeline for tumor experiments. FIG. 10B depicts the change in tumor volume observed after injection of SEQ ID NO: 4 peptide (15 mg/kg, 10 mg/kg, or 5 mg/kg) or a Flag control (15 mg/kg).
[0020] FIGS. 11A-11C show Half Maximal Inhibitory Concentration (IC50) curves for SEQ ID NO: 4 and a control peptide (TAT-Flag peptide) against different KRAS-mutant cell lines. FIG. HA shows IC50 curves for the control peptide (top) or SEQ ID NO: 4 peptide (bottom) for the H358 cell line; FIG. 11B shows IC50 curves for the control peptide (top) or SEQ ID NO: 4 peptide (bottom) for the H441 cell line; and FIG. 11C shows IC50 curves for the control peptide (top) and SEQ ID NO: 4 peptide (bottom) for the SW480 cell line.
[0021] FIGS. 12A-12B show the tumor weight from necropsy of animals after 4 weeks of treatment. FIG. 12A shows the grouped data from the vehicle group, the control peptide (TAT- FLAG) group, the SEQ ID NO: 4 peptide low dose group, and the SEQ ID NO: 4 peptide high dose group. FIG. 12B shows the individual data from the vehicle group, the control peptide (TAT-FLAG) group, the SEQ ID NO: 4 peptide low dose group, and the SEQ ID NO: 4 peptide high dose group. On both graphs, the tumor weight is shown on the Y-axis, the tumor group is indicated on the X-axis, and the number of animals per group is indicated below the X axis. From left to right, the data is presented as the vehicle group, the control peptide (TAT-FLAG) group, the SEQ ID NO: 4 peptide low dose group, and the SEQ ID NO: 4 peptide high dose group.
[0022] FIGS. 13A-13C show the mean tumor volumes for the SW480 model, the NCI-H358 model, and the NCI-H441 model. FIG. 13A shows the mean tumor volume for the SW480 model. FIG. 13B shows the mean tumor volume for the NCI-H358 model. FIG. 13C shows the mean tumor volume for the NCI-H441 model. On all graphs, the tumor volume (mm3) is shown on the Y-axis, and the days post start of dosing is indicated on the X-axis. The tumor volume was measured with a caliper.
[0023] FIGS. 14A-14C show tumor volume by tumor weight correlations for the SW480 model, the NCI-H358 model, and the NCI-H441 model FIG. 14A shows the tumor volume by tumor weight correlation for the SW480 model. FIG. 14B shows the tumor volume by tumor weight correlation for the NCI-H358 model. FIG. 14C shows the tumor volume by tumor weight correlation for the NCI-H441 model. In all figures, the tumor volume is shown on the Y-axis and the tumor weight is shown on the X-axis. G1 is the vehicle group, G2 is the control TAT-Flag peptide group, G3 is the SEQ ID NO: 4 peptide low dose group, and G4 is the SEQ ID NO: 4 peptide high dose group.
[0024] FIGS. 15A-15C show the mean body weights of mice for the SW480 model, the NCI- H358 model, and the NC1-H441 model. FIG. 15A shows the mean body weight for the SW480 model. FIG. 15B shows the mean body weight for the NCI-H358 model. FIG. 15C shows the mean body weight for the NCI-H441 model. On all graphs, percent body weight change is shown on the Y-axis, and the days from the start of the dosing is indicated on the X-axis.
DETAILED DESCRIPTION
Overview
[0025] Disclosed herein are engineered peptides, methods of screening for engineered peptides, and methods of treating diseases or conditions utilizing engineered peptides. An engineered peptide of the present disclosure can be a therapeutic peptide and can be selected to exhibit cellular toxicity upon administration, which can be useful for treating diseases such as cancer.
Definitions
[0026] Unless defined otherwise, all terms of art, notations and other technical and scientific terms or terminology used herein are intended to have the same meaning as is commonly understood by one of ordinary skill in the art to which the claimed subject matter pertains. In some cases, terms with commonly understood meanings are defined herein for clarity and/or for ready reference, and the inclusion of such definitions herein should not necessarily be construed to represent a substantial difference over what is generally understood in the art.
[0027] Throughout this application, various embodiments are presented in a range format. It should be understood that the description in range format is merely for convenience and brevity and should not be construed as an inflexible limitation on the scope of the disclosure.
Accordingly, the description of a range should be considered to have specifically disclosed all the possible subranges as well as individual numerical values within that range. For example, description of a range such as from 1 to 6 should be considered to have specifically disclosed subranges such as from 1 to 3, from 1 to 4, from 1 to 5, from 2 to 4, from 2 to 6, from 3 to 6 etc., as well as individual numbers within that range, for example, 1 , 2, 3, 4, 5, and 6. This applies regardless of the breadth of the range.
[0028] The term “substantially” or “essentially” refers to a qualitative condition that exhibits an entire or nearly total range or degree of a feature or characteristic of interest. In some cases, substantially refers to at least about: 70%, 75%, 80%, 85%, 90%, 95%, 99%, 99.9% or 99.99% of the total range or degree of a feature or characteristic of interest. In some cases, the substantially or essentially refers to an amount that can be about 100% of a total amount.
[0029] As used herein, the term “about” a number can refer to that number plus or minus 10% of that number.
[0030] The terms “determining,” “measuring,” “evaluating,” “assessing,” “assaying,” and “analyzing” can be used interchangeably herein to refer to forms of measurement. The terms include determining if an element is present or not (for example, detection). These terms can
include quantitative, qualitative or quantitative and qualitative determinations. Assessing can be relative or absolute. “Detecting the presence of’ can include determining the amount of something present in addition to determining whether it is present or absent depending on the context.
[0031] The term “encode,” as used herein, refers to an ability of a polynucleotide to provide information or instructions sequence sufficient to produce a corresponding gene expression product. In a non-limiting example, mRNA can encode for a polypeptide during translation, whereas DNA can encode for an mRNA molecule during transcription.
[0032] The term “ex vivo” refers to an event that takes place outside of a subject’s body. An ex vivo assay may not be performed on a subject. Rather, it can be performed upon a sample separate from a subject. An example of an ex vivo assay performed on a sample can be an “in vitro” assay.
[0033] The term percent “identity,” in the context of two or more nucleic acid or polypeptide sequences, refers to two or more sequences or subsequences that have a specified percentage of nucleotides or amino acid residues that are the same, when compared and aligned for maximum correspondence, as measured using one of the sequence comparison algorithms described below (e.g., BLASTP and BLASTN or other algorithms available to persons of skill) or by visual inspection. Depending on the application, the percent “identity” can exist over a region of the sequence being compared, e.g., over a functional domain, or, alternatively, exist over the full length of the two sequences to be compared.
[0034] For sequence comparison, typically one sequence acts as a reference sequence (also called the subject sequence) to which test sequences (also called query sequences) are compared. The percent sequence identity is defined as a test sequence’s percent identity to a reference sequence For example, when stated “Sequence A having a sequence identity of 50% to Sequence B,” Sequence A is the test sequence and Sequence B is the reference sequence. When using a sequence comparison algorithm, test and reference sequences are input into a computer program, subsequence coordinates are designated, if necessary, and sequence algorithm program parameters are designated. The sequence comparison algorithm then aligns the sequences to achieve the maximum alignment, based on the designated program parameters, introducing gaps in the alignment if necessary. The percent sequence identity for the test sequence(s) relative to the reference sequence can then be determined from the alignment of the test sequence to the reference sequence. The equation for percent sequence identity from the aligned sequence is as follows: [(Number of Identical Positions)/(Total Number of Positions in the Test Sequence)] x 100%
[0035] For purposes herein, percent identity and sequence similarity calculations are performed using the BLAST algorithm for sequence alignment, which is described in Altschul et al., J. Mol Biol. 215:403-410 (1990). Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information (www.ncbi.nlm.nih.gov/). The BLAST algorithm uses a test sequence (also called a query sequence) and a reference sequence (also called a subject sequence) to search against, or in some cases, a database of multiple reference sequences to search against. The BLAST algorithm performs sequence alignment by finding high-scoring alignment regions between the test and the reference sequences by scoring alignment of short regions of the test sequence (termed “words”) to the reference sequence. The scoring of each alignment is determined by the BLAST algorithm and takes factors into account, such as the number of aligned positions, as well as whether introduction of gaps between the test and the reference sequences would improve the alignment. The alignment scores for nucleic acids can be scored by set match/mismatch scores. For protein sequences, the alignment scores can be scored using a substitution matrix to evaluate the significance of the sequence alignment, for example, the similarity between aligned amino acids based on their evolutionary probability of substitution. For purposes herein, the substitution matrix used is the BLOSUM62 matrix. For purposes herein, the public default values of April 6, 2023 are used when using the BLASTN and BLASTP algorithms. The BLASTN and BLASTP algorithms then output a “Percent Identity” output value and a “Query Coverage” output value. The overall percent sequence identity' as used herein can then be calculated from the BLASTN or BLASTP output values as follows: Percent Sequence Identity = (“Percent Identity” output value) x (“Query Coverage” output value) [0036] The following non-limiting examples illustrate the calculation of percent identity between two nucleic acids sequences. The percent identity' is calculated as follows: [(number of identical nucleotide positions)/(total number of nucleotides in the test sequence)] x 100%. Percent identity' is calculated to compare test sequence 1: AAAAAGGGGG (SEQ ID NO: 11) (length = 10 nucleotides) to reference sequence 2: AAAAAAAAAA (SEQ ID NO: 12) (length = 10 nucleotides). The percent identity between test sequence 1 and reference sequence 2 would be [(5)/(10)] x!00% = 50%. Test sequence 1 has 50% sequence identity to reference sequence 2. In another example, percent identity is calculated to compare test sequence 3: CCCCCGGGGGGGGGGCCCCC (SEQ ID NO: 13) (length = 20 nucleotides) to reference sequence 4: GGGGGGGGGG (SEQ ID NO: 14) (length = 10 nucleotides). The percent identity between test sequence 3 and reference sequence 4 would be [(10)/(20)] xioo% = 50%. Test sequence 3 has 50% sequence identity to reference sequence 4. In another example, percent identity is calculated to compare test sequence 5: GGGGGGGGGG (SEQ ID NO: 14) (length = 10 nucleotides) to reference sequence 6: CCCCCGGGGGGGGGGCCCCC (SEQ ID NO: 13)
(length = 20 nucleotides). The percent identity between test sequence 5 and reference sequence 6 would be [(10)/(l 0)] * 100% = 100%. Test sequence 5 has 100% sequence identity to reference sequence 6.
[0037] The following non-limiting examples illustrate the calculation of percent identity between two protein sequences. The percent identity is calculated as follows: [(number of identical amino acid positions)/(total number of amino acids in the test sequence)] x 100%. Percent identity' is calculated to compare test sequence 7: FFFFFYYYYY (SEQ ID NO: 15) (length = 10 amino acids) to reference sequence 8: YYYYYYYYYY (SEQ ID NO: 16) (length = 10 amino acids). The percent identity between test sequence 7 and reference sequence 8 would be [(5)/(10)J ><100% = 50%. Test sequence 7 has 50% sequence identity to reference sequence 8. In another example, percent identity is calculated to compare test sequence 9: LLLLLFFFFFYYYYYLLLLL (SEQ ID NO: 17) (length = 20 amino acids) to reference sequence 10: FFFFFYYYYY (SEQ ID NO: 15) (length = 10 amino acids). The percent identity between test sequence 9 and reference sequence 10 would be [(10)7(20)] * 100% = 50%. Test sequence 9 has 50% sequence identity to reference sequence 10. In another example, percent identity is calculated to compare test sequence 11: FFFFFYYYYY (SEQ ID NO: 15) (length = 10 amino acids) to reference sequence 12: LLLLLFFFFFYYYYYLLLLL (SEQ ID NO: 17) (length = 20 amino acids). The percent identity between test sequence 11 and reference sequence 12 would be [(10)/(10)] x ioo% = 100%. Test sequence 11 has 100% sequence identity to reference sequence 12..
[0038] For sequence comparison, typically one sequence acts as a reference sequence to which test sequences are compared. When using a sequence comparison algorithm, test and reference sequences are input into a computer, subsequence coordinates are designated, if necessary, and sequence algorithm program parameters are designated. The sequence comparison algorithm then calculates the percent sequence identity for the test sequence(s) relative to the reference sequence, based on the designated program parameters.
[0039] For purposes herein, percent identity and sequence similarity can be performed using the BLAST algorithm, which is described in Altschul et al. (J. Mol. Biol. 215:403-410 (1990)). Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information.
[0040] The term “in vitro” refers to an event that takes places contained in a container for holding laboratory reagent such that it can be separated from the biological source from which the material can be obtained. In vitro assays can encompass cell-based assays in which living or dead cells can be employed. In vitro assays can also encompass a cell-free assay in which no intact cells can be employed.
[0041] The term “in vivo” refers to an event that takes place in a subject’s body.
[0042] As used herein, the term “polynucleotide” refers to a single or double-stranded polymer of deoxyribonucleotide (DNA) or ribonucleotide (RNA) bases read from the 5’ to the 3’ end. The term “RNA” is inclusive of dsRNA (double stranded RNA), snRNA (small nuclear RNA), IncRNA (long non-coding RNA), mRNA (messenger RNA), miRNA (microRNA) RNAi (inhibitory RNA), siRNA (small interfering RNA), shRNA (short hairpin RNA), tRNA (transfer RNA), rRNA (ribosomal RNA), snoRNA (small nucleolar RNA), and cRNA (complementary RNA). The term DNA is inclusive of cDNA, genomic DNA, and DNA-RNA hybrids. A sequence of a polynucleotide may be provided interchangeably as an RNA sequence (containing U) or a DNA sequence (containing T). A sequence provided as an RNA sequence is intended to also cover the corresponding DNA sequence and the reverse complement RNA sequence or DNA sequence. A sequence provided as a DNA sequence is intended to also cover the corresponding RNA sequence and the reverse complement RNA sequence or DNA sequence.
[0043] The term “protein”, “peptide” and “polypeptide” can be used interchangeably and in their broadest sense can refer to a compound of two or more subunit amino acids, amino acid analogs or peptidomimetics. The subunits can be linked by peptide bonds. In another embodiment, the subunit can be linked by other bonds, e.g., ester, ether, etc. A protein or peptide can contain at least two amino acids and no limitation can be placed on the maximum number of amino acids which can comprise a protein’s or peptide's sequence. As used herein the term “amino acid” can refer to either natural amino acids, unnatural amino acids, or synthetic amino acids, including glycine and both the D and L optical isomers, amino acid analogs and peptidomimetics. As used herein, the term “fusion protein” can refer to a protein comprised of domains from more than one naturally occurring or recombinantly produced protein, where generally each domain serves a different function. In this regard, the term “linker” can refer to a protein fragment that can be used to link these domains together - optionally to preserve the conformation of the fused protein domains, prevent unfavorable interactions between the fused protein domains which can compromise their respective functions, or both.
[0044] As used herein, “pharmaceutically acceptable salt” may refer to pharmaceutical molecules, which may be formed as a weak acid or base, chemically made into their salt forms, most frequently as the hydrochloride, sodium, or sulfate salts. Drug products synthesized as salts may enhance drug dissolution, boost absorption into the bloodstream, facilitate therapeutic effects, and increase its effectiveness. Pharmaceutically acceptable salts may also facilitate the development of controlled-release dosage forms, improve drug stability, extend shelf life, enhance targeted drug delivery, and improve drug effectiveness.
[0045] The terms “subject,” “individual,” or “patient” can be used interchangeably herein. A “subject” refers to a biological entity containing expressed genetic materials. The biological entity can be a plant, animal, or microorganism, including, for example, bacteria, viruses, fungi, and protozoa. The subject can be tissues, cells and their progeny of a biological entity obtained in vivo or cultured in vitro. The subject can be a mammal. The mammal can be a human. The subject can be diagnosed or suspected of being at high risk for a disease. In some cases, the subject is not necessarily diagnosed or suspected of being at high risk for the disease [0046] As used herein, the terms “treatment” or “treating” can be used in reference to a pharmaceutical or other intervention regimen for obtaining beneficial or desired results in the recipient. Beneficial or desired results include but are not limited to a therapeutic benefit and/or a prophylactic benefit. A therapeutic benefit can refer to eradication or amelioration of one or more symptoms of an underlying disorder being treated. Also, a therapeutic benefit can be achieved with the eradication or amelioration of one or more of the physiological symptoms associated with the underlying disorder such that an improvement can be observed in the subject, notwithstanding that the subject can still be afflicted with the underlying disorder. A prophylactic effect includes delaying, preventing, or eliminating the appearance of a disease or condition, delaying or eliminating the onset of one or more symptoms of a disease or condition, slowing, halting, or reversing the progression of a disease or condition, or any combination thereof. For prophylactic benefit, a subject at risk of developing a particular disease, or to a subject reporting one or more of the physiological symptoms of a disease can undergo treatment, even though a diagnosis of this disease may not have been made.
Engineered Peptides
[0047] Disclosed herein are engineered peptides useful for treatment of a disease or condition in a subject. An engineered peptide as disclosed herein can be a therapeutic peptide. As disclosed herein, a therapeutic peptide exhibits a therapeutic property useful for treatment of a disease or condition. In some instances, the disease or condition is a cancer.
[0048] In some embodiments, an engineered peptide of the present disclosure is a therapeutic peptide that exhibits cellular toxicity. As disclosed herein, an engineered peptide of the present disclosure is a therapeutic peptide exhibiting cellular toxicity can be useful to treat diseases or conditions such as cancer. In some instances, contacting an engineered peptide of the present disclosure with a cancer cell can arrest cancer cell growth. In some instances, contacting an engineered of the present disclosure can reduce the size of a cancer cell (e.g. can decrease tumor volume). In some instances, contacting an engineered of the present disclosure can induce apoptosis or cell death of the cancer cell.
[0049] In some embodiments, an engineered peptide of the present disclosure can be alphahelical (e g. adopts an alpha-helical structure at physiological salt concentrations and physiological temperature). In some cases, a physiological temperature can be from about 36 °C to about 38 °C, or about 37 °C degrees. In some cases, a physiological salt concentration can be from about 0.5% to about 15%, 1% to about 10%, 1% to about 5%, or about 0.9%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10% of a solution. In some cases, a physiological salt can be a sodium chloride, a sodium phosphate, a potassium phosphate, a sodium carbonate, a potassium iodide, or any combination thereof. Without withing to be bound by theory, an alpha-helical engineered peptide of the present disclosure may have improved cell permeability, relative to a corresponding non-alpha helical peptide. As such, an alpha-helical engineered peptide of the present disclosure is useful for producing cellular toxicity to treat diseases or conditions described herein.
[0050] In some embodiments, an engineered peptide of the present disclosure can be a stapled peptide. In some embodiments, an alpha-helical engineered peptide of the present disclosure can be a stapled peptide. A stapled peptide of the present disclosure is a peptide in which two or more amino acids of the peptide are covalently linked by way of their side chains. Without wishing to be bound by theory, utilizing peptide stapling can stabilize a secondary structure adopted by the stapled peptide. Where the engineered peptide is an alpha helical engineered peptide, utilizing peptide stapling to produce a stapled alpha helical engineered peptide can stabilize the alpha helical structure of the engineered peptide, thus reducing the entropic penalty for adopting the alpha helical secondary structure. In some cases, a peptide herein can comprise one or more staples. In some cases, a stapled peptide encompasses a stitched peptide having, for example, a plurality of staples (e.g., 2, 3, 4, 5, 6, or 7 staples). A stitched peptide contains 2 or more staples. In some cases, a first residue (i) can be stapled to a residue that is n residues downstream (i+n). For example, a first residue (i) can be stapled to a residue 3 amino acids downstream (i+3), 4 amino acids downstream (i+4), 5 amino acids downstream (i+5), 6 amino acids downstream (i+6), 7 amino acids downstream (i+7), 8 amino acids downstream (i+8), 9 amino acids downstream (i+9), 10 amino acids downstream (i+10), 11 amino acids downstream (i+11), 12 amino acids downstream (i+12), 13 amino acids downstream (i+13), 14 amino acids downstream (i+14), etc. In some embodiments, a therapeutic peptide of the present disclosure is an (i, i+3) stapled peptide. In some embodiments, an engineered peptide of the present disclosure is an (i, i+7) stapled peptide. The first residue (i) in a peptide staple can be any residue that is at least n upstream of the last residue an engineered peptide as disclosed herein. For example, in an engineered peptide having a length of 13 amino acids and comprising a first residue (i) stapled to a residue n amino acids downstream (i+n) wherein n is 7, the first residue (i) can be amino acid
1, 2, 3, 4, 5, or 6 of the engineered peptide. In some embodiments, an engineered peptide having a length of 13 amino acids and a stapled peptide at (i, i+7) comprises a first residue (i) at amino acid 3 of the engineered peptide that is stapled to residue (i+7) at amino acid 10 of the engineered peptide. For example, in an engineered peptide having a length of 14 amino acids and comprising a first residue (i) stapled to a residue n amino acids downstream (i+n) wherein n is 7, the first residue (i) can be amino acid 1, 2, 3, 4, 5, 6, or 7 of the engineered peptide. In some embodiments, an engineered peptide having a length of 14 amino acids and a stapled peptide at (i, i+7) comprises a first residue (i) at amino acid 4 of the engineered peptide that is stapled to residue (i+7) at amino acid 11 of the engineered peptide. As another example, in an engineered peptide having a length of 13 ammo acids and comprising a first residue (i) stapled to a residue n amino acids downstream (i+n) wherein n is 3, the first residue (i) can be amino acid 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 of the engineered peptide. As another example, in an engineered peptide having a length of 14 amino acids and comprising a first residue (i) stapled to a residue n amino acids downstream (i+n) wherein n is 3, the first residue (i) can be amino acid 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or 11 of the engineered peptide. In some embodiments, a (i) residue is a non-natural amino acid. In some embodiments, a (i+n) residue that is n amino acids downstream of the (i) residue is a non-natural amino acid. In some embodiments, the (i) residue is an a, oc-disubstituted nonnatural amino acid. In some embodiments, the (i) residue is S-pentenylalanme (S5), R- pentylalanine (R5), S-octenylalanine (S8), or R-octenylalanine (R8). In some embodiments, the (i+n) residue is S-pentenylalanine (S5), R-pentylalanine (R5), S-octenylalanine (S8), or R- octenylalanine (R8). For example, in an engineered peptide comprising an (i) residue stapled to an (i+n) residue, the residue (i) can be R8 and the (i+n) residue can be S5.
[0051] Engineered peptides of the present disclosure can be engineered or non-naturally occurring peptides. As disclosed herein, an engineered peptide indicates the involvement of the hand of man. An engineered peptide is at least substantially free from at least one feature that is naturally associated or found in a naturally occurring peptide (e.g., length), and/or contains a modification (e.g, chemical modification or ammo acid sequence) that is not present in the naturally occurring peptide. In some cases, engineered peptides of the present disclosure are selected through screening, rational design, and the like, to exhibit improved properties relative to naturally occurring peptides. For example, an engineered peptide of the present disclosure can have increased cellular toxicity relative to a naturally occurring peptide, and/or can have increased cell permeability relative to a naturally occurring peptide. In some cases, a peptide herein can have an N-terminal modification such as an acetyl modification. In some cases, a peptide herein can have a C-terminal modification such as an amide modification.
[0052] In some embodiments, an engineered peptide of the present disclosure has an half maximal inhibitory concentration (ICso) of less than 200 pM, less than 165 pM, less than 100 pM, less than 95 pM, less than 90 pM, less than 85 pM, less than 80 pM, less than 75 pM, less than 70 pM, less than 65 pM, less than 60 pM, less than 55 pM, less than 50 pM, less than 45 pM, less than 40 pM, less than 35 pM, less than 30 pM, less than 25 pM, less than 20 pM, less than 15 pM, less than 10 pM, less than 5 pM, less than 1 pM, less than 100 nM, or less than 10 nM ; as determined in an in vitro assay against a cancer cell line. In some embodiments, an engineered peptide of the present disclosure has an ICso of from about 1 nM to about 50 pM, 1 pM to about 50 pM, from about 100 pM to about 200 pM, from about 150 pM to about 200 pM, from about 10 pM to about 100 pM, from about 10 pM to about 60 pM, from about 10 pM to about 50 pM, from about 10 pM to about 45 pM, from about 5 pM to about 10 pM, from about 5 pM to about 15 pM, from about 40 pM to about 60 pM, from about 10 pM to about 30 pM, from about 10 pM to about 25 pM, from about 10 pM to about 20 pM, from about 10 pM to about 15 pM, from about 1 pM to about 5 pM, from about 500 nM to about 1 pM, from about 100 nM to about 500 nM, from about 10 nM to about 100 nM, from about 0. 1 nM to about 1 nM, from about 0.01 nM to about 0. 1 nM, or from about 1 nM to about 10 nM; as determined in an in vitro assay against a cancer cell line. In some embodiments, an engineered peptide of the present disclosure has an ICso of about 50 pM, about 49 pM, about 48 pM, about 47 pM, about 46 pM, about 45 pM, about 44 pM, about 43 pM, about 42 pM, about 41 pM, 40 pM, about 39 pM, about 38 pM, about 37 pM, about 36 pM, about 35 pM, about 34 pM, about 33 pM, about 32 pM, about 31 pM, about 30 pM, about 29 pM, about 28 pM, about 27 pM, about 26 pM, about 25 pM, about 24 pM, about 23 pM, about 22 pM, about 21 pM, about 20 pM, about 19 pM, about 18 pM, about 17 pM, about 16 pM, about 15 pM, about 14 pM, about 13 pM, about 12 pM, about 11 pM, about 10 pM, about 9 pM, about 8 pM, about 7 pM, about 6 pM, about 5 pM, about 4 pM, about 3 pM, about 2 pM, about 1 pM, about 900 nM, about 800 nM, about 700 nM, about 600 nM, about 500 nM, about 400 nM, about 300 nM, about 200 nM, about 100 nM, about 90 nM, about 80 nM, about 70 nM, about 60 nM, about 50 nM, about 40 nM, about 30 nM, about 20 nM, about 10 nM, about 9 nM, about 8 nM, about 7 nM, about 6 nM, about 5 nM, about 4 nM, about 3 nM, about 2 nM, about 1 nM, about 0.5 nM, or about 0. 1 nM; as determined in an in vitro assay against a cancer cell line. In some embodiments, an engineered peptide of the present disclosure has an ICso of from 10 pM to 60 pM, from 10 pM to 50 pM, from 1 pM to 50 pM, from 10 pM to 45 pM, from 40 pM to 60 pM, from 5 pM to 10 pM, from 5 pM to 15 pM, from 10 pM to 30 pM, from 10 pM to 25 pM, from 10 pM to 15 pM, from 10 pM to 20 pM, from 1 pM to 5 pM, from 500 nM to 1 pM, from 500 nM to 800 nM, from 100 nM to 500 nM, from 50 nM to 250 nM, from 10 nM to 100 nM, from 0.1 nM to 1 nM, from 0.01 nM to 0. 1 nM,
or from 1 nM to 10 nM; as determined in an in vitro assay against a cancer cell line. In some embodiments, an engineered peptide of the present disclosure has an ICso of no more than 50 pM, no more than 49 pM, no more than 48 pM, no more than 47 pM, no more than 46 pM, no more than 45 pM, no more than 44 pM, no more than 43 pM, no more than 42 pM, no more than 41 pM, no more than 40 pM, no more than 39 pM, no more than 38 pM, no more than 37 pM, no more than 36 pM, no more than 35 pM, no more than 34 pM, no more than 33 pM, no more than 32 pM, no more than 31 pM, no more than 30 pM, no more than 29 pM, no more than 28 pM, no more than 27 pM, no more than 26 pM, no more than 25 pM, no more than 24 pM, no more than 23 pM, no more than 22 pM, no more than 21 pM, no more than 20 pM, no more than 19 pM, no more than 18 pM, no more than 17 pM, no more than 16 pM, no more than 15 pM, no more than 14 pM, no more than 13 pM, no more than 12 pM, no more than 11 pM, no more than 10 pM, no more than 9 pM, no more than 8 pM, no more than 7 pM, no more than 6 pM, no more than 5 pM, no more than 4 pM, no more than 3 pM, no more than 2 pM, no more than 1 pM, no more than 900 nM, no more than 800 nM, no more than 700 nM, no more than 600 nM, no more than 500 nM, no more than 400 nM, no more than 300 nM, no more than 200 nM, no more than 100 nM, no more than 90 nM, no more than 80 nM, no more than 70 nM, no more than 60 nM, no more than 50 nM, no more than 40 nM, no more than 30 nM, no more than 20 nM, no more than 10 nM, no more than 9 nM, no more than 8 nM, no more than 7 nM, no more than 6 nM, no more than 5 nM, no more than 4 nM, no more than 3 nM, no more than 2 nM, no more than 1 nM, no more than 0.5 nM, or no more than 0.1 nM; as determined in an in vitro assay against a cancer cell line.
[0053] In some embodiments, an engineered peptide of the present disclosure can comprise a portion of a naturally occurring peptide. For example, an engineered peptide of the present disclosure can comprise a portion of an alpha helical domain of a naturally occurring protein. As described herein, such portions can be further engineered in the development of the engineered peptides to deviate from the portion of the naturally occurring peptide. In some embodiments, an engineered peptide of the present disclosure can comprise, or can be derived from prior to engineering, a portion of an RBI peptide, a CHEK2 peptide, an MDM2 peptide, a RAFI peptide, a RAC1 peptide, an RRAS2 peptide, a FAC1 peptide, a PIK3Ca peptide, a PIK3R1 peptide, a VHL peptide, a DDX3X peptide, or a CTNNB1 peptide. In some embodiments, a therapeutic peptide of the present disclosure can have at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to a contiguous portion of an RBI peptide, a CHEK2 peptide, an MDM2 peptide, a RAFI peptide, a RAC1 peptide, an RRAS2 peptide, a FAC1 peptide, a PIK3Ca peptide, a PIK3R1 peptide, a VHL peptide, a DDX3X peptide, or a CTNNB1 peptide.
[0054] In some cases, an engineered peptide can comprise, or be derived from a portion of a naturally occurring protein that is from about 5 amino acids to about 40 amino acids, from about 6 amino acids to about 40 amino acids, from about 7 amino acids to about 40 amino acids, from about 8 amino acids to about 40 amino acids, from about 9 amino acids to about 40 amino acids, from about 10 amino acids to about 40 amino acids, from about 11 amino acids to about 40 amino acids, from about 12 amino acids to about 40 ammo acids, from about 13 amino acids to about 40 amino acids, from about 14 amino acids to about 40 amino acids, from about 15 amino acids to about 40 amino acids, from about 16 amino acids to about 40 amino acids, from about 17 amino acids to about 40 amino acids, from about 18 amino acids to about 40 amino acids, from about 19 ammo acids to about 40 ammo acids, from about 20 ammo acids to about 40 amino acids, from about 21 amino acids to about 40 amino acids, from about 22 amino acids to about 40 amino acids, from about 23 amino acids to about 40 amino acids, from about 24 amino acids to about 40 amino acids, from about 25 amino acids to about 40 amino acids, from about 26 amino acids to about 40 amino acids, from about 27 amino acids to about 40 amino acids, from about 28 amino acids to about 40 amino acids, from about 29 amino acids to about 40 amino acids, from about 30 amino acids to about 40 amino acids, from about 31 amino acids to about 40 amino acids, from about 32 amino acids to about 40 amino acids, from about 33 amino acids to about 40 amino acids, from about 34 amino acids to about 40 amino acids, from about 35 amino acids to about 40 amino acids, from about 36 amino acids to about 40 amino acids, from about 37 amino acids to about 40 amino acids, from about 38 amino acids to about 40 amino acids, or from about 39 amino acids to about 40 amino acids. In some embodiments, an engineered peptide can comprise, or be derived from prior to engineered, a portion of a naturally occurring protein that is from about 5 amino acids to about 20 amino acids, from about 6 ammo acids to about 20 amino acids, from about 7 amino acids to about 20 amino acids, from about 8 amino acids to about 20 amino acids, from about 9 amino acids to about 20 amino acids, from about 10 amino acids to about 20 amino acids, from about 11 amino acids to about 20 amino acids, from about 12 amino acids to about 20 amino acids, from about 13 amino acids to about 20 amino acids, from about 14 amino acids to about 20 amino acids, from about 15 amino acids to about 20 amino acids, from about 16 amino acids to about 20 amino acids, from about 17 amino acids to about 20 amino acids, from about 18 amino acids to about 20 amino acids, or from about 19 amino acids to about 20 amino acids. In some cases, an engineered peptide can comprise, or be denved from, a portion of a naturally occurring protein that is from 5 ammo acids to 40 amino acids, from 6 amino acids to 40 amino acids, from 7 amino acids to 40 amino acids, from 8 amino acids to 40 amino acids, from 9 amino acids to 40 amino acids, from 10 amino acids to 40 amino acids, from 11 amino acids to 40 amino acids, from 12 amino acids to
40 amino acids, from 13 amino acids to 40 amino acids, from 14 amino acids to 40 ammo acids, from 15 amino acids to 40 amino acids, from 16 amino acids to 40 amino acids, from 17 amino acids to 40 amino acids, from 18 amino acids to 40 amino acids, from 19 amino acids to 40 amino acids, from 20 amino acids to 40 amino acids, from 21 amino acids to 40 amino acids, from 22 amino acids to 40 amino acids, from 23 amino acids to 40 amino acids, from 24 amino acids to 40 amino acids, from 25 amino acids to 40 amino acids, from 26 amino acids to 40 amino acids, from 27 amino acids to 40 amino acids, from 28 amino acids to 40 amino acids, from 29 amino acids to 40 amino acids, from 30 amino acids to 40 amino acids, from 31 amino acids to 40 amino acids, from 32 amino acids to 40 amino acids, from 33 amino acids to 40 ammo acids, from 34 ammo acids to 40 ammo acids, from 35 ammo acids to 40 ammo acids, from 36 amino acids to 40 amino acids, from 37 amino acids to 40 amino acids, from 38 amino acids to 40 amino acids, or from 39 amino acids to 40 amino acids. In some cases, an engineered peptide can comprise, or be derived from, a portion of a naturally occurring protein that is from 5 amino acids to 39 amino acids, from 6 amino acids to 39 amino acids, from 7 amino acids to 39 amino acids, from 8 amino acids to 39 amino acids, from 9 amino acids to 39 amino acids, from 10 amino acids to 39 amino acids, from 11 amino acids to 39 amino acids, from 12 amino acids to 39 amino acids, from 13 amino acids to 39 amino acids, from 14 amino acids to 39 amino acids, from 15 amino acids to 39 amino acids, from 16 amino acids to 39 amino acids, from 17 amino acids to 39 amino acids, from 18 amino acids to 39 amino acids, from 19 amino acids to 39 amino acids, from 20 amino acids to 39 amino acids, from 21 amino acids to 39 amino acids, from 22 amino acids to 39 amino acids, from 23 amino acids to 39 amino acids, from 24 amino acids to 39 amino acids, from 25 amino acids to 39 amino acids, from 26 amino acids to 39 amino acids, from 27 amino acids to 39 amino acids, from 28 amino acids to 39 amino acids, from 29 amino acids to 39 amino acids, from 30 amino acids to 39 amino acids, from 31 amino acids to 39 amino acids, from 32 amino acids to 39 amino acids, from 33 amino acids to 39 amino acids, from 34 amino acids to 39 amino acids, from 35 amino acids to 39 amino acids, from 36 amino acids to 39 amino acids, from 37 amino acids to 39 amino acids, or from 38 amino acids to 39 amino acids. In some embodiments, an engineered peptide can comprise, or be derived from, a portion of a naturally occurring protein that is from 5 amino acids to 20 amino acids, from 6 amino acids to 20 amino acids, from 7 amino acids to 20 amino acids, from 8 amino acids to 20 amino acids, from 9 amino acids to 20 amino acids, from 10 amino acids to 20 ammo acids, from 10 ammo acids to 15 ammo acids, from 11 ammo acids to 20 ammo acids, from 12 amino acids to 20 amino acids, from 13 amino acids to 20 amino acids, from 14 amino acids to 20 amino acids, from 15 amino acids to 20 amino acids, from 16 amino acids to 20 amino acids, from 17 amino acids to 20 amino acids, from 18 amino acids to 20 amino acids, or
from 19 amino acids to 20 amino acids. In some embodiments, an engineered peptide can comprise, or be derived from, a portion of a naturally occurring protein that is at most 40 amino acids, at most 39 amino acids, at most 38 amino acids, at most 37 amino acids, at most 36 amino acids, at most 35 amino acids, at most 34 amino acids, at most 33 amino acids, at most 32 amino acids, at most 31 amino acids, at most 30 amino acids, at most 29 amino acids, at most 28 amino acids, at most 27 amino acids, at most 26 amino acids, at most 25 amino acids, at most 24 amino acids, at most 23 amino acids, at most 22 amino acids, at most 21 amino acids, at most 20 amino acids, at most 19 amino acids, at most 18 amino acids, at most 17 amino acids, at most 16 amino acids, at most 15 amino acids, at most 14 amino acids, at most 13 amino acids, at most 12 amino acids, at most 11 amino acids, at most 10 ammo acids, at most 9 ammo acids, at most 8 ammo acids, at most 7 amino acids, at most 6 amino acids, or at most 5 amino acids. In some embodiments, an engineered peptide can comprise, or be derived from, a portion of a naturally occurring protein that is 40 amino acids, 39 amino acids, 38 amino acids, 37 amino acids, 36 amino acids, 35 amino acids, 34 amino acids, 33 amino acids, 32 amino acids, 31 amino acids, 30 amino acids, 29 amino acids, 28 amino acids, 27 amino acids, 26 amino acids, 25 amino acids, 24 amino acids, 23 amino acids, 22 amino acids, 21 amino acids, 20 amino acids, 19 amino acids, 18 amino acids, 17 amino acids, 16 amino acids, 15 amino acids, 14 amino acids, 13 amino acids, 12 amino acids, 11 amino acids, 10 amino acids, 9 amino acids, 8 amino acids, 7 amino acids, 6 amino acids, or 5 amino acids.
[0055] In some cases, an engineered peptide can consist of a portion of a naturally occurring protein or of a portion derived a naturally occurring protein that is from about 5 amino acids to about 40 amino acids, from about 6 amino acids to about 40 amino acids, from about 7 amino acids to about 40 ammo acids, from about 8 amino acids to about 40 amino acids, from about 9 amino acids to about 40 amino acids, from about 10 amino acids to about 40 amino acids, from about 11 amino acids to about 40 amino acids, from about 12 amino acids to about 40 amino acids, from about 13 amino acids to about 40 amino acids, from about 14 amino acids to about 40 amino acids, from about 15 amino acids to about 40 amino acids, from about 16 amino acids to about 40 amino acids, from about 17 amino acids to about 40 amino acids, from about 18 amino acids to about 40 amino acids, from about 19 amino acids to about 40 amino acids, from about 20 amino acids to about 40 amino acids, from about 21 amino acids to about 40 amino acids, from about 22 amino acids to about 40 amino acids, from about 23 amino acids to about 40 ammo acids, from about 24 ammo acids to about 40 ammo acids, from about 25 ammo acids to about 40 amino acids, from about 26 amino acids to about 40 amino acids, from about 27 amino acids to about 40 amino acids, from about 28 amino acids to about 40 amino acids, from about 29 amino acids to about 40 amino acids, from about 30 amino acids to about 40 amino
acids, from about 31 amino acids to about 40 amino acids, from about 32 amino acids to about 40 amino acids, from about 33 amino acids to about 40 amino acids, from about 34 amino acids to about 40 amino acids, from about 35 amino acids to about 40 amino acids, from about 36 amino acids to about 40 amino acids, from about 37 amino acids to about 40 amino acids, from about 38 amino acids to about 40 amino acids, or from about 39 amino acids to about 40 amino acids. In some embodiments, an engineered peptide can consist of a portion of a naturally occurring protein or of a portion derived a naturally occurring protein that is from about 5 amino acids to about 20 amino acids, from about 6 amino acids to about 20 amino acids, from about 7 amino acids to about 20 amino acids, from about 8 amino acids to about 20 amino acids, from about 9 ammo acids to about 20 ammo acids, from about 10 ammo acids to about 20 amino acids, from about 11 amino acids to about 20 amino acids, from about 12 amino acids to about 20 amino acids, from about 13 amino acids to about 20 amino acids, from about 14 amino acids to about 20 amino acids, from about 15 amino acids to about 20 amino acids, from about 16 amino acids to about 20 amino acids, from about 17 amino acids to about 20 amino acids, from about 18 amino acids to about 20 amino acids, or from about 19 amino acids to about 20 amino acids. In some cases, an engineered peptide can consist of a portion of a naturally occurring protein or of a portion derived a naturally occurring protein that is from 5 amino acids to 40 amino acids, from 6 amino acids to 40 amino acids, from 7 amino acids to 40 amino acids, from 8 amino acids to 40 amino acids, from 9 amino acids to 40 amino acids, from 10 amino acids to 40 amino acids, from 11 amino acids to 40 amino acids, from 12 amino acids to 40 amino acids, from 13 amino acids to 40 amino acids, from 14 amino acids to 40 amino acids, from 15 amino acids to 40 amino acids, from 16 amino acids to 40 amino acids, from 17 amino acids to 40 amino acids, from 18 amino acids to 40 amino acids, from 19 amino acids to 40 amino acids, from 20 amino acids to 40 amino acids, from 21 amino acids to 40 amino acids, from 22 amino acids to 40 amino acids, from 23 amino acids to 40 amino acids, from 24 amino acids to 40 amino acids, from 25 amino acids to 40 amino acids, from 26 amino acids to 40 amino acids, from 27 amino acids to 40 amino acids, from 28 amino acids to 40 amino acids, from 29 amino acids to 40 amino acids, from 30 amino acids to 40 amino acids, from 31 amino acids to 40 amino acids, from 32 amino acids to 40 amino acids, from 33 amino acids to 40 amino acids, from 34 amino acids to 40 amino acids, from 35 amino acids to 40 amino acids, from 36 amino acids to 40 amino acids, from 37 amino acids to 40 amino acids, from 38 amino acids to 40 amino acids, or from 39 ammo acids to 40 ammo acids. In some cases, an engineered peptide can consist of a portion of a naturally occurring protein or of a portion derived a naturally occurring protein that is from 5 amino acids to 39 amino acids, from 6 amino acids to 39 amino acids, from 7 amino acids to 39 amino acids, from 8 amino acids to 39 amino acids, from 9 amino acids to
39 amino acids, from 10 amino acids to 39 amino acids, from 11 amino acids to 39 amino acids, from 12 amino acids to 39 amino acids, from 13 amino acids to 39 amino acids, from 14 amino acids to 39 amino acids, from 15 amino acids to 39 amino acids, from 16 amino acids to 39 amino acids, from 17 amino acids to 39 amino acids, from 18 amino acids to 39 amino acids, from 19 amino acids to 39 amino acids, from 20 amino acids to 39 amino acids, from 21 amino acids to 39 amino acids, from 22 amino acids to 39 amino acids, from 23 amino acids to 39 amino acids, from 24 amino acids to 39 amino acids, from 25 amino acids to 39 amino acids, from 26 amino acids to 39 amino acids, from 27 amino acids to 39 amino acids, from 28 amino acids to 39 amino acids, from 29 amino acids to 39 amino acids, from 30 amino acids to 39 amino acids, from 31 ammo acids to 39 ammo acids, from 32 amino acids to 39 ammo acids, from 33 amino acids to 39 amino acids, from 34 amino acids to 39 amino acids, from 35 amino acids to 39 amino acids, from 36 amino acids to 39 amino acids, from 37 amino acids to 39 amino acids, or from 38 amino acids to 39 amino acids. In some embodiments, an engineered peptide can consist of a portion of a naturally occurring protein or of a portion derived a naturally occurring protein that is from 5 amino acids to 20 amino acids, from 6 amino acids to 20 amino acids, from 7 amino acids to 20 amino acids, from 8 amino acids to 20 amino acids, from 9 amino acids to 20 amino acids, from 10 amino acids to 20 amino acids, from 10 amino acids to 15 amino acids, from 11 amino acids to 20 amino acids, from 12 amino acids to 20 amino acids, from 13 amino acids to 20 amino acids, from 14 amino acids to 20 amino acids, from 15 amino acids to 20 amino acids, from 16 amino acids to 20 amino acids, from 17 amino acids to 20 amino acids, from 18 amino acids to 20 amino acids, or from 19 amino acids to 20 amino acids. In some embodiments, an engineered peptide can consist of a portion of a naturally occurring protein or of a portion derived a naturally occurring protein that is at most 40 amino acids, at most 39 amino acids, at most 38 amino acids, at most 37 amino acids, at most 36 amino acids, at most 35 amino acids, at most 34 amino acids, at most 33 amino acids, at most 32 amino acids, at most 31 amino acids, at most 30 amino acids, at most 29 amino acids, at most 28 amino acids, at most 27 amino acids, at most 26 amino acids, at most 25 amino acids, at most 24 amino acids, at most 23 amino acids, at most 22 amino acids, at most 21 amino acids, at most 20 amino acids, at most 19 amino acids, at most 18 amino acids, at most 17 amino acids, at most 16 amino acids, at most 15 amino acids, at most 14 amino acids, at most 13 amino acids, at most 12 amino acids, at most 11 amino acids, at most 10 amino acids, at most 9 amino acids, at most 8 amino acids, at most 7 ammo acids, at most 6 ammo acids, or at most 5 ammo acids. In some embodiments, an engineered peptide can consist of a portion of a naturally occurring protein or of a portion derived a naturally occurring protein that is 40 amino acids, 39 amino acids, 38 amino acids, 37 amino acids, 36 amino acids, 35 amino acids, 34 amino acids, 33 amino acids,
32 amino acids, 31 amino acids, 30 amino acids, 29 amino acids, 28 amino acids, 27 amino acids, 26 amino acids, 25 amino acids, 24 amino acids, 23 amino acids, 22 amino acids, 21 amino acids, 20 amino acids, 19 amino acids, 18 amino acids, 17 amino acids, 16 amino acids, 15 amino acids, 14 amino acids, 13 amino acids, 12 amino acids, 11 amino acids, 10 amino acids, 9 amino acids, 8 amino acids, 7 amino acids, 6 amino acids, or 5 amino acids in length. [0056] An engineered peptide of the present disclosure can have varying lengths depending on their functionality. In some cases, engineered peptides of the present disclosure are short peptides of low molecular weight. In some embodiments, an engineered peptide of the present disclosure can have a length of at most 40 amino acids, at most 39 amino acids, at most 38 amino acids, at most 37 amino acids, at most 36 ammo acids, at most 35 ammo acids, at most 34 ammo acids, at most 33 amino acids, at most 32 amino acids, at most 31 amino acids, at most 30 amino acids, at most 29 amino acids, at most 28 amino acids, at most 27 amino acids, at most 26 amino acids, at most 25 amino acids, at most 24 amino acids, at most 23 amino acids, at most 22 amino acids, at most 21 amino acids, at most 20 amino acids, at most 19 amino acids, at most 18 amino acids, at most 17 amino acids, at most 16 amino acids, at most 15 amino acids, at most 14 amino acids, at most 13 amino acids, at most 12 amino acids, at most 11 amino acids, at most 10 amino acids, at most 9 amino acids, at most 8 amino acids, at most 7 amino acids, at most 6 amino acids, or at most 5 amino acids. In some embodiments, an engineered peptide of the present disclosure can have a length of from about 5 amino acids to about 40 amino acids, from about 6 amino acids to about 40 amino acids, from about 7 amino acids to about 40 amino acids, from about 8 amino acids to about 40 amino acids, from about 9 amino acids to about 40 amino acids, from about 10 amino acids to about 40 amino acids, from about 11 amino acids to about 40 amino acids, from about 12 amino acids to about 40 ammo acids, from about 13 amino acids to about 40 amino acids, from about 14 amino acids to about 40 amino acids, from about 15 amino acids to about 40 amino acids, from about 16 amino acids to about 40 amino acids, from about 17 amino acids to about 40 amino acids, from about 18 amino acids to about 40 amino acids, from about 19 amino acids to about 40 amino acids, from about 20 amino acids to about 40 amino acids, from about 21 amino acids to about 40 ammo acids, from about 22 amino acids to about 40 amino acids, from about 23 amino acids to about 40 amino acids, from about 24 amino acids to about 40 amino acids, from about 25 amino acids to about 40 amino acids, from about 26 amino acids to about 40 amino acids, from about 27 amino acids to about 40 amino acids, from about 28 ammo acids to about 40 ammo acids, from about 29 ammo acids to about 40 amino acids, from about 30 amino acids to about 40 amino acids, from about 31 amino acids to about 40 amino acids, from about 32 amino acids to about 40 amino acids, from about 33 amino acids to about 40 amino acids, from about 34 amino acids to about 40 amino acids, from about
35 amino acids to about 40 amino acids, from about 36 amino acids to about 40 amino acids, from about 37 amino acids to about 40 amino acids, from about 38 amino acids to about 40 amino acids, or from about 39 amino acids to about 40 amino acids. In some embodiments, an engineered peptide of the present disclosure can have a length of from about 5 amino acids to about 20 amino acids, from about 6 amino acids to about 20 amino acids, from about 7 amino acids to about 20 amino acids, from about 8 amino acids to about 20 amino acids, from about 9 amino acids to about 20 amino acids, from about 10 amino acids to about 20 amino acids, from about 10 amino acids to about 15 amino acids, from about 11 amino acids to about 20 amino acids, from about 12 amino acids to about 20 amino acids, from about 13 amino acids to about 20 ammo acids, from about 14 ammo acids to about 20 ammo acids, from about 15 ammo acids to about 20 amino acids, from about 16 amino acids to about 20 amino acids, from about 17 amino acids to about 20 amino acids, from about 18 amino acids to about 20 amino acids, or from about 19 amino acids to about 20 amino acids. In some cases, an engineered peptide of the present disclosure can have a length of from 5 amino acids to 40 amino acids, from 6 amino acids to 40 amino acids, from 7 amino acids to 40 amino acids, from 8 amino acids to 40 amino acids, from 9 amino acids to 40 amino acids, from 10 amino acids to 40 amino acids, from 11 amino acids to 40 amino acids, from 12 amino acids to 40 amino acids, from 13 amino acids to 40 amino acids, from 14 amino acids to 40 amino acids, from 15 amino acids to 40 amino acids, from 16 amino acids to 40 amino acids, from 17 amino acids to 40 amino acids, from 18 amino acids to 40 amino acids, from 19 amino acids to 40 amino acids, from 20 amino acids to 40 amino acids, from 21 amino acids to 40 amino acids, from 22 amino acids to 40 amino acids, from 23 amino acids to 40 amino acids, from 24 amino acids to 40 amino acids, from 25 amino acids to 40 amino acids, from 26 ammo acids to 40 amino acids, from 27 amino acids to 40 amino acids, from 28 amino acids to 40 amino acids, from 29 amino acids to 40 amino acids, from 30 amino acids to 40 amino acids, from 31 amino acids to 40 amino acids, from 32 amino acids to 40 amino acids, from 33 amino acids to 40 amino acids, from 34 amino acids to 40 amino acids, from 35 amino acids to 40 amino acids, from 36 amino acids to 40 amino acids, from 37 amino acids to 40 amino acids, from 38 amino acids to 40 amino acids, or from 39 amino acids to 40 amino acids. In some cases, an engineered peptide can have a length of from 5 amino acids to 39 amino acids, from 6 amino acids to 39 amino acids, from 7 amino acids to 39 amino acids, from 8 amino acids to 39 amino acids, from 9 amino acids to 39 amino acids, from 10 ammo acids to 39 ammo acids, from 11 ammo acids to 39 ammo acids, from 12 amino acids to 39 amino acids, from 13 amino acids to 39 amino acids, from 14 amino acids to 39 amino acids, from 15 amino acids to 39 amino acids, from 16 amino acids to 39 amino acids, from 17 amino acids to 39 amino acids, from 18 amino acids to 39 amino acids, from 19 amino acids to
39 amino acids, from 20 amino acids to 39 amino acids, from 21 amino acids to 39 ammo acids, from 22 amino acids to 39 amino acids, from 23 amino acids to 39 amino acids, from 24 amino acids to 39 amino acids, from 25 amino acids to 39 amino acids, from 26 amino acids to 39 amino acids, from 27 amino acids to 39 amino acids, from 28 amino acids to 39 amino acids, from 29 amino acids to 39 amino acids, from 30 amino acids to 39 amino acids, from 31 amino acids to 39 amino acids, from 32 amino acids to 39 amino acids, from 33 amino acids to 39 amino acids, from 34 amino acids to 39 amino acids, from 35 amino acids to 39 amino acids, from 36 amino acids to 39 amino acids, from 37 amino acids to 39 amino acids, or from 38 amino acids to 39 amino acids. In some cases, an engineered peptide of the present disclosure can have a length of from 5 ammo acids to 20 amino acids, from 6 ammo acids to 20 amino acids, from 7 amino acids to 20 amino acids, from 8 amino acids to 20 amino acids, from 9 amino acids to 20 amino acids, from 10 amino acids to 20 amino acids, from 11 amino acids to 20 amino acids, from 12 amino acids to 20 amino acids, from 13 amino acids to 20 amino acids, from 14 amino acids to 20 amino acids, from 15 amino acids to 20 amino acids, from 16 amino acids to 20 amino acids, from 17 amino acids to 20 amino acids, from 18 amino acids to 20 amino acids, or from 19 amino acids to 20 amino acids. In some embodiments, an engineered peptide can have a length of 40 amino acids, 39 amino acids, 38 amino acids, 37 amino acids, 36 amino acids, 35 amino acids, 34 amino acids, 33 amino acids, 32 amino acids, 31 amino acids, 30 amino acids, 29 amino acids, 28 amino acids, 27 amino acids, 26 amino acids, 25 amino acids, 24 amino acids, 23 amino acids, 22 amino acids, 21 amino acids, 20 amino acids, 19 amino acids, 18 amino acids, 17 amino acids, 16 amino acids, 15 amino acids, 14 amino acids, 13 amino acids, 12 amino acids, 11 amino acids, 10 amino acids, 9 amino acids, 8 amino acids, 7 amino acids, 6 amino acids, or 5 amino acids. In some embodiments, an engineered peptide can have a length of 10 amino acids. In some embodiments, an engineered peptide can have a length of 11 amino acids. In some embodiments, an engineered peptide can have a length of 12 amino acids. In some embodiments, an engineered peptide can have a length of 13 amino acids. In some embodiments, an engineered peptide can have a length of 14 amino acids. In some embodiments, an engineered peptide can have a length of 15 amino acids.
[0057] In some embodiments, an engineered peptide can have at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO: 1. In some embodiments, an engineered peptide can have a polypeptide sequence of SEQ ID NO: 1. In some embodiments, an engineered peptide can have at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at
least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO: 2. In some embodiments, an engineered peptide can have a polypeptide sequence of SEQ ID NO: 2. In some embodiments, an engineered peptide can have at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO: 3. In some embodiments, an engineered peptide can have a polypeptide sequence of SEQ ID NO: 3.
[0058] In some embodiments, an engineered peptide can have at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO: 1 and further comprise a peptide staple. In some embodiments, an engineered peptide can have a polypeptide sequence of SEQ ID NO: 1 and further comprise a peptide staple. In some embodiments, an engineered peptide can have at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO: 2 and further comprise a peptide staple. In some embodiments, an engineered peptide can have a polypeptide sequence of SEQ ID NO: 2 and further comprise a peptide staple. In some embodiments, an engineered peptide can have at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO: 3 and further comprise a peptide staple. In some embodiments, an engineered peptide can have a polypeptide sequence of SEQ ID NO: 3 and further comprise a peptide staple. The peptide staple can be (i, i+n) as previously described. In some embodiments, an engineered peptide can have at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO: 1 and further comprise a peptide staple (i, i+7), wherein i is 3, the (i) residue is R8 and the (i+7) residue is S5. In some embodiments, an engineered peptide can have a polypeptide sequence of SEQ ID NO: 1 and further comprise a peptide staple further comprise a peptide staple (i, i+7), wherein i is 3, the (i) residue is R8 and the (i+7) residue is S5. In some embodiments, an engineered peptide can have at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least
86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO: 2 and further comprise a peptide staple (i, i+7), wherein i is 3, the (i) residue is R8 and the (i+7) residue is S5. In some embodiments, an engineered peptide can have a polypeptide sequence of SEQ ID NO: 2 and further comprise a peptide staple (i, i+7), wherein i is 3, the (i) residue is R8 and the (i+7) residue is S5. In some embodiments, an engineered peptide can have at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO: 3 and further comprise a peptide staple (i, i+7), wherein i is 4, the (i) residue is R8 and the (i+7) residue is S5. In some embodiments, an engineered peptide can have a polypeptide sequence of SEQ ID NO: 3 and further comprise a peptide staple (i, i+7), wherein i is 4, the (i) residue is R8 and the (i+7) residue is S5.
[0059] In some embodiments, an engineered peptide can have at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO: 4. In some embodiments, an engineered peptide can have a polypeptide sequence of SEQ ID NO: 4. In some embodiments, an engineered peptide can have at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO: 5. In some embodiments, an engineered peptide can have a polypeptide sequence of SEQ ID NO: 5. In some embodiments, an engineered peptide can have at least 80%, at least 81 %, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO: 6. In some embodiments, an engineered peptide can have a polypeptide sequence of SEQ ID NO: 6. In some embodiments, an engineered peptide can be a stapled peptide having a polypeptide sequence of SEQ ID NO: 4, SEQ ID NO: 5, or SEQ ID NO: 6.
Pharmaceutical Compositions
[0060] Engineered peptides as descnbed herein can be formulated with a pharmaceutically acceptable carrier for administration to a subject (e.g., a human or a non-human animal). A pharmaceutically acceptable carrier can include, but is not limited to, phosphate buffered saline
solution, water, emulsions (e.g., an oil/water emulsion or a water/oil emulsions), glycerol, liquid polyethylene glycols, aprotic solvents such (e g., dimethylsulfoxide, N-methylpyrrolidone, or mixtures thereof), and various types of wetting agents, solubilizing agents, anti-oxidants, bulking agents, protein carriers such as albumins, any and all solvents, dispersion media, coatings, sodium lauryl sulfate, isotonic and absorption delaying agents, disintegrants (e.g., potato starch or sodium starch glycolate), and the like. The compositions also can include stabilizers and preservatives. Additional examples of carriers, stabilizers and adjuvants consistent with the compositions of the present disclosure can be found in, for example, Remington's Pharmaceutical Sciences, 21st Ed., Mack Publ. Co., Easton, Pa. (2005), incorporated herein by reference in its entirety.
[0061] In some examples, the pharmaceutical composition can be formulated in unit dose forms or multiple-dose forms. In some examples, the unit dose forms can be physically discrete units suitable for administration to human or non-human subjects (e.g., animals). In some examples, the unit dose forms can be packaged individually. In some examples, each unit dose contains a predetermined quantity of an active ingredient(s) that can be sufficient to produce the desired therapeutic effect in association with pharmaceutical carriers, diluents, excipients, or any combination thereof. In some examples, the unit dose forms comprise ampules, syringes, or individually packaged tablets and capsules, or any combination thereof. In some instances, a unit dose form can be comprised in a disposable syringe. In some instances, unit-dosage forms can be administered in fractions or multiples thereof. In some examples, a multiple-dose form comprises a plurality of identical unit dose forms packaged in a single container, which can be administered in segregated a unit dose form. In some examples, multiple dose forms comprise vials, bottles of tablets or capsules, or bottles of pints or gallons. In some instances, a multipledose forms comprise the same pharmaceutically active agents. In some instances, a multipledose forms comprise different pharmaceutically active agents.
[0062] In some embodiments, the peptides disclosed herein can be formulated as a salt of the peptide. In some cases, the salt comprises an HC1 salt, an ascorbic acid salt, a mandelic acid salt, an aspartic acid salt, a carbonic acid salt, a citric acid salt, a formic acid salt, a glutamic acid salt, a lactic acid salt, a lauric acid salt, a maleic acid salt, a borate salt, a bitartrate salt, a palmitic acid salt, a phosphoric acid salt, or any combination thereof. In some cases, a salt comprises an acetate salt. In some cases, a salt comprises a trifluoroacetate (TFA) salt.
[0063] In some aspects, pharmaceutically acceptable salts include, but are not limited to, metal salts such as a sodium salt, a potassium salt, a cesium salt and the like; an alkaline earth metal salt such as a calcium salt, a magnesium salt and the like; an organic amine salts such as a tri ethylamine salt, a pyridine salt, a picoline salt, a ethanolamine salt, a triethanolamine salt, a
dicyclohexylamine salt, a N,N'-dibenzylethylenediamme salt and the like; an inorganic acid salt such as a hydrochloride, a hydrobromide, a phosphate, a sulphate and the like; an organic acid salt such as a citrate, a lactate, a tartrate, a maleate, a fumarate, a mandelate, an acetate, a dichloroacetate, a trifluoroacetate, an oxalate, a formate and the like; a sulfonate such as a methanesulfonate, a benzenesulfonate, a p-toluenesulfonate and the like; and an amino acid salt such as an arginate, an asparginate, a glutamate and the like. In some cases, a pharmaceutically acceptable salt comprises an acetate salt.
[0064] In some examples, the pharmaceutical composition comprises a pharmaceutically acceptable excipient. In some examples, the excipient comprises a buffering agent, a cryopreservative, a preservative, a stabilizer, a binder, a compaction agent, a lubricant, a chelator, a dispersion enhancer, a disintegration agent, a flavoring agent, a sweetener, or a coloring agent, or any combination thereof.
[0065] In some examples, an excipient comprises a buffering agent. In some examples, the buffering agent comprises sodium citrate, magnesium carbonate, magnesium bicarbonate, calcium carbonate, calcium bicarbonate, or any combination thereof. In some examples, the buffering agent comprises sodium bicarbonate, potassium bicarbonate, magnesium hydroxide, magnesium lactate, magnesium glucomate, aluminum hydroxide, sodium citrate, sodium tartrate, sodium acetate, sodium carbonate, sodium polyphosphate, potassium polyphosphate, sodium pyrophosphate, potassium pyrophosphate, disodium hydrogen phosphate, dipotassium hydrogen phosphate, trisodium phosphate, tripotassium phosphate, potassium metaphosphate, magnesium oxide, magnesium hydroxide, magnesium carbonate, magnesium silicate, calcium acetate, calcium glycerophosphate, calcium chloride, or calcium hydroxide and other calcium salts, or any combination thereof.
[0066] In some examples, an excipient comprises a cryopreservative. In some examples, the cryopreservative comprises DMSO, glycerol, polyvinylpyrrolidone (PVP), or any combination thereof. In some examples, a cryopreservative comprises a sucrose, a trehalose, a starch, a salt of any of these, a derivative of any of these, or any combination thereof. In some examples, an excipient comprises a pH agent (to minimize oxidation or degradation of a component of the composition), a stabilizing agent (to prevent modification or degradation of a component of the composition), a buffering agent (to enhance temperature stability), a solubilizing agent (to increase protein solubility), or any combination thereof. In some examples, an excipient comprises a surfactant, a sugar, an ammo acid, an antioxidant, a salt, a non-iomc surfactant, a solubilizer, a triglyceride, an alcohol, or any combination thereof. In some examples, an excipient comprises sodium carbonate, acetate, citrate, phosphate, poly -ethylene glycol (PEG), human serum albumin (HSA), sorbitol, sucrose, trehalose, polysorbate 80, sodium phosphate,
sucrose, disodium phosphate, mannitol, polysorbate 20, histidine, citrate, albumin, sodium hydroxide, glycine, sodium citrate, trehalose, arginine, sodium acetate, acetate, HC1, disodium edetate, lecithin, glycerin, xanthan rubber, soy isoflavones, polysorbate 80, ethyl alcohol, water, teprenone, or any combination thereof. In some examples, the excipient can be an excipient described in the Handbook of Pharmaceutical Excipients, American Pharmaceutical Association (1986).
[0067] In some examples, the excipient comprises a preservative. In some examples, the preservative comprises an antioxidant, such as alpha-tocopherol and ascorbate, an antimicrobial, such as parabens, chlorobutanol, and phenol, or any combination thereof. In some examples, the antioxidant comprises EDTA, citric acid, ascorbic acid, but lated hydroxytoluene (BHT), butylated hydroxy anisole (BHA), sodium sulfite, p-amino benzoic acid, glutathione, propyl gallate, cysteine, methionine, ethanol or N- acetyl cysteine, or any combination thereof. In some examples, the preservative comprises validamycin A, TL-3, sodium ortho vanadate, sodium fluoride, N-a-tosyl-Phe- chloromethylketone, N-a-tosyl-Lys-chloromethylketone, aprotinin, phenylmethylsulfonyl fluoride, diisopropylfluorophosphate, kinase inhibitor, phosphatase inhibitor, caspase inhibitor, granzyme inhibitor, cell adhesion inhibitor, cell division inhibitor, cell cycle inhibitor, lipid signaling inhibitor, protease inhibitor, reducing agent, alkylating agent, antimicrobial agent, oxidase inhibitor, or other inhibitors, or any combination thereof.
[0068] In some examples, the excipient comprises a binder. In some examples, the binder comprises starches, pregelatinized starches, gelatin, polyvinylpyrolidone, cellulose, methylcellulose, sodium carboxymethylcellulose, ethylcellulose, polyacrylamides, polyvinyloxoazolidone, polyvinylalcohols, C12-C18 fatty acid alcohol, polyethylene glycol, polyols, saccharides, oligosaccharides, or any combination thereof.
[0069] In some examples, the binder can be a starch, for example a potato starch, com starch, or wheat starch; a sugar such as sucrose, glucose, dextrose, lactose, or maltodextrin; a natural and/or synthetic gum; a gelatin; a cellulose derivative such as microcrystalline cellulose, hydroxypropyl cellulose, hydroxyethyl cellulose, hydroxypropyl methyl cellulose, carboxymethyl cellulose, methyl cellulose, or ethyl cellulose; polyvinylpyrrolidone (povidone); polyethylene glycol (PEG); a wax; calcium carbonate; calcium phosphate; an alcohol such as sorbitol, xylitol, mannitol, or water, or any combination thereof.
[0070] In some examples, the excipient comprises a lubricant. In some examples, the lubricant comprises magnesium stearate, calcium stearate, zinc stearate, hydrogenated vegetable oils, sterotex, polyoxyethylene monostearate, talc, polyethyleneglycol, sodium benzoate, sodium lauryl sulfate, magnesium lauryl sulfate, or light mineral oil, or any combination thereof. In some examples, the lubricant comprises metallic stearates (such as magnesium stearate, calcium
stearate, aluminum stearate), fatty acid esters (such as sodium stearyl fumarate), fatty acids (such as stearic acid), fatty alcohols, glyceryl behenate, mineral oil, paraffins, hydrogenated vegetable oils, leucine, polyethylene glycols (PEG), metallic lauryl sulphates (such as sodium lauryl sulphate, magnesium lauryl sulphate), sodium chloride, sodium benzoate, sodium acetate or talc or a combination thereof.
[0071] In some examples, the excipient comprises a dispersion enhancer. In some examples, the dispersion enhancer comprises starch, alginic acid, polyvinylpyrrolidones, guar gum, kaolin, bentonite, purified wood cellulose, sodium starch glycolate, isomorphous silicate, or microcrystalline cellulose, or any combination thereof as high HLB emulsifier surfactants.
[0072] In some examples, the excipient comprises a dismtegrant. In some examples, a disintegrant comprises a non-efferv escent disintegrant. In some examples, a non-effervescent disintegrants comprises starches such as com starch, potato starch, pregelatinized and modified starches thereof, sweeteners, clays, such as bentonite, micro-crystalline cellulose, alginates, sodium starch glycolate, or gums such as agar, guar, locust bean, karaya, pectin, and tragacanth, or any combination thereof. In some examples, a disintegrant comprises an effervescent disintegrant. In some examples, a suitable elfervescent disintegrant comprises bicarbonate in combination with citric acid, and sodium bicarbonate in combination with tartaric acid.
[0073] In some examples, the excipient comprises a sweetener, a flavoring agent or both. In some examples, a sweetener comprises glucose (com syrup), dextrose, invert sugar, fructose, and mixtures thereof (when not used as a carrier); saccharin and its various salts such as a sodium salt; dipeptide sweeteners such as aspartame; dihydrochalcone compounds, glycyrrhizin; Stevia Rebaudiana (Stevioside); chloro derivatives of sucrose such as sucralose; and sugar alcohols such as sorbitol, mannitol, sylitol, and the like, or any combination thereof. In some cases, flavoring agents incorporated into a composition comprise synthetic flavor oils and flavoring aromatics; natural oils; extracts from plants, leaves, flowers, and fruits; or any combination thereof. In some embodiments, a flavoring agent comprises a cinnamon oils; oil of wintergreen; peppermint oils; clover oil; hay oil; anise oil; eucalyptus; vanilla; citrus oil such as lemon oil, orange oil, grape and grapefruit oil; and fruit essences including apple, peach, pear, strawberry, raspberry, cherry, plum, pineapple, and apricot, or any combination thereof.
[0074] In some examples, the excipient comprises a pH agent (e.g., to minimize oxidation or degradation of a component of the composition), a stabilizing agent (e.g., to prevent modification or degradation of a component of the composition), a buffenng agent (e.g., to enhance temperature stability), a solubilizing agent (e.g., to increase protein solubility), or any combination thereof. In some examples, the excipient comprises a surfactant, a sugar, an amino acid, an antioxidant, a salt, a non-ionic surfactant, a solubilizer, a trigylceride, an alcohol, or any
combination thereof. In some examples, the excipient comprises sodium carbonate, acetate, citrate, phosphate, poly-ethylene glycol (PEG), human serum albumin (HSA), sorbitol, sucrose, trehalose, polysorbate 80, sodium phosphate, sucrose, disodium phosphate, mannitol, polysorbate 20, histidine, citrate, albumin, sodium hydroxide, glycine, sodium citrate, trehalose, arginine, sodium acetate, acetate, HC1, disodium edetate, lecithin, glycerine, xanthan rubber, soy isoflavones, polysorbate 80, ethyl alcohol, water, teprenone, or any combination thereof. In some examples, the excipient comprises a cryo-preservative. In some examples, the excipient comprises DMSO, glycerol, polyvinylpyrrolidone (PVP), or any combination thereof. In some examples, the excipient comprises a sucrose, a trehalose, a starch, a salt of any of these, a derivative of any of these, or any combination thereof.
[0075] In some examples, the pharmaceutical composition comprises a diluent. In some examples, the diluent comprises water, glycerol, methanol, ethanol, or other similar biocompatible diluents, or any combination thereof. In some examples, a diluent comprises an aqueous acid such as acetic acid, citric acid, maleic acid, hydrochloric acid, phosphoric acid, nitric acid, sulfuric acid, or any combination thereof. In some examples, a diluent comprises an alkaline metal carbonates such as calcium carbonate; alkaline metal phosphates such as calcium phosphate; alkaline metal sulphates such as calcium sulphate; cellulose derivatives such as cellulose, microcrystalline cellulose, cellulose acetate; magnesium oxide, dextrin, fructose, dextrose, glyceryl palmitostearate, lactitol, choline, lactose, maltose, mannitol, simethicone, sorbitol, starch, pregelatinized starch, talc, xylitol and/or anhydrates, hydrates and/or pharmaceutically acceptable derivatives thereof or combinations thereof.
[0076] In some examples, the pharmaceutical composition comprises a carrier. In some examples, the carrier comprises a liquid or solid filler, solvent, or encapsulating material. In some examples, the carrier comprises additives proteins, peptides, amino acids, lipids, and carbohydrates (e.g., sugars, including monosaccharides, di-, tri-, tetra-oligosaccharides, and oligosaccharides; derivatized sugars such as alditols, aldolic acids, esterified sugars and the like; and polysaccharides or sugar polymers), alone or in combination.
[0077] Also disclosed herein are kits comprising the pharmaceutical compositions herein. In some cases, a kit comprises a container. A container can be any material such as a glass, a metal, a plastic or a combination thereof. A kit can comprise an engineered peptide disclosed herein such as a peptide of SEQ ID NOs: 1-6 and optionally, a pharmaceutically acceptable: excipient, earner, or diluent.
Methods of Screening
[0078] Also disclosed herein are methods of screening for engineered peptides of the present disclosure. In some embodiments, an initial screen can be utilized to select for portions of polypeptides that exhibit a property of interest. An example of such screening can be found in WO2021041953, which is incorporated by reference in its entirety. In some embodiments, an initial screen can be used to tile portions of oncogenes that display cell toxicity. Hits from the initial screen can be further engineered as described herein to produce improved engineered peptides with enhanced efficacy relative to naturally occurring portions of oncogenes.
[0079] In some embodiments, peptide candidates found in an initial screen to display cellular toxicity are curated to select for certain properties using external databases such as Unitprot, Genebank, and PDB. For example, in some instances peptide candidates can be selected based on their propensity to form an alpha helical structure in the context of a full length peptide. As described herein, and without wishing to be bound by theory, an alpha-helical engineered peptide of the present disclosure can have improved cell permeability, relative to a corresponding nonalpha helical peptide. Alpha helical propensity can be determined by comparing the peptide candidates to deposited protein structures showing the presence of the peptide candidate in an annotated alpha helical structure in the deposited protein structure.
[0080] Curated peptide candidates (e.g. peptide candidates selected for cellular toxicity in an initial screen and for their propensity to form alpha helices based on deposited structures) can be further engineered to improve their activity. In some instances, mutagenesis can be utilized to improve the activity of the candidate peptides. In some instances, high throughput screening can be utilized to screen libraries of rationally designed engineered peptides based on peptide candidates selected in the initial screen. In some instances, computational screening (e.g., computational alanine scanning) can be performed to map key residues to improve the properties of the peptide candidate. In some cases, both methods can be combined to generate engineered peptides with improved properties relative to the peptide candidates.
[0081] Advanced candidates selected by screening with improved properties relative to the peptide candidates can be further optimized to improve efficacy. For example, each advanced candidate can be modeled to predict the key interactions between the candidate peptide and the target. Based on the modeling, the length of the candidate can be modified to include key residues. In some embodiments, based on the modeling, the length of the candidate can be modified to minimize the length of the peptide while still including key residues. Further, modifications such as stapling can be employed as described herein to stabilize the secondary structure (e.g. alpha helical structure) of the therapeutic peptide by reducing the entropic penalty for adopting the structure.
Methods of Treatment
[0082] Engineered peptides as described herein can be used to treat diseases or conditions upon administration to a subject in need thereof. Without wishing to be bound by theory, engineered peptides of the present disclosure exhibit cellular toxicity that allows for treatment of diseases such as cancer. In some instances, contacting an engineered peptide of the present disclosure with a cancer cell can arrest cancer cell growth. In some instances, contacting an engineered peptide of the present disclosure w ith a cancer cell can inhibit cancer cell proliferation. In some instances, contacting an engineered peptide of the present disclosure can reduce the size of a cancer cell (e.g. can decrease tumor volume). In some instances, contacting an engineered peptide of the present disclosure can induce apoptosis or cell death of the cancer cell. In some cases, the arrest of cancer cell growth, the inhibition of cancer cell proliferation, the reduction of the tumor volume, or the induction of apoptosis of a cell by a peptide of the present disclosure can be compared to the results from a control peptide.
[0083] An engineered peptide of the present disclosure can be used to treat cancer upon administration. In some embodiments, the cancer is selected from the group consisting of: adrenocortical carcinoma, AIDS-related cancers, AIDS-related lymphoma, anal cancer, anorectal cancer, cancer of the anal canal, appendix cancer, childhood cerebellar astrocytoma, childhood cerebral astrocytoma, basal cell carcinoma, skin cancer (non-melanoma), biliary cancer, extrahepatic bile duct cancer, intrahepatic bile duct cancer, bladder cancer, urinary bladder cancer, bone and joint cancer, osteosarcoma and malignant fibrous histiocytoma, brain cancer, brain tumor, brain stem glioma, cerebellar astrocytoma, cerebral astrocytoma/malignant glioma, ependymoma, medulloblastoma, supratentorial primitive neuroectodermal tumors, visual pathway and hypothalamic glioma, breast cancer, including triple negative breast cancer, bronchial adenomas/carcinoids, carcinoid tumor, gastrointestinal, nervous system cancer, nervous system lymphoma, central nervous system cancer, central nervous system lymphoma, cervical cancer, childhood cancers, chronic lymphocytic leukemia, chronic myelogenous leukemia, chronic myeloproliferative disorders, colon cancer, colorectal cancer, cutaneous T-cell lymphoma, lymphoid neoplasm, mycosis fungoides, Seziary Syndrome, endometrial cancer, esophageal cancer, extracranial germ cell tumor, extragonadal germ cell tumor, extrahepatic bile duct cancer, eye cancer, intraocular melanoma, retinoblastoma, gallbladder cancer, gastric (stomach) cancer, gastrointestinal carcinoid tumor, gastrointestinal stromal tumor (GIST), germ cell tumor, ovarian germ cell tumor, gestational trophoblastic tumor glioma, head and neck cancer, hepatocellular (liver) cancer, Hodgkin lymphoma, hypopharyngeal cancer, intraocular melanoma, ocular cancer, islet cell tumors (endocrine pancreas), Kaposi Sarcoma, kidney cancer, renal cancer, laryngeal cancer, acute lymphoblastic leukemia, acute myeloid leukemia, chronic
lymphocytic leukemia, chronic myelogenous leukemia, hairy cell leukemia, lip and oral cavity cancer, liver cancer, lung cancer, non-small cell lung cancer, small cell lung cancer, AIDS-related lymphoma, non-Hodgkin lymphoma, primary central nervous system lymphoma, Waldenstram macroglobulinemia, medulloblastoma, melanoma, intraocular (eye) melanoma, merkel cell carcinoma, mesothelioma malignant, mesothelioma, metastatic squamous neck cancer, mouth cancer, cancer of the tongue, multiple endocrine neoplasia syndrome, mycosis fungoides, myelodysplastic syndromes, myelodysplastic/ myeloproliferative diseases, chronic myelogenous leukemia, acute myeloid leukemia, multiple myeloma, chronic myeloproliferative disorders, nasopharyngeal cancer, neuroblastoma, oral cancer, oral cavity cancer, oropharyngeal cancer, ovarian cancer, ovarian epithelial cancer, ovarian low malignant potential tumor, pancreatic cancer, islet cell pancreatic cancer, paranasal sinus and nasal cavity cancer, parathyroid cancer, penile cancer, pharyngeal cancer, pheochromocytoma, pineoblastoma and supratentorial primitive neuroectodermal tumors, pituitary tumor, plasma cell neoplasm/multiple myeloma, pleuropulmonary blastoma, prostate cancer, rectal cancer, renal pelvis and ureter, transitional cell cancer, retinoblastoma, rhabdomyosarcoma, salivary gland cancer, ewing family of sarcoma tumors, soft tissue sarcoma, uterine cancer, uterine sarcoma, skin cancer (non-melanoma), skin cancer (melanoma), papillomas, actinic keratosis and keratoacanthomas, merkel cell skin carcinoma, small intestine cancer, soft tissue sarcoma, squamous cell carcinoma, stomach (gastric) cancer, supratentorial primitive neuroectodermal tumors, testicular cancer, throat cancer, thymoma, thymoma and thymic carcinoma, thyroid cancer, transitional cell cancer of the renal pelvis and ureter and other urinary organs, gestational trophoblastic tumor, urethral cancer, endometrial uterine cancer, uterine sarcoma, uterine corpus cancer, vaginal cancer, vulvar cancer, and Wilm's Tumor. In some embodiments, the cancer is a colorectal cancer. In some embodiments, the cancer is a lung cancer. In some embodiments, the cancer is a melanoma cancer. In some embodiments, the cancer is a breast cancer. In some embodiments, the cancer is a pancreatic cancer, a bladder cancer, a triple negative breast cancer, an ovarian cancer, a juvenile myelomonocytic leukemia (IMML), a hematologic malignancy, a cholangiocarcinoma, a uterine cancer, a cervical cancer, a testicular cancer, or any combination thereof. In some embodiments, the cancer is a cancer comprising a KRAS mutation. In some cases, a KRAS mutation can comprise a G12V mutation, a G12C mutation, or a G12D mutation of KRAS. In some cases, a KRAS mutation can comprise a G13D mutation, a G12R mutation, or a G12A mutation of KRAS. For example, an administration of a peptide herein can be used to treat any cancer with a KRAS mutation, such as those with a G12V mutation, a G12C mutation, or a G12D mutation. [0084] Administration disclosed herein to an area in need of treatment or therapy can be achieved by, for example, and not by way of limitation, oral administration, topical
administration, intravenous administration, inhalation administration, or any combination thereof. In some embodiments, delivery can include inhalation, otic, buccal, conjunctival, dental, endocervical, endosinusial, endotracheal, enteral, epidural, extra-amniotic, extracorporeal, hemodialysis, infiltration, interstitial, intraabdominal, intraamniotic, intraarterial, intraarticular, intrabiliary, intrabronchial, intrabursal, intracardiac, intracartilaginous, intracaudal, intracavemous, intracavitary, intracerebroventricular, mtracistemal, intracorneal, intracoronal, intracoronary, intracorpous cavemaosum, intradermal, intradiscal, intraductal, intraduodenal, intradural, intraepidermal, intraesophageal, intragastric, intragingival, intrahippocampal, intraileal, intralesional, intraluminal, intralymphatic, intramedullary, intrameningeal, intramuscular, intraocular, intraovanan, mtrapencardial, intraperitoneal, intrapleural, intraprostatic, intrapulmonary, intrasinal, intraspinal, intrasynovial, intratendinous, intratesticular, intrathoracic, intratubular, intratumor, intratympanic, intrauterine, intravascular, intravenous, intravenous bolus, intravenous drip, intravesical, intravitreal, iontophoresis, irrigation, laryngeal, nasal, nasogastric, ophthalmic, oral, oropharyngeal, parenteral, percutaneous, periarticular, peridural, perineural, periodontal, rectal, retrobulbar, subarachnoid, subconjunctival, subcutaneous, sublingual, submucosal, topical, transdermal, transmucosal, transplacental, transtracheal, transtympanic, ureteral, urethral, vaginal, infraorbital, intraparenchymal, intrathecal, intraventricular, stereotactic, or any combination thereof. Delivery can include parenteral administration (including intravenous, subcutaneous, intrathecal, intraperitoneal, intramuscular, intravascular or infusion), oral administration, inhalation administration, intraduodenal administration, rectal administration, or a combination thereof. Delivery can include direct application to the affected tissue or region of the body. In some cases, topical administration can comprise administering a lotion, a solution, an emulsion, a cream, a balm, an oil, a paste, a stick, an aerosol, a foam, a jelly, a foam, a mask, a pad, a powder, a solid, a tincture, a butter, a patch, a gel, a spray, a drip, a liquid formulation, an ointment to an external surface of a surface, such as a skin. Delivery can include a parenchymal injection, an intra-thecal injection, an intra-ventricular injection, intratumoral injection, or an intra-cistemal injection. A composition provided herein can be administered by any method. A method of administration can be by intra-arterial injection, intracistemal injection, intramuscular injection, intraparenchymal injection, intraperitoneal injection, intraspinal injection, intrathecal injection, intravenous injection, intraventricular injection, stereotactic injection, subcutaneous injection, epidural, or any combination thereof. Delivery can include parenteral administration (including intravenous, subcutaneous, intrathecal, intraperitoneal, intramuscular, intravascular or infusion administration). In some embodiments, delivery can comprise a nanoparticle, a liposome, an exosome, an extracellular vesicle, an implant, or a combination thereof. In some cases, delivery
can be from a device. In some instances, delivery can be administered by a pump, an infusion pump, or a combination thereof. In some embodiments, delivery can be by an enema, an eye drop, a nasal spray, or any combination thereof. In some instances, a subject can administer the composition in the absence of supervision. In some instances, a subject can administer the composition under the supervision of a medical professional (e.g., a physician, nurse, physician’s assistant, orderly, hospice worker, etc.). In some embodiments, a medical professional can administer the composition.
[0085] Dosing may include single or multiple administrations of a pharmaceutical composition described herein. Examples include: multiple times a day, daily, every other day, 1, 2, 3, 5, 6, or 7 times a week, weekly, or less often, a single administration, a course of treatment involving several treatments on a regular or irregular basis, or multiple administrations for a period of time until the treatment of a cancer is achieved. In some embodiments, dosing may be performed for about: 1 day to about 8 days, 1 week to about 5 weeks, 1 month to about 12 months, 1 year to about 3 years, 3 years to about 10 years, 10 years to about 50 years, 25 years to about 100 years, or 50 years to about 130 years. In some cases, dosing can occur every day, 2 days, 3 days, 4 days, 5 days, 6 days, 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, 1 year, 2 years, or as needed. The dosing regimen, including the regularity of and mode of administration, may be dependent on factors including but not limited to the subject being treated; the severity of the condition; the manner of administration, or the presence of one or more additional diseases or conditions.
[0086] In some examples, a pharmaceutical composition disclosed herein can be administered at dosage levels sufficient to deliver from about 0.0001 mg/kg to about 100 mg/kg, from about 0.001 mg/kg to about 0.05 mg/kg, from about 0.005 mg/kg to about 0.05 mg/kg, from about 0.001 mg/kg to about 0.005 mg/kg, from about 0.05 mg/kg to about 0.5 mg/kg, from about 0.01 mg/kg to about 50 mg/kg, from about 0. 1 mg/kg to about 40 mg/kg, from about 0.5 mg/kg to about 30 mg/kg, from about 0.01 mg/kg to about 10 mg/kg, from about 0. 1 mg/kg to about 10 mg/kg, from about 1 mg/kg to about 25 mg/kg, from about 1 mg/kg to about 300 mg/kg, from about 0.001 mg/kg to about 300 mg/kg, from about 10 mg/kg to about 300 mg/kg, from about 50 mg/kg to about 300 mg/kg, from about 75 mg/kg to about 300 mg/kg, from about 100 mg/kg to about 300 mg/kg, from about 200 mg/kg to about 300 mg/kg, from about 5 mg/kg to about 250 mg/kg, from about 50 mg/kg to about 250 mg/kg, from about 100 mg/kg to about 250 mg/kg, from about 150 mg/kg to about 250 mg/kg, from about 50 mg/kg to about 150 mg/kg, or from about 100 mg/kg to about 200 mg/kg of subject body weight per day, one or more times a day, to obtain the desired therapeutic, diagnostic, or prophylactic, effect. In some examples, a
pharmaceutical composition disclosed herein can be administered at dosage levels sufficient to deliver from 0.0001 mg/kg to 100 mg/kg, from 0.001 mg/kg to 0.05 mg/kg, from 0.005 mg/kg to 0.05 mg/kg, from 0.001 mg/kg to 0.005 mg/kg, from 0.05 mg/kg to 0.5 mg/kg, from 0.01 mg/kg to 50 mg/kg, from 0. 1 mg/kg to 40 mg/kg, from 0.5 mg/kg to 30 mg/kg, from 0.01 mg/kg to 10 mg/kg, from 0. 1 mg/kg to 10 mg/kg, from 5 mg/kg to 20 mg/kg, from 5 mg/kg to 15 mg/kg, from 8 mg/kg to 12 mg/kg, from 5 mg/kg to 10 mg/kg, from 40 mg/kg to 70 mg/kg, from 50 mg/kg to 70 mg/kg, from 55 mg/kg to 65 mg/kg, from 58 mg/kg to 64 mg/kg, from 59 mg/kg to 61 mg/kg, from 1 mg/kg to 25 mg/kg, from 1 mg/kg to 300 mg/kg, from 0.001 mg/kg to 300 mg/kg, from 10 mg/kg to 300 mg/kg, from 50 mg/kg to 300 mg/kg, from 75 mg/kg to 300 mg/kg, from 100 mg/kg to 300 mg/kg, from 200 mg/kg to 300 mg/kg, from 5 mg/kg to 250 mg/kg, from 50 mg/kg to 250 mg/kg, from 100 mg/kg to 250 mg/kg, from 150 mg/kg to 250 mg/kg, from 50 mg/kg to 150 mg/kg, or from 100 mg/kg to 200 mg/kg subject body weight per day, one or more times a day, to obtain the desired therapeutic, diagnostic, or prophylactic, effect. In some embodiments, a pharmaceutical composition disclosed herein can be administered at dosage levels sufficient to deliver about 0.0001 mg/kg, about 0.001 mg/kg, about 0.005 mg/kg, about 0.01 mg/kg, about 0.05 mg/kg, about 0.1 mg/kg, about 0.5 mg/kg, about 1 mg/kg, about 5 mg/kg, about 6 mg/kg, about 7 mg/kg, about 8 mg/kg, about 9 mg/kg, about 10 mg/kg, about 11 mg/kg, about 12 mg/kg, about 13 mg/kg, about 14 mg/kg, about 15 mg/kg, about 20 mg/kg, about 25 mg/kg, about 30 mg/kg, about 35 mg/kg, about 40 mg/kg, about 45 mg/kg, about 50 mg/kg, about 55 mg/kg, about 56 mg/kg, about 57 mg/kg, about 58 mg/kg, about 59 mg/kg, about 60 mg/kg, about 61 mg/kg, about 62 mg/kg, about 63 mg/kg, about 64 mg/kg, about 65 mg/kg, about 70 mg/kg, about 75 mg/kg, about 80 mg/kg, about 85 mg/kg, about 90 mg/kg, about 95 mg/kg, about 100 mg/kg, about 120 mg/kg, about 140 mg/kg, about 160 mg/kg, about 180 mg/kg, about 200 mg/kg, about 220 mg/kg, about 240 mg/kg, about 260 mg/kg, about 280 mg/kg, or about 300 mg/kg, of subject body weight per day, one or more times a day, to obtain the desired therapeutic, diagnostic, or prophylactic effect. In some embodiments, a pharmaceutical composition disclosed herein can be administered at dosage levels sufficient to deliver 0.0001 mg/kg, 0.001 mg/kg, 0.005 mg/kg, 0.01 mg/kg, 0.05 mg/kg, 0.1 mg/kg, 0.5 mg/kg, 1 mg/kg, 5 mg/kg, 6 mg/kg, 7 mg/kg, 8 mg/kg, 9 mg/kg, 10 mg/kg, 11 mg/kg, 12 mg/kg, 13 mg/kg, 14 mg/kg, 15 mg/kg, 20 mg/kg, 25 mg/kg, 30 mg/kg, 35 mg/kg, 40 mg/kg, 45 mg/kg, 50 mg/kg, 55 mg/kg, 56 mg/kg, 57 mg/kg, 58 mg/kg, 59 mg/kg, 60 mg/kg, 61 mg/kg, 62 mg/kg, 63 mg/kg, 64 mg/kg, 65 mg/kg, 70 mg/kg, 75 mg/kg, 80 mg/kg, 85 mg/kg, 90 mg/kg, 95 mg/kg, 100 mg/kg, 120 mg/kg, 140 mg/kg, 160 mg/kg, 180 mg/kg, 200 mg/kg, 220 mg/kg, 240 mg/kg, 260 mg/kg, 280 mg/kg, or 300 mg/kg, of subject body weight per day, one or more times a day, to obtain the desired therapeutic, diagnostic, or prophylactic, effect. In some
embodiments, the dosage levels of the pharmaceutical composition as disclosed herein are administered to a mammal, including, but not limited to a human, a non-human primate, a dog, a cat, a hamster, a guinea pig, a rat, or a mouse. In some embodiments a subject in need thereof is a mammal, including, but not limited to a human, a non-human primate, a dog, a cat, a hamster, a guinea pig, a rat, or a mouse. In some embodiments, the subject is an infant. The infant can be up to 24 months old. In some embodiments, the subject is a child. The child may be 2 years to 21 years old. In some embodiments, the subject is an adult. Adults may be 21 years old or more. In some embodiments, the adult is of advanced age, such as 65 years or older.
[0087] In some embodiments, a method can comprise administering a second therapy. In some cases, a second therapy can be administered concurrently or consecutively with a composition disclosed herein. In some cases, a second therapy can comprise a chemotherapy, a radiation therapy, a hormone therapy, a hyperthermia therapy, an immunotherapy, a photodynamic therapy, a stem cell therapy, a surgery, a targeted therapy, or any combination thereof. In some cases, a chemotherapy can comprise an altretamine, a bendamustine, a busulfan, a carboplatin, a carmustine, a chlorambucil, a cisplatin, a cyclophosphamide, a dacarbazine, an ifosfamide, a lomustine, a mechlorethamine, a melphalan, an oxaliplatin, a temozolomide, a thiotepa, a trabectedin, or any combination thereof. In some cases, a chemotherapy can comprise an altretamine, a bendamustine, a busulfan, a carboplatin, a carmustine, a chlorambucil, a cisplatin, a cyclophosphamide, a dacarbazine, an ifosfamide, a lomustine, a mechlorethamine, a melphalan, an oxaliplatin, a temozolomide, a thiotepa, a trabectedin, a salt of any of these, or any combination thereof. In some cases, a chemotherapy can comprise a carmustine, a lomustine, a streptozocin, an azacitidine, a 5 -fluorouracil (5-fu), a 6-mercaptopurine (6-mp), a capecitabine, a cladribine, a clofarabine, a cytarabine (ara-c), a decitabine, a floxundme, a fludarabine, a gemcitabine, a hydroxyurea, a methotrexate, a nel arabine, a pemetrexed, a pentostatin, a pralatrexate, a thioguanine, a trifluridine/tipiracil combination, a daunorubicin, a doxorubicin, an epirubicin, an idarubicin, a valrubicin, a irinotecan, a topotecan, an etoposide (vp-16), a mitoxantrone, a teniposide, a vinblastine, a vincristine, a vinorelbine, a vinorelbine, a prednisone, a methylprednisolone, a dexamethasone, a all-trans-retinoic acid, an arsenic trioxide, an asparaginase, a eribulin, a hydroxyurea, a ixabepilone, a mitotane, an omacetaxine, a pegaspargase, a procarbazine, a romidepsin, a vorinostat, a salt of any of these, or any combination thereof. In some cases, a radiation therapy can comprise an internal radiation therapy or an external radiation therapy. In some cases, a hormone therapy can comprise an anastrozole, an exemestane, a letrozole, a tamoxifen, a raloxifene, a fulvestrant, a toremifene, a goserelin, a leuprolide, a triptorelinan apalutamide, an enzalutamide, a darolutamide, a bicalutamide, a flutamide, a nilutamide, an abiraterone, a ketoconazole, a degarelix, a
medroxyprogesterone, a megestrol, an etrozole, an anastrozole, and an exemestane. a mitotane, a fulvestrant, atoremifene, a salt of any of these, or any combination thereof In some cases, an immunotherapy can comprise a checkpoint inhibitor, an atezolizumab, an avelumab, a dostarlizumab, a durvalumab, an ipilimumab, an nivolumab, an pembrolizumab, an interferon, an interleukin, a Bacillus Calmette-Guerin (BCG), a oncolytic virus therapy, a CAR T-Cell therapy, a CAR cell therapy, a cancer vaccine, a salt of any of these, or any combination thereof. In some cases, a targeted therapy can comprise an angiogenesis inhibitor, a monoclonal antibody, a proteasome inhibitor, a signal transduction inhibitor. In some cases, a targeted therapy can comprise a denosumab, a romidepsin, a ofatumumab, a pazopanib, an everolimus, a nilotinib, a temsirolimus, a lapatmib, a sumtinib malate, a dasatmib, a vonnostat, a panitumumab, a sorafenib tosylate, a erlotinib, a bevacizumab, a cetuximab, a tositumomab, a bortezomib, a gefitinib, an ibritumomab tiuxetan, an alemtuzumab, an imatinib, a gemtuzumab ozogamicin, a denileukin diftitox, a trastuzumab, a rituximab, a salt of any of these, or any combination thereof. [0088] In some embodiments, a method can comprise diagnosing a patient with a cancer prior to, during, or after treatment with a composition herein. In some cases, the diagnosing can comprise a physical examination, a blood test, an imaging assay, a neurological examination, an immunological assay, or any combination thereof. In some cases, an imaging assay can comprise an X-ray, a computed tomography (CT scan), a magnetic resonance imaging (MRI), an ultrasound, a positron emission tomography (PET scan), a fluoroscopy, or any combination thereof.
EXAMPLES
[0089] For a better understanding of the present disclosure and of its many advantages, the following examples are given by way of illustration and without limiting the scope of this disclosure.
Example 1: Initial Screening of Therapeutic Peptides against Cancer
[0090] This example demonstrates initial screening of 40mer peptides generated from various oncogenes. Each peptide was screened for its ability to exhibit cell toxicity, and variants displaying cell toxicity were utilized in the subsequent examples.
[0091] Design of peptide coding gene fragment libraries
[0092] Peptide coding gene fragments from target genes were composed of the DNA coding sequence for all 40mer amino acids from the genes/mutants listed in TABLE 1 below:
[0093] For fitness screens the 5’ and 3’ ends of each gene fragment were modified to contain a start and stop codon, as well as ~20bp of DNA homologous to the expression plasmid for downstream Gibson cloning.
[0094] Cancer driver gene fragment cloning
[0095] Peptide coding gene fragment libraries were synthesized as pooled single stranded oligonucleotides by Custom Array. These oligonucleotides were then PCR amplified to generate double stranded gene fragments compatible with Gibson cloning. 50ml PCR reactions were set up with 25 ng of pooled oligonucleotide template and 2.5 ml of primers PEP_1 and PEP_2 (lOmM). The thermal cycler was programmed to run at 95C for 3 minutes, followed by 12 cycles of 98C for 20 seconds, 65C for 15 seconds, and 72C for 45 seconds. This was followed by a final 5-minute extension at 72C. PCR products were then purified.
[0096] Fitness screening in mammalian cell lines
[0097] Hs578T cells and MDA-MB-231 cells were cultured in DMEM media supplemented with 10% FBS. Cells were transduced with the peptide coding gene fragment library at an MOI <.3 to ensure each cell received a single construct. Viral transduction was performed in media containing 8mg/ml polybrene to improve transduction efficiency. For each cell line, screening was conducted with two biological replicates. 24 hours after transduction the cell culture media was changed back to DMEM without polybrene supplementation.
[0098] 48 hours after transduction, the cell culture media was changed to DMEM containing puromycin to select for transduced cells. 2mg/ml puromycin was used to select the Hs578T cells, and 3.5mg/ml puromycin was used to select the MDA-MB-231 cells. In the pilot screens, more than 6,000,000 cells (from each cell line) were transduced to ensure greater than 1000-fold coverage of the library. The cells were cultured for 14 days after transduction, and genomic DNA was isolated at days 3 and 14. For the larger screens, the number of cells transduced was scaled up accordingly.
[0099] HTS library preparation and sequencing
[00100] Peptide coding gene fragments for each time point and replicate were then amplified from the genomic DNA. The fragments serve as their own barcodes for downstream abundance calculations. Illumina compatible libraries were prepared using 2.5ml of primers PEP_3 and PEP_4 (lOrnM) per 50ml reaction. For each sample (i.e. time point and replicate) from the pilot library, 10 separate 50ml PCR reactions with 4mg of gDNA each (40mg total) were performed to ensure adequate library coverage. Thermal cycling parameters were identical to those used to amplify the gene fragment oligos, with the exception that the gDNA required 26 cycles to amplify. Sequencing was performed and samples were indexed. Greater than 500-fold sequencing depth was used to ensure accurate abundance quantitation. For the larger libraries, the number of PCR reactions was scaled to process 300mg of total gDNA per timepoint and replicate. The larger libraries were then sequenced with 100-bp paired end reads.
Example 2 - Curation of Peptide Hits from Initial Screen
[00101] Hits selected in the initial screen of Example 1 were curated to identify hit alpha helical peptides for further engineering to improve binding affinity and enable more effective drug-like function. To this end, the data from Example 1 was filtered to only have peptide fragments that had a Log2FC of less than 2.5 and a computed fitness score of less than 0, which selects for peptides with a negative impact on cell fitness. The peptides were then mapped to the Uniprot database for their gene names, annotated regions for containing alpha helices and regions that had crystal structures available. The focus was primarily on extracting alpha helices as it was needed for engineering staples and crystal structure availability as it was needed for the downstream algorithms for optimizing binding affinity. Additionally, the Interactome INSIDER database was used to extract experimentally curated and computationally predicted interacting residues/regions of proteins. The peptide fragments filtered earlier with a negative impact on cell fitness based on our screen was then filtered to ensure crystal structure availability, include alpha helical region, and span the predicted interacting residue regions. The count distribution of the peptides that passed these filters are shown in FIG 1.
[00102] Based on the count distribution above, the fitness score cutoff was adjusted to less than 0.5 and a final list of 66 peptide fragments for 18 genes were compiled. With the goal of picking a best binder for each gene for further binding affinity optimization, the RCSB database was then manually searched for each peptide fragment to filter fragments that had co-crystal structures with different binding partners. Those that did not have crystal structures with binding partners and/or had too many unmodelled residues were dropped. For each peptide fragment that spanned the same region and shared the same structure file for its binding partners, the most negative Log2FC fragment was chosen. The final list of peptides consisted of 11 peptide fragments for 11 genes summarized in TABLE 2. The alpha coverage is the number of residues that are part of an alpha helix contained in the 40-mer peptide and the PDB IDs are the ID of the structure files that contains both the target protein and a binding partner.
[00103] TABLE 2. Summary table of final list of manually filtered alpha helical hit peptide fragments.
Example 3 - Mutagenesis to Improve Binding Affinity
[00104] With the list of alpha helical hit peptides extracted from the fitness screen data in Example 2, a workflow was developed to improve the binding affinity of these peptides computationally (FIG. 2).
[00105] The workflow consists of starting with the structure file (PDB) of an identified alpha helical 40-mer peptide binding to an interacting protein. The computational alanine scanning algorithm is then used to identify residues in the binding interface by calculating the binding energy of the structure after mutating each residue at the interface to alanine. The residue mutated that destabilizes the binding is predicted to be a residue that is important for binding. With the list of residues important for binding, in silico site saturation mutagenesis is conducted and binding affinity differences is evaluated with the point mutation scanning algorithm (pmut scan) to identify mutants with the highest binding affinity. This was done with the built in pmut scan method in the Rosetta software. An example of using this workflow with an identified alpha helical 40-mer peptide derived from RAFI (RAF1_78) is shown in FIG. 3A and FIG. 3B. [00106] FIG. 3A depicts a heatmap of computational alanine scanning results of identified alpha helical 40-mer peptides (5 out of 11) binding to interacting proteins. The Protein Data Bank Identifier (PDB ID) followed by the interacting protein is labeled on the right side. The amino acid sequence of the 40-mer peptide is labeled on the bottom and the corresponding computational alanine binding energy with the interacting protein, delta-delta-G (ddG), is plotted. The higher the value is, the more likely that particular residue is important for binding. FIG. 3B is a heatmap of the point mutation scanning result of RAF1 78 binding to RAP1 A (PDB ID: 1C1Y). The residues for conducting site saturation mutagenesis are identified via the results from computational scanning and is labelled on the bottom. The mutated amino acids are labelled to the left and the ddG of the final mutated structure is plotted. The more negative the value is, the higher the binding affinity is between the 40-mer peptide-interacting protein complex. The circled residue is A85K and has been identified as increasing binding affinity between RAF I and HRAS.
[00107] FIG. 4 depicts the structure of the interaction between RAFI and an interacting protein (RAP1 A or HRAS).
Example 4 - RAC1 and RAFI helix engineering and stapling
[00108] RAC1 and RAFI were identified from the workflow of Example 1 and Example 2 regarding identifying alpha-helical 40-mer peptides from the peptide screens and the workflow of Example 3 was performed on select identified alpha-helical 40-mer peptides. During the step of manually verifying peptides and their co-crystal structures, RAC1-61 and RAFI-78 were two alpha-helical 40-mer peptides that had a region of alpha helix that fit the binding interface with their interacting proteins really well. Based on their co-crystal structures as shown in FIG. 5A- 5B, the 40-mer peptide was shortened to only span the alpha helical region. Additionally, staples were designed to enable cell-penetrating capabilities of these peptides to improve their drug-like
function. Shorter staples (i, i + 3) and longer (i, i + 7) staples were both evaluated. The longer staple (i, i + 7) was chosen for the subsequent examples.
[00109] The final sequence details of the RAC1 and RAFI helical peptides for stapling are indicated in TABLE 3 below:
[00111] R-octenylalanine (R8) and S-pentenylalanine (S5) are non-naturally occurring amino acid residues that allow the formation of the hydrocarbon staple. The image below discloses SEQ ID NOS 8-10, respectively, in order of appearance.
Example 5 - In vitro experiments
[00112] Activity
[00113] MDA-MB-231 and A375 cell lines were treated with various doses of either TAT- Flag peptide (control), or peptide of SEQ ID NO: 4, SEQ ID NO: 5, or SEQ ID NO: 6 (0. 1 pM, 0.3 pM, 1 pM, 3 pM, 10 pM, 30 pM, 100 pM). FIG. 6A and FIG. 6B depicts dose response curves for each peptide. Cell viability was measured at 24-hours (FIG. 6A) and 48-hours (FIG. 6B) post treatment using the colorimetric assay Cell Counting Kit-8 (CCK8). TAT-Flag peptide treatment did not affect cell viability at 24 and 48 hours, while peptide of SEQ ID NO: 4 or SEQ ID NO: 5 affected cell viability of both cell lines, and peptide of SEQ ID NO: 6 only affected cell viability of A375 cells. At 48 hours, peptide of SEQ ID NO: 6 displayed an IC50= 41.8 pM with a maximum effect of 77.8% cell death in A375 cells, whereas MDA-MB-231 cell survival is not significantly altered by peptide of SEQ ID NO: 6. A375 and MDA-MB-231 cells responded to both peptide of SEQ ID NO: 4 and peptide of SEQ ID NO: 5 in a similar fashion as shown by the overlapping dose response curves. Therefore, there was no differential bioactivity on cell death between WT and A85K RAFI stapled peptides. Between MDA-MB-231 andA375 cell lines a slight difference of sensitivity towards both peptide of SEQ ID NO: 4 and peptide of
SEQ ID NO: 5 was observed. Indeed, peptide of SEQ ID NO: 4 and peptide of SEQ ID NO: 5 had respectively an IC 0=21.2-23.2 pM with a maximum effect of 89.6 % on cell death in MDA- MB-231 cells and IC5o=16.9-2O.8 LIM with a maximum effect of 96.2 % on cell death in A375 cells.
[00114] Impact of Serum Starvation
[00115] A375 cells were starved by replacing the normal media (DMEM/10% FBS) by a media without FBS (DMEM/0% FBS) for 24 hours. Then, cells were treated with peptide of SEQ ID NO: 4 at 10 pM for 48 hours and cell viability was quantified using colorimetric assay CCK8. Under normal condition (10% FBS), treatment with SEQ ID NO: 4 peptide decreased cell viability by 16.6 % compared to the vehicle condition. When A375 were depnved of FBS, treatment with SEQ ID NO: 4 peptide decreased cell viability by 49.6 % compared to the vehicle under starved condition. Thus, when A375 cells were starved, sensitivity to SEQ ID NO: 4 peptide was increased by ~3 fold.
[00116] FIG. 7A and 7B show starvation potentiates the anti-proliferative effect of SEQ ID NO: 4 peptide. In FIG. 7A, A375 cells were treated for 48-hours with SEQ ID NO: 4 peptide at lOpM or vehicle (PBS) with either 10% FBS or 0% FBS (starvation condition). Bright field images were taken with 20x magnification objective. Scale bar = 100pm. FIG. 7B shows quantification of cell viability measured by CCK8.
Example 6 - Tumor experiments
[00117] This example shows tumor growth arrest in vivo after administration of SEQ ID NO: 4 peptide in three different sets of tumor efficacy experiments.
[00118] FIG. 8A shows atimeline for a first set of tumor efficacy experiments. 1.5 million A375 cells in 50% Matrigel were injected subcutaneously in the back ofNOD-scid gamma mice. At Day 9 post-injection, tumor volumes reach an average of 102 ± 31 mm3 and then mice were split into two groups with similar tumor size distribution. At Day 12 postinjections, tumors were injected with either SEQ ID NO: 4 peptide, or Flag peptides (Flag) resuspended in PBS at 60 mg/kg. Each mouse was treated with 1 intra-tumoral injection every day for 3 days. FIG. 8B depicts the change in tumor volume observed with SEQ ID NO: 4 peptide or a Flag (Flag) control. At Day 14, a significant difference of the tumor volume between Flag (342 ± 76 mm3) and SEQ ID NO: 4 peptide (165 ± 55 mm3) treated mice was observed. At Day 16, tumors of the Flag group kept growing (572 ± 149 mm3) whereas tumor volume of the SEQ ID NO: 4 peptide treated group remained steady compare the previous time point at Day 14. Thus, treatment with SEQ ID NO: 4 peptide led to tumor growth arrest in vivo.
[00119] FIG. 9A shows a timeline for a second set of tumor efficacy experiments. 1.5 million A375 cells in 50% Matrigel were injected subcutaneously in the back ofNOD-scid gamma mice. 13 days later (D-l), tumor volumes reached an average of 149 ± 27 mm3 and mice were divided into two cohorts, Flag 60 mg/kg and SEQ ID NO: 4 peptide 60 mg/kg. Tumor volumes were measured every two days. At day 6, tumors volume in both groups were greater than 500 mm3. At day 7 and 8, tumors were treated by intratumoral injections with either Flag or SEQ ID NO: 4 peptides at 60 mg/kg. Each mouse received two injections in total. Strikingly, the day after the first injection (day 8), tumors appeared to flatten down in SEQ ID NO: 4 peptide treated group but not in the Flag treated group (FIG. 9C). This observation was confirmed by tumor volume measurement on day 8. In the Flag treated group, tumors kept growing after the first injection reaching 2001 mm3 on day 13, while tumors in SEQ ID NO: 4 peptide treated group appeared to stop growing (FIG. 9B).
[00120] FIG. 10A shows a timeline for a third set of tumor efficacy experiments. 1.5 million A375 cells in 50% Matrigel were injected subcutaneously in the back ofNOD-scid gamma mice. 13 days later (D-l), tumor volumes reached an average of about 200 mm3 and mice were divided into four cohorts: Flag 15 mg/kg, and SEQ ID NO: 4 peptide at 15 mg/kg, 10 10 mg/kg, or 5 mg/kg. Mice were treated with the control (Flag) or SEQ ID NO: 4 peptides at the indicated dosage every day for 11 days. Tumor volumes were measured about every two days. At day 6, tumors volume in all groups were greater than 500 mm3. At day 13 the mice receiving the SEQ ID NO: 4 peptide at the indicated dosage had reduced tumor volumes as compared to the control group (Flag peptide), as shown in FIG. 10B.
[00121] The tumors in the first set of tumor efficacy experiments and the second set of tumor efficacy experiments were treated with dose of 60 mg/kg but at different stage of tumor growth. The tumors in the first set of tumor efficacy experiments were treated once reaching a volume greater than 100 mm3 versus tumors in the second set of tumor efficacy experiments were treated tumors were greater than 500 mm3. In both sets of experiments, SEQ ID NO: 4 peptide stopped the tumor growth, and the effect on the tumor shape could be observed one day after the injection. Similarly, in the third experiment mice treated daily with SEQ ID NO: 4 peptide had reduced tumor volume in all tested conditions (5-15 mg/kg) compared to the control. In conclusion, SEQ ID NO: 4 peptide had in vivo bioactivity and reduced tumor growth of human melanoma cells.
Example 7 - Tumor experiments
[00122] This example describes assessment of tumor growth in vivo after administration of SEQ ID NO: 1 peptide, SEQ ID NO: 2 peptide, SEQ ID NO: 3 peptide, SEQ ID NO: 4
peptide, SEQ ID NO: 5 peptide, or SEQ ID NO: 6 peptide in different KRAS mutant tumor models.
[00123] A pancreatic tumor cell line having a G12V KRAS mutation or G12C KRAS mutation in 50% Matrigel are injected subcutaneously in the back of NOD-scid gamma mice. Tumor volumes are allowed to grow and then mice are split into two groups with similar tumor size distribution. Tumors are injected either intra-tumoral or intraperitoneally with SEQ ID NO: 1 peptide, SEQ ID NO: 2 peptide, SEQ ID NO: 3 peptide, SEQ ID NO: 4 peptide, SEQ ID NO: 5 peptide, SEQ ID NO: 6 peptide or a control peptide resuspended in PBS at 5 mg/kg, 15 mg/kg, 60 mg/kg, or 240 mg/kg. Each mouse is treated with 1 intra-tumoral injection every 3 days. Tumor growth is measured.
[00124] A lung tumor cell line having a G12V KRAS mutation or G12C KRAS mutation in 50% Matrigel are injected subcutaneously in the back of NOD-scid gamma mice. Tumor volumes are allowed to grow and then mice are split into two groups with similar tumor size distribution. Tumors are injected either intra-tumoral or intraperitoneally with SEQ ID NO: 1 peptide, SEQ ID NO: 2 peptide, SEQ ID NO: 3 peptide, SEQ ID NO: 4 peptide, SEQ ID NO: 5 peptide, SEQ ID NO: 6 peptide or a control peptide resuspended in PBS at 5 mg/kg, 15 mg/kg, 60 mg/kg, or 240 mg/kg. Each mouse is treated with 1 intra-tumoral injection every 3 days. Tumor growth is measured.
[00125] A colorectal tumor cell line having a G12V KRAS mutation or G12C KRAS mutation in 50% Matrigel are injected subcutaneously in the back of NOD-scid gamma mice. Tumor volumes are allowed to grow and then mice are split into two groups with similar tumor size distribution. Tumors are injected either intra-tumoral or intraperitoneally with SEQ ID NO: 1 peptide, SEQ ID NO: 2 peptide, SEQ ID NO: 3 peptide, SEQ ID NO: 4 peptide, SEQ ID NO: 5 peptide, SEQ ID NO: 6 peptide or a control peptide resuspended in PBS at 5 mg/kg, 15 mg/kg, 60 mg/kg, or 240 mg/kg. Each mouse is treated with 1 intra-tumoral or intraperitoneal injection every 3 days. Tumor growth is measured.
Example 8 - In vitro selection of tumor cell lines
[00126] This example shows in vitro testing of SEQ ID NO: 4 peptide potency against KRAS-mutant cell lines and selection of cell lines for in vivo testing.
[00127] Prior to in vitro testing, the SEQ ID NO: 4 peptide was determined to have solubility in PBS of up to at least 100 mg/mL. The peptide was prepared by a contract manufacturer and lyophilized prior to being reconstituted. The acetate salt of the SEQ ID NO: 4 peptide and the control peptide was used in this example and the examples described below. SEQ ID NO: 4 was tested in a 10-point dose curve at a 1 :2 dilution with a top concentration of 100
pM and a 72 hour endpoint against different KRAS-mutant cell lines. A cell titer-glo assay was used to determine the potency of the peptide against different cell lines. The summary of the potency of SEQ ID NO: 4 against different KRAS-mutant cell lines is shown on TABLE 4. TABLE 4 shows the mutant cell line tested, the tumor type of the mutant cell line, the KRAS mutation status, the half maximal effective concentration (EC50) of the TAT-Flag control (GRKKRRQRRRPQDYKDDDDK SEQ ID NO: 7), the EC50 of the SEQ ID NO: 4 peptide, and if the cell line was selected for an in vivo study (Example 9).
[00128] FIGS. 11A-11C show IC50 curves for SEQ ID NO: 4 peptide and a control peptide (TAT-Flag peptide, SEQ ID NO: 7) against different KRAS-mutant cell lines for a 72- hour endpoint and using a Cell Titer Gio assay. FIG. 11A shows an IC50 of 1.667e-005 M of the SEQ ID NO: 4 peptide against the NC1-H358 cell line; FIG. 11B shows EC50 of 9.187e-006 M of the SEQ ID NO: 4 peptide against the NCI-H441 cell line; and FIG. 11C shows EC50 of 5.231e-005 for the SEQ ID NO: 4 peptide against for the SW480 cell line. The NCI-H441 cell line (lung tumor), NCI-H358 cell line (lung tumor), and the SW480 cell line (colorectal tumor) were selected for further in vivo studies (See Example 9). Overall, SEQ ID NO: 4 peptide had EC50 values ranging from 9.18 pM to 161 pM against most of the KRAS mutant cell lines tested.
Example 9 - In vivo tumor experiments
[00129] This example shows tumor growth arrest in vivo after administration of SEQ ID NO: 4 peptide in different mice tumor cell models.
[00130] The mice tumor models are summarized in TABLE 5, which shows the cell line used for the tumor model, the mouse strain used for the tumor model, the number of cells injected subcutaneously in the back of the mice, the volume of cells injected and the formulation used for injection, the tumor size at the randomization and start of treatment, and the max tumor volume observed. In all three tumor groups (NCI-H358, NCI-H441, and SW480) the mouse age at the start of the study was 8-12 weeks. The mouse strain for the NCI-H358 (H358) tumor model was Female CB.17 severe combined immunodeficient (SCID) mouse. The mouse strain for the NCI-H441 (H441) tumor model and the SW480 tumor model was the Female NCr mouse.
[00131] In each tumor study (NCI-H358, NCI-H441, and SW480), the mice were separated into 4 groups with 8 mice per group. Group 1, was the vehicle alone; Group 2 was the TAT-Flag control peptide (SEQ ID NO: 7) at 4.5 mg per dose; Group 3 was low dose SEQ ID NO: 4 peptide at 1.5 mg per dose; and Group 4 was high dose SEQ ID NO: 4 peptide at 4.5 mg per dose. The peptides were administered mtra-tumorally three times weekly and for four weeks (or until the tumor volume was too large). Measurements were recorded such as body weight, tumor volume, and tumor weight. A summary of the study design is shown in TABLE 6.
[00132] In the SW480 group 4 (SEQ ID NO: 4 peptide - high dose) dosing was stopped after Day 13 due to ulcerations and deaths in the group precluding statistical analysis. In the SW480 model, G1A6 (Vehicle animal 6), G3A4 (SEQ ID NO: 4 peptide - low dose animal 4), G3A8 (SEQ ID NO: 4 peptide - low dose animal 8), G4A1 (SEQ ID NO: 4 peptide - high dose animal 1), G4A3 (SEQ ID NO: 4 peptide - high dose animal 3), G4A5 (SEQ ID NO: 4 peptide - high dose animal 5), G4A6 (SEQ ID NO: 4 peptide - high dose animal 6), and G4A8 (SEQ ID NO: 4 peptide - high dose animal 8) died in the study. SW480 group animals were either found dead or reached a humane endpoint due to ulcerations. G4A5 and G4A6 were found dead and listed as not treatment-related as the ulcerations did not appear significant enough to induce death. G4A3 had a physical injury that prevented mobility so euthanasia was required. G4A8 and G4A1 were euthanized for extensive ulceration. In the H441 group, G4A4 (SEQ ID NO: 4 peptide - high dose animal 4) died in the study.
[00133] The tumor weight results after 4 weeks of treatment are shown in FIGS. 12A and 12B. The results show that treatment by injecting SEQ ID NO: 4 peptide reduced the tumor weight in the H358 and SW480 tumor mouse models as compared to the vehicle and control peptide. In the SW480 model, both the low dose (1.5 mg) and the high dose (4.5 mg) of SEQ ID NO: 4 peptide lowered the tumor weight of the animal. In the H358 model, the high dose (4.5 mg) of SEQ ID NO: 4 peptide lowered the tumor weight of the animal. These results show the peptide (SEQ ID NO: 4 peptide) is effective for treating lung and colorectal cancers.
[00134] Mean tumor volumes for the groups were recorded throughout the study and are shown in FIGS. 13A-13C for the SW480 (FIG. 13A), NC1-H358 (FIG. 13B), and NC1-H441 (FIG. 13C) treatment groups. As shown in FIG. 13A, the tumor volume was decreased in the SEQ ID NO: 4 peptide low dose (1.5 mg) and high dose (4.5 mg) treatment groups in the SW480 tumor model as compared to the control treatment groups. This data shows the peptide (SEQ ID NO: 4 peptide) can reduce tumor volume.
[00135] FIGS. 14A-14C show tumor volume by tumor weight correlations for the SW480 model (FIG. 14A), the NCI-H358 model (FIG. 14B), and the NCI-H441 model (FIG. 14C). The correlation demonstrates the difficulty of caliper-based volume measurements with ulceration/scabbing in the H441 model and SW480 model. This measurement difficulty is illustrated for the G3 (SEQ ID NO: 4 peptide low dose) and G4 (SEQ ID NO: 4 peptide high dose) treatment groups. FIGS. 14A-14C show that tumor volumes may not be the most correlative measurement to track anti-tumor efficacy. The control group’s tumor weight and volume correlate, however the treated group’s tumor weight and volume do not correlate. This is likely due to ulceration and the difficulties of measuring volume by calipers.
[00136] Mean body weights for the groups were recorded throughout the study and are shown in FIGS. 15A-15C for the SW480 (FIG. 15A), NCI-H358 (FIG. 15B), and NCI-H441 (FIG. 15C) treatment groups. The mean body weights were overall comparable between the groups. In the NCI-H358 treatment model, the SEQ ID NO: 4 peptide low dose group showed a decrease in mean body weight at the end of the study as compared to the controls.
[00137] Overall, in vivo tumor weight as an endpoint may be a more reliable measurement of efficacy than tumor volume for the H441 model and the SW480 model due to inflammation, ulceration, and scabbing. Several animals in high dose group (SEQ ID NO: 4 peptide - 4.5 mg) for the SW480 model were found dead or had to be euthanized but this is likely a modeldependent byproduct of anti-tumor efficacy rather than compound toxicity. In vivo efficacy was observed for the SEQ ID NO: 4 peptide with 3x per week intra-tumoral dosing in the H358 model and SW480 model and shows the peptides of the present disclosure can be used to treat cancers.
Example 10 - SystemicaBy administered Tn vivo tumor experiments
[00138] This example describes assessment of tumor growth in vivo after administration of SEQ ID NO: 1 peptide, SEQ ID NO: 2 peptide, SEQ ID NO: 3 peptide, SEQ ID NO: 4 peptide, SEQ ID NO: 5 peptide, or SEQ ID NO: 6 peptide an SW480 model and/or aH358 mouse model.
[00139] A SW480 and/or NCI-H358 tumor cell line having a G12V KRAS mutation or G12C KRAS mutation in 50% Matrigel are injected subcutaneously in the back of NOD-scid gamma mice. Tumor volumes are allowed to grow and then mice are split into groups with similar tumor size distribution. Mice are systemically administered and repeat-dosed with SEQ ID NO: 1 peptide, SEQ ID NO: 2 peptide, SEQ ID NO: 3 peptide, SEQ ID NO: 4 peptide, SEQ ID NO: 5 peptide, SEQ ID NO: 6 peptide or a control peptide resuspended in PBS at 5 mg/kg, 15 mg/kg, 60 mg/kg, or 100 mg/kg. Tumor growth is measured.
[00140] Prior to the systemic study, a pharmacokinetics assessment is completed with a small single dose rodent study. This is used to determine and confirm doses and administration schedules for the systemic in vivo study.
[00141] While exemplary embodiments have been shown and described herein, it will be obvious to those skilled in the art that such embodiments are provided by way of example only. Numerous variations, changes, and substitutions will occur to those skilled in the art. It should be understood that various alternatives to the embodiments described herein may be employed. It is intended that the following claims define the scope of the disclosure and that methods and structures within the scope of these claims and their equivalents be covered thereby.
Claims
1. An engineered peptide having at least about 84% sequence identity to any one of SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3.
2. The engineered peptide of claim 1, wherein the engineered peptide has a length of from about 10 amino acids to about 40 amino acids or of from about 10 amino acids to 39 amino acids.
3. The engineered peptide of claim 1, wherein the engineered peptide has a length of at most 15 amino acids.
4. The engineered peptide of claim 1, wherein the engineered peptide has a length of 13 amino acids or 14 amino acids.
5. The engineered peptide of any one of claims 1-4, having the amino acid sequence of any one of SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3
6. The engineered peptide of any one of claims 1-5, wherein the engineered peptide adopts an alpha helical structure at physiological salt concentrations and physiological temperature.
7. The engineered peptide of any one of claims 1-4 or 6, wherein the engineered peptide is a stapled peptide.
8. The engineered peptide of claim 7, wherein the stapled peptide is an (i, i + 3) stapled peptide or an (i, i + 7) stapled peptide.
9. The engineered peptide of claim 7, wherein the stapled peptide is an (i, i + 7) stapled peptide.
10. The engineered peptide of claim 8 or 9, wherein the (i) residue of the stapled peptide is R-octenylalanine (R8), S-octenylalanine (S8), R-pentylalanine (R5), or S-pentenylalanine (S5).
11. The engineered peptide of any one of claims 8-10, wherein the (i+3) residue or the (i+7) residue of the stapled peptide is R-octenylalanine (R8), S-octenylalanine (S8), R- pentylalanine (R5), or S-pentenylalanine (S5).
12. The engineered peptide of any one of claims 8-11, wherein the (i) residue of the stapled peptide is at ammo acid 3 or ammo acid 4 of any one of SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3.
13. The engineered peptide of any one of claims 8 or 10-12, wherein the (i) residue of the stapled peptide is R-octenylalanine (R8) and the (i+3) residue of the stapled peptide is S- pentenylalanine (S5).
The engineered peptide of any one of claims 9-12, wherein the (i) residue of the stapled peptide is R-octenylalanine (R8) and the (i+7) residue of the stapled peptide is S- pentenylalanine (S5). The engineered peptide of any one of claims 1-4, or 6-12 having at least 84% sequence identity to any one of SEQ ID NO: 4, SEQ ID NO: 5, or SEQ ID NO: 6. The engineered peptide of any one of claims 1-4, or 6-12 having the amino acid sequence of any one of SEQ ID NO: 4, SEQ ID NO: 5, or SEQ ID NO: 6. The engineered peptide of any one of claims 1-16, wherein the engineered peptide has an IC50 of from about 1 nM to about 50 pM against a cancer cell line, as determined in an in vitro assay. An engineered peptide that comprises:
(a) at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to a contiguous portion of an RBI peptide, a CHEK2 peptide, an MDM2 peptide, a RAFI peptide, an RRAS2 peptide, a RAC1 peptide, a PIK3Ca peptide, a PIK3R1 peptide, a VHL peptide, a DDX3X peptide, or a CTNNB1 peptide; and
(b) a length of from about 10 amino acids to about 20 amino acids; wherein the engineered peptide has an IC50 of from about 1 nM to about 50 pM against a cancer cell line, as determined in an in vitro assay. The engineered peptide of claim 18, wherein the engineered peptide is a salt of an engineered peptide. The engineered peptide of claim 19, wherein the salt of the engineered peptide is a acetate salt or a trifluoroacetate (TFA) salt. The engineered peptide of any one of claims 18-20, wherein the engineered peptide is a stapled peptide. The engineered peptide of claim 21, wherein the stapled peptide is an (i, i + 3) stapled peptide or an (i, i + 7) stapled peptide. The engineered peptide of claim 21, wherein the stapled peptide is an (i, i + 7) stapled peptide. A pharmaceutical composition that comprises the engineered peptide of any one of claims 1-23 and a pharmaceutically acceptable excipient, diluent, or carrier. The pharmaceutical composition of claim 24, in unit dose form. The pharmaceutical composition of claim 25, wherein the engineered peptide in unit dose form is about 5 mg/kg, about 15 mg/kg, about 50 mg/kg, about 55 mg/kg, about 60 mg/kg. about 65 mg/kg, about 75 mg/kg, about 100 mg/kg, about 150 mg/kg, about 200 mg/kg, about 240 mg/kg, or about 300 mg/kg.
A method of treating a disease or condition in a subject in need thereof, the method comprising administering to the subject the engineered peptide of any one of claims 1-23 or the pharmaceutical composition of any one of claims 24-26, wherein the administering is sufficient to treat the disease or condition. The method of claim 27, wherein the disease or condition is a cancer. The method of claim 28, wherein the cancer comprises a KRAS mutation. The method of claim 29, wherein the KRAS mutation comprises a G12V mutation, a G12C mutation, or a G12D mutation of KRAS. The method of claim 28, wherein the cancer is a melanoma, a colorectal cancer, a pancreatic cancer, a bladder cancer, a breast cancer, a triple negative breast cancer, an ovarian cancer, a juvenile myelomonocytic leukemia (JMML), a hematologic malignancy, a cholangiocarcinoma, a uterine cancer, a cervical cancer, a testicular cancer, a lung cancer, or any combination thereof. The method of any one of claims 27-31, wherein the administering is parenteral or intra- tumoral. The method of any one of claims 27-32, wherein the subject in need thereof is a mammal. The method of any one of claim 33, wherein the mammal is a human, a non-human primate, a dog, a cat, a hamster, a guinea pig, a rat, or a mouse. The method of any one of claims 27-34, further comprising administering a second therapy to the subject. The method of claim 35, wherein the second therapy comprises a chemotherapy, a radiation therapy, a hormone therapy, a hyperthermia therapy, an immunotherapy, a photodynamic therapy, a stem cell therapy, a surgery, a targeted therapy, or any combination thereof. The method of claim 35-36, wherein the second therapy is administered concurrently or consecutively with the engineered peptide or the pharmaceutical composition. A method of making engineered therapeutic peptides for treatment of cancer, the method comprising:
(a) selecting portions of a candidate polypeptide that display cellular toxicity, as determined in an in vitro assay;
(b) curating the portions of the candidate polypeptides to select a subset of the portions of the candidate polypeptide that adopt an alpha helical structure, as determined by x-ray crystallography:
(c) modifying the subset using mutagenesis to generate engineered therapeutic peptides, and
(d) selecting engineered therapeutic peptides having an IC50 of from about 1 nM to about 50 pM against a cancer cell line, as determined in an in vitro assay. The method of claim 38, wherein the modifying of (c) further comprising making an (i, i+7) staple within the engineered therapeutic peptides. A method of inhibiting cell proliferation in a cancerous cell, the method comprising administering to the cancerous cell the engineered peptide of any one of claims 1-23 or the pharmaceutical composition of any one of claims 24-26, wherein the administering is sufficient to inhibit proliferation of the cancerous cell.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202263404990P | 2022-09-09 | 2022-09-09 | |
US63/404,990 | 2022-09-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2024054892A1 true WO2024054892A1 (en) | 2024-03-14 |
Family
ID=90191874
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2023/073613 WO2024054892A1 (en) | 2022-09-09 | 2023-09-07 | Therapeutic peptides |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2024054892A1 (en) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20170037084A1 (en) * | 2014-04-02 | 2017-02-09 | Rudi Fasan | Macrocyclic peptidomimetics for alpha-helix mimicry |
US20200237885A1 (en) * | 2015-05-13 | 2020-07-30 | Agenus Inc. | Vaccines for treatment and prevention of cancer |
WO2021247623A1 (en) * | 2020-06-01 | 2021-12-09 | President And Fellows Of Harvard College | Compositions and methods for optogenetic control |
WO2022020652A2 (en) * | 2020-07-22 | 2022-01-27 | Fog Pharmaceuticals, Inc. | Stapled peptides and methods thereof |
US20220249599A1 (en) * | 2018-03-13 | 2022-08-11 | Peptilogics, Inc. | Treatment of implants with engineered antimicrobial amphiphilic peptides |
-
2023
- 2023-09-07 WO PCT/US2023/073613 patent/WO2024054892A1/en unknown
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20170037084A1 (en) * | 2014-04-02 | 2017-02-09 | Rudi Fasan | Macrocyclic peptidomimetics for alpha-helix mimicry |
US20200237885A1 (en) * | 2015-05-13 | 2020-07-30 | Agenus Inc. | Vaccines for treatment and prevention of cancer |
US20220249599A1 (en) * | 2018-03-13 | 2022-08-11 | Peptilogics, Inc. | Treatment of implants with engineered antimicrobial amphiphilic peptides |
WO2021247623A1 (en) * | 2020-06-01 | 2021-12-09 | President And Fellows Of Harvard College | Compositions and methods for optogenetic control |
WO2022020652A2 (en) * | 2020-07-22 | 2022-01-27 | Fog Pharmaceuticals, Inc. | Stapled peptides and methods thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20230093875A1 (en) | Ionic liquids for internal delivery | |
US20230338588A1 (en) | Granzyme B Directed Imaging and Therapy | |
US20230022573A1 (en) | Combination of hdac inhibitor and anti-pd-1 antibody for treatment of cancer | |
ES2843586T3 (en) | Antibodies directed against CSF1R to treat SVNP | |
JP2018519335A (en) | Combination of HDAC inhibitor and anti-PD-L1 antibody for the treatment of cancer | |
US11524012B1 (en) | Quinolone analogs and their salts, compositions, and method for their use | |
JP2021152032A (en) | Treatment of protein aggregation myopathic and neurodegenerative diseases by parenteral administration of trehalose | |
ES2811124T3 (en) | Using reslizumab to treat moderate to severe eosinophilic asthma | |
WO2019126739A1 (en) | Pyrvinium pamoate anti-cancer therapies | |
WO2021104454A1 (en) | Use of bi853520 in cancer treatment | |
ES2650267T3 (en) | Method for the treatment of neurodegenerative diseases | |
KR20200014790A (en) | Tinostamustine used to treat ovarian cancer | |
TW201904607A (en) | Dosing regimen for administration of a glyphosate-peptide-2 (GLP-2) analogue | |
ES2587837T3 (en) | Interferon-beta for use as monotherapy or in combination with other cancer therapies | |
US11795217B2 (en) | Interleukin-1 inhibition for combination treatment of pancreatic cancer cachexia | |
US20190175560A1 (en) | Mebendazole cancer therapies and methods of use | |
KR20190085935A (en) | Use of beta-catenin as a biomarker for the treatment of cancer using anti-DKK-1 antibodies | |
JP2024012649A (en) | Methods of treatment of cancer comprising chk1 inhibitors | |
JP2015518053A (en) | Use of AMG900 for the treatment of cancer | |
TW201000116A (en) | Peptide compound and use thereof | |
AU2018352382B2 (en) | Compounds and methods for treating cancer | |
JP2017502040A (en) | Methods and compositions for treating cancer using peptide nucleic acid drugs | |
US20200246283A1 (en) | Pharmaceutical composition for preventing and treating pancreatic cancer, containing gossypol and phenformin as active ingredients | |
US20220144914A1 (en) | Methods and compositions for protein delivery | |
WO2024054892A1 (en) | Therapeutic peptides |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 23863983 Country of ref document: EP Kind code of ref document: A1 |